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Photodynamic therapy (PDT) is a minimally invasive oncologic intervention that 
involves the administration of a tumor-localizing photosensitizer (PS), which is 
subsequently activated by visible light of specific wavelength (400 – 700 nm), 
resulting in tumor cell death. Although PDT was approved by US Food and Drug 
Administration almost 2 decades ago, it still remains underutilized clinically. This is 
mainly due to the limited penetration depth of visible light that excites most of the 
currently available PSs, limiting PDT to the treatment of superficial and flat lesions. 
This study focusses on the use of upconversion nanoparticles (UCN) to overcome the 
current limitations of PDT. UCNs convert low energy near-infrared (NIR) light to 
high energy visible or ultraviolet (UV) light, which can then excite the PS attached to 
UCNs. As the NIR light can achieve much deeper penetration in biological tissues, 
indirect excitation of PS with NIR light enables cell killing at much deeper layers in 
tissues. Recently, numerous studies using various UCN constructs loaded with 
different PS have been reported. However, such nanoconstructs suffer from certain 
drawbacks such as unstable PS loading, low PS loading capacity, batch-to-batch 
variation in PS loading and PS quenching, resulting in low bioavailabity and 
ineffective therapeutic outcome.  
The overall aim of this thesis is to fabricate UCN based PDT nanoconstruct with 
stable coating of the PS, and develop it further for targeted PDT against oral cancers. 
Firstly, a NIR to ultraviolet (UV) upconverting UCN core stably surface coated with a 
well-studied photocatalyst titanium dioxide (TiO2) was synthesized (TiO2-UCNs). 
Although TiO2-UCNs were found to generate significant amount of reactive oxygen 








aggregates in physiological solutions; an undesirable characteristic that could 
eventually lead to reduced bioavailability and ROS production. To solve the issue of 
aggregation, TiO2-UCNs were further surface modified with maleimide functionalized 
polyethylene glycol (PEG) to form Mal-PEG-TiO2-UCN. These nanoparticles formed 
stable dispersion, demonstrated good ROS generation ability, negligible toxicity and 
efficient cell death following NIR-PDT in vitro. Thereafter, “proof of concept” in vivo 
studies following intratumoral administration of Mal-PEG-TiO2-UCNs demonstrated 
significant delay in tumor growth in NIR-PDT treated group. To develop targeted 
nanoparticles for systemic delivery against epithelial growth factor receptor (EGFR) 
expressing oral cancers, anti-EGFR affibodies were tagged to the PEGylated TiO2-
UCNs (anti-EGFR-PEG-TiO2-UCNs). Anti-EGFR-PEG-TiO2-UCNs displayed 
efficient targeting abilities, biocompatibility and selective cell killing in vitro. In vivo 
toxicity and biodistribution studies revealed no major adverse effects or 
histopathological changes. Finally, therapeutic efficiency of NIR-PDT post systemic 
administration of anti-EGFR-PEG-TiO2-UCN was compared with conventional 
Chlorin-e6 (Ce6) PDT at 665 nm light. While the conventional Ce6-PDT failed to 
produce any therapeutic effect when the tumors were blocked with 10 mm tissue 
phantom, NIR-PDT following systemic delivery of anti-EGFR-PEG-TiO2-UCN 
demonstrated considerable control of tumor growth.  To sum up, the results of this 
study may perhaps pave the way for further development and translation of this 
technique to the clinics, in a bid to improve the scope and applicability of PDT for the 
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Cancer accounted for 7.6 million deaths (around 13% of all deaths) world-wide in 
2008.
1
 Almost 13 million cancer cases are newly diagnosed every year and deaths are 
projected to rise, with an estimated 13.1 million in 2030. Although regular screening 
and surveillance programs as well as early intervention are best ways to improve the 
outcome and survival, efforts need to be divided at finding better cancer therapeutic 
options that are effective, efficient, affordable and acceptable to patients. The 
conventional cancer treatment options are chemotherapy, radiotherapy and surgery, 
and more recently small molecule-based therapies and immunotherapy along with a 
combination of these strategies are being practised. However, chemotherapy is often 
associated with systemic side-effects, high recurrence rate is associated with surgical 
resection of tumors, while radiation therapy is limited by the cumulative radiation 
dose. While refinement of the conventional cancer treatment modalities is important, 
researches have also focused on developing alternate treatment modalities that are 
safe, potent and cost-effective. Photodynamic therapy (PDT) is an alternative tumor-
ablative and function-sparing oncologic intervention. Since its inception in early 
1900’s and its first modern demonstration by Dougherty et al. in 1975,2 PDT has 
undergone extensive investigations and has emerged as a disease site specific 
treatment modality. Essentially, it involves the administration of a tumor-localizing 
photosensitizer (PS) followed by local illumination of the tumor with light of a 
specific wavelength to activate the PS. The excited PS then transfers its energy to 
molecular oxygen, thus generating cytotoxic reactive oxygen species (ROS), such as 
singlet oxygen (
1
O2) that can oxidize key cellular macromolecules leading to tumor 







 Hence, PDT employs 3 non-toxic components that by its own do not 
have any toxic effects on the biological systems, unlike chemotherapy drugs that 
induce systemic toxicity and ionising light of radiation therapy that damages 
neighbouring normal tissues. Clearly, PDT has its own merits compared to the 
conventional treatment methods due to its minimal invasiveness, repeatability without 
cumulative toxicity, excellent functional and cosmetic results, reduced long term 
morbidity and improved quality of life of the patients. Over the last four decades PDT 
has proven to be effective in superficial bladder cancer,
5





 head and neck cancers,
9
 and skin cancer.
10
 It is also 




Despite the wide-spread and rapidly growing applications, PDT has yet to gain 
clinical acceptance as a first-line oncological intervention due to certain limitations 
including lack of an ideal PS, challenges in formulating PS, limited depth of 
penetration of the visible light that is utilized to activate most of the conventional 
photosensitizer, difficulties in choosing the right light dosimetry for a complete and 
effective treatment and monitoring the treatment response.
15
 The application of 
nanoparticles in PDT has been a major stride forward in resolving at least some of the 
challenges associated with classic PS.
15
 Nanoparticles can be effective carriers of PSs 
and transport high PS “payload” to the tumor site. Additional surface modification 
and functionalization with targeting moieties could further enhance the selective 
accumulation of the PS loaded nanoparticles at the target site. In the recent years, 
much effort has been channelled in the development of multifunctional theranostic 
agents where a number of diverse diagnostic and therapeutic functionalities have been 
incorporated in a single nanoplatform for a “see and treat” approach. The versatility of 





such agents allow delivery of drugs to the diseased/target site with enhanced spatial 
specificity while achieving simultaneous real-time imaging, monitoring as well as 
therapeutic capabilities.  
Among the various nanoconstructs developed for PDT, polymeric (synthetic or 
natural), liposomal or dendrimeric nanoparticles are biocompatible and biodegradable, 
and hence have the added advantage of being enzymatically hydrolysed and excreted 
from the body, minimizing long term accumulation.
16
 These nanoparticles are very 
versatile due to the existence of a variety of polymers and manufacturing methods, 
and thus the chemical composition and architecture of the nanoparticles can be 
customized to accommodate PSs with varying degrees of hydrophobicity, molecular 
weight or charge.
17, 18
 Furthermore, the surface properties, morphologies, and 
compositions of polymeric matrices can be easily optimized to achieve controlled 
degradation of the polymer and drug release kinetics.
19
 While these nanoparticles can 
be tailored to carry multiple functionalities such as targeting moieties or additional 
imaging and therapeutic capabilities; non-biodegradable nanoparticles such as silica, 
gold and magnetic iron-oxide nanoparticles provide in-built multifunctional 
capabilities due to its intrinsic properties. Some nanoparticles such as fullerenes, 
titanium dioxide (TiO2) and zinc oxide (ZnO) can also be excited by light of specific 
wavelength to induce generation of ROS. A third type can transduce energy to the 
accompanying PS via Förster resonance energy transfer (FRET), in order to excite PS 
indirectly at wavelengths that it does not normally absorb, such as X-ray 
nanoparticles, quantum dots (QDs) and gold nanorods. Theoretically, although two-
photon PDT (TP-PDT) might allow deep-tissue penetration via simultaneous 
excitation with two low-energy near-infrared (NIR) photon, the treatment is restricted 





to a tiny tissue volume resulting in prolonged treatment time, thus limiting its clinical 
use.   
In the recent years, PDT using Upconversion Nanoparticles (UCNs) doped with PS is 
becoming the new sensation in the field with clear advantages over most other 
nanoparticles. UCNs act both as carriers of PS as well as enables indirect excitation of 
the accompanying PS with upconverted light upon excitation with low energy and 
deep tissue penetrating NIR light. Indirect excitation of the PS with NIR light offers 
the additional advantage of achieving cell death at a greater depth in the cancer tissue, 
which is otherwise impossible with direct excitation using visible light. Recently, 
there has been a growth in the number of literature available in this area which clearly 
depicts the growing interest, clear advantages and possibility of further developments 
in the field. However, long multi-step reaction methods associated with UCN 
synthesis and unstable PS loading often leads to batch to batch differences, making it 
difficult to compare results. In fact majority of the published effort, are limited to 
solution or cell-based studies, due to the large size variations in UCN constructs, 
agglomerate formation and inconsistencies in the loading of the PSs. This is because 
even subtle changes in composition arising from minute deviations in the 
manufacturing process could substantially affect the pharmacokinetic, biodistribution, 
toxicity and PDT efficiency in vivo.
20, 21
 Moreover, the different PS loading strategies 
on UCNs developed so far, lead to PS leakage while it is still in circulation resulting 
in reduced bioavailability in target site, reducing the PDT efficacy and compromising 
the reproducibility. Thus, stringent control in terms of UCN synthesis and stability in 
PS loading is very crucial for improving the PDT efficiency, reproducibility and 
commercialization of this technology.  





The overall aim of this thesis is to develop a strategy for stable loading of PS on the 
UCN construct, so as to achieve efficient and reproducible treatment response 
following NIR-PDT of solid tumors, upon systemic delivery of these nanoconstruct in 
vivo. Here, a well-studied photocatalyst TiO2 is chosen as the PS which is generally 
excited with ultraviolet (UV) light to generate ROS. TiO2 is uniformly and stably 
surface coated around individual UCN core under strictly controlled and optimized set 
of parameters, to form a well-defined core-shell structured nanoconstruct. As the 
nanoparticle dispersions rarely reflect its distribution at the primary particle size, the 
developed nanoparticles are subjected to rigorous testing in solutions close to 
physiological settings. Such studies are expected to further streamline the 
optimization of the developed nanoconstruct very early during its evolution and steer 
its development as a better PDT agent, both in vitro and in vivo. The synthesized 
nanoconstructs are further surface modified and decorated with targeting moieties 
which specifically attaches to surface receptors over expressed in cancer cells. The 
biodistribution, long term toxicity and PDT efficiency of these nanocomposites 
following systemic administration is evaluated in this study, in an attempt to assess its 
development into a feasible clinical solution to overcome the current tissue 
penetration depth limitations associated with conventional PDT. 
  









2.1. PRINCIPLE OF PHOTODYNAMIC THERAPY 
 
2.1.1. Photodynamic reaction 
A PS absorbs a photon of light and becomes activated from ground state to a short-
lived excited singlet state (
1
PS*) (Figure 2.1). The excited PS may either decay back 
to ground state by emitting fluorescence, a property that can be clinically exploited 
for imaging and photodetection; or it can undergo intersystem crossing whereby the 





 The triplet excited PS can then directly interact with a substrate, such as 
the cell membrane or a molecule, and transfer a proton or an electron to form a 
radical anion or cation, respectively; which then react with oxygen to produce 
oxygenated products such as superoxide anion radicals, hydroxyl radicals and 
hydrogen peroxides (type I reaction). Alternatively, the energy of the excited PS can 
be directly transferred to molecular oxygen (itself a triplet in the ground state), to 
form 
1
O2 (type II reaction). The energy required for the transition of oxygen from 
triplet ground state to excited singlet state is 22 kcal mol
−1
, which corresponds to a 
wavelength of 1274 nm.
23




 The by-products formed as a result of the type I and type II reactions are 
responsible for the cell killing and therapeutic effect in PDT. It is to be noted that 
both type I and type II reactions can occur simultaneously, and the ratio between 
these processes depends on the type of PS, as well as the concentrations of 
molecular oxygen and substrate present.
22
 However, most of the studies indicate 
type II reactions, hence 
1
O2 play a dominant role in PDT.
25, 26
 












Figure 2.1 Schematic illustration of a typical Photodynamic Reaction. Adapted 
from ref
15
. Copyright 2015 American Chemical Society. 
 
 
2.1.2. Mechanism of tumor destruction 
Following PDT, the extent of photo-induced tumor destruction depends on various 
factors such as the type of PS, its concentration and localization in the tumor 
microenvironment or its sub-cellular location at the time of irradiation, the time 
between PS administration and light irradiation (drug-light interval, DLI), light 
fluence rate, the total fluence, the type of tumor and its level of oxygenation.
3, 27-29
 
PDT’s downstream targets include tumor cells, tumor as well as normal 
microvasculature and the inflammatory and immune host system.  The ROS 
generated by the photodynamic reaction is the key effector causing irreversible 
damage to the tumor cells and microvasculature, ensuing a plethora of inflammatory 




A. Direct tumor cell destruction  
Generally, the site of photodamage is considered to coincide with the location of 
accumulation of the PS in the tumor cells, as 
1
O2 has a very short life (half-life: 0.03 
to 0.18 ms),
30
 restricting its diffusion in biological systems to a radius of 





< 0.02 μm.31 Oxidation of the lipids, amino-acids and proteins by 1O2 induce 
irreversible photodamage to vital subcellular targets such as plasma membrane and 
organelles like mitochondria, lysosomes, Golgi apparatus and endoplasmic 
reticulum. The location where the PS ultimately resides within the cell is extremely 
important to define the mechanism and efficiency of photoinduced cell death  and 
this generally depends on its structural features such as the net ionic charge (ranges 
from −4 to +4), the degree of hydrophobicity expressed as the logarithm of the 
octanol/water partition coefficient as well as the degree of asymmetry of PS 
molecule.
22
 Hydrophobic PSs with two or less negative charges tend to have highest 
intracellular uptake and can diffuse across the plasma membrane. PSs that are less 
hydrophobic tend to be too polar to diffuse across the plasma membrane, and are 
therefore taken up by endocytosis.
22
 PS with anionic substituents, such as 
sulphonate or carboxyl groups, have been reported to localize preferentially in the 
cytoplasm,
32
 whereas PS functionalized with cationic groups traverse the 
mitochondrial membrane and accumulate in the mitochondrion.
33
 Studies have 
shown that microlocalization of the PS with in the cell is more relevant in defining 
PDT efficiency than photochemical reactivity, and PS localizing the mitochondria 
might be more efficient in inducing cell death even if they generate significantly 
lesser amount of ROS compared to PS that induce greater but nonspecific ROS 
generation.
34
 As most of the PSs do not accumulate in cell nuclei, PDT typically has 
very low chances of causing mutations.
3
 PDT induced cell death can occur by 
apoptosis, necrosis or autophagy and does not depend on the phase of the cell 
cycle.
35, 36
 Necrotic cell death, is often triggered when high PS and/or light doses are 
used. It is typically characterized by swelling of cytoplasm, devastation of 
organelles and disruption of the plasma membrane, leading to the release of 





intracellular contents triggering an inflammatory response. While apoptotic cell 
death (programmed cell death) remain the preferred mode of cell death following 
PDT, which is characterized by cell shrinkage, membrane blebbing,  nuclear 
fragmentation, chromatin condensation, chromosomal DNA fragmentation and 
formation of apoptotic bodies that are scavenged by phagocytes in vivo thus 
preventing an inflammatory response. The mode of cell death also depends on the 
microlocalization of PS; for example if the PS is localized in the endoplasmic 
reticulum or mitochondria, the cell death occurs via an apoptotic pathway, while 
their localization in the plasma membrane or lysosomes could delay or block 
apoptosis. This is when the cell takes alternative routes of cell-death, such as the 
autophagic or necrotic pathway.
36
  
B. Vascular damage 
The growth of solid tumors is dependent on their capacity to induce the growth of 
blood vessels (angiogenesis) to supply them with oxygen and nutrients. Generally, 
these abnormal and leaky vessels,
37
 may serve as an additional means for PS 
accumulation in tumor region as it leaks through. Moreover, PSs bound to carrier 
molecules such as albumin, high-density lipoprotein or low-density lipoprotein, 
have high affinity to endothelial cells and tumor microvascular because of the 
presence of high number of specific receptors in their structure.
38
 Activation of PS 
either confined in the blood circulation, localized in endothelial cells or bound to the 
vessel walls, results in damage to the endothelial cells characterized by the loss of 
tight junctions and exposure of vascular basement membranes.
39
 These primary 
changes within the vessel lumen leads to the formation of thrombogenic sites and 
initiates a cascade of reactions such as platelet aggregation, release of vasoactive 
molecules, leukocyte adhesion, increase in vascular permeability and vessel 







 All these effects ultimately lead to partial or complete vascular 
shutdown, blood flow stasis and tissue hemorrhages leading to persistent post-PDT 
tumor hypoxia and long-term tumor control.
41
 
C. Inflammatory and immune response 
While direct tumor cell destruction and vascular damage are mainly responsible for 
initial tumor ablation, anti-tumor specific immune process and enhancement of host 
immune system might play important roles in secondary cytotoxicity which could 
probably aid in the long-term tumor control and/or complete tumor response to 
PDT.
42, 43
 The principal characteristic of the inflammatory process is the release of 
inflammatory mediators that occur from the treated region, which include 
components of the complement system, proteinases, peroxidases, cytokines, growth 
factors and other immuno-regulators.
29, 44
 This in turn stimulates various white 
blood cell components such as neutrophils and macrophages which converge on the 
treated site. Macrophages remove the damaged cancer cells by phagocytosis and 
present proteins from the tumor cells to CD4 helper T lymphocytes, which then 
activate CD8 cytotoxic T lymphocytes. The latter then not only induce necrosis but 
may also induce apoptosis whenever tumor cells are found, leading to long-term 
tumor control.
44
 Thus, PDT has an added advantage of being an immune-stimulatory 
modality, whereas surgery and chemotherapy are immunosuppressive. 
2.2. CURRENT LIMITATIONS OF PHOTODYNAMIC 
THERAPY 
Although, PDT has the potential to be a stand-alone modality for the treatment and 
management of cancers at different stages, currently it is only being used in the 
treatment of superficial and flat lesions, lesions that are accessible through 





endoscopes or as a surgical adjuvant and prophylactic treatment of dysplasias and 
primary lesions. The fundamental problem lies in the inability of PDT to treat solid, 
bulky tumors or deep-seated tumors. Although, some studies have reported success 
in ablating larger and deep-seated lesions with interstitial PDT, this method involves 
insertion of multiple laser fibers directly into the tumor through needles positioned 
under image guidance. Often interstitial PDT requires detailed and individualized 
dosimetry, taking into account spatially resolved light fluence, sensitizer 
concentration and level of tissue oxygenation in order to achieve the full advantages 
of the modality and several groups have successfully addressed these challenges. 
However, as the fibers are positioned into the tumors through needles, it may 
stimulate metastasis along the needle track. Generally, PDT also cannot be used for 
the treatment of advanced disseminated disease because whole body irradiation is 
not possible at least with the currently available technologies. This is partly due to 
the short-comings in the properties of the PSs that are currently available, and partly 
due to the incomplete knowledge about the light dose to be delivered to the tumor 
without affecting the surrounding normal tissue; making it difficult for the clinicians 
to plan and customize the treatment. As PDT is a localized treatment, it essentially 
requires an appropriate dose of light to reach every point in the tumor, for it to be 
effective in eradicating the tumor. Despite advanced Monte Carlo calculations, often 
clinical PDT fails to control residual tumor regrowth and prevent tumor recurrence 
due to under-illumination of the tumors.
45
 In some other cases, over-illumination 
could induce excessive toxicity to adjacent normal tissue, again leading to 
unfavourable response. Unlike radiation therapy, in which the biological response is 
well correlated with the energy absorbed per unit mass of tissue, there is a clear lack 
of a widely accepted definition of PDT light dose. This is a fairly complicated 





problem mainly due to the inherent complexity of the PDT mechanism along with 
lack of suitable techniques to measure it clinically. Yet, a frequently practiced, but a 
rather crude method involves measuring the light fluence, amount of PS and 
oxygen, which are then used to calculate the 
1
O2 yield (explicit dosimetry).
46
 The 
distribution of light is determined by the light source characteristics and the tissue 
optical properties.  However, due to the complexity of tissue architecture and the 
relatively sparse knowledge on tissue optical properties, measurement and 
interpretation of light fluence seems rather challenging. Although the distribution of 
oxygen and PS can be measured by optical spectroscopy, the actual distribution 
could vary due to oxygen consumption during the photodynamic reaction and 
photobleaching, respectively. Hence, a more dynamic modelling of the 
photodynamic process is required. An alternative approach, involves measuring a 
“surrogate” directly associated with biological response (implicit dosimetry).47, 48 
For example, measuring the fluorescence photobleaching of the PS, indirectly 




 A third method - direct dosimetry, relies on the 
direct detection of  
1





 Hence, there is a clear need to develop integrated 
dosimetry systems with light delivery devices as well as multimodality imaging 
(anatomic and diffuse optical tomography) systems with real-time PDT response 
monitoring capabilities, which will enable clinicians to customize and plan PDT 
treatment regimens on a case by case basis.  
It is well known that PDT is an oxygen consuming modality. In other words, the 
anti-tumor effects of PDT will be severely affected in the absence of tissue oxygen. 
Tumor hypoxia can occur either due to the presence of pre-existing hypoxic cells 
that formed as a results of exhaustion of blood supply through the rapid tumor 





growth; or could be induced during PDT through rapid shut down of tumor 
vasculature and fast depletion of local oxygen supply.
39
 Solid tumors with high 
fraction of hypoxic cells are reported to have a poor prognosis to PDT, as hypoxic 
tumor cells in solid tumors are PDT-resistant.
50
 Among the various methods adopted 
to deal with depletion of tissue oxygenation, fractionation of light irradiation into 
controlled light and dark periods,
51-53





 has been extensively studied. These techniques are considered to 
promote reperfusion of tissue oxygen, to compensate for oxygen depletion. 
However, the hypoxia caused by pre-existing hypoxic cells is not affected by these 
techniques.
57
 Besides, both reduction in fluence rate and light fractionation would 
lead to significant increase in time of irradiation required for delivery of specific 
light dose. A third method involves hyperoxygenation therapy, which is found to 
compensate tumor hypoxia in both pre-existing hypoxic cells and those that are 
acutely induced by PDT. When C3H mouse transplanted with mammary carcinoma 
cells MCa were subjected to hyperoxygenation, up to 80% of the tumors showed no 
regrowth after 60 days; whereas in animals that inhaled room air, only 20% did not 
regrow tumors.
57
 Following hyperoxygenation, oxygen was found to reach critical, 
chronic hypoxic cells; and also resulted in better tumor response to PDT due to 
enhanced direct and secondary tumor cell killing effect.
58
 In the molecular level, the 
effect of hypoxia is mediated by hypoxia-inducible factor-1 (HIF-1),
59
 a 
heterodimeric protein, comprising of HIF-1α and HIF-1β subunits; both of which 
are transcription factors. While HIF-1α is cytoplasmic protein responsive to oxygen 
tension, HIF-1β is a nuclear protein that is constitutively expressed and independent 
of oxygen level.
60, 61
 In normoxic cells, HIF-1α is continuously degraded, whereas 
under hypoxic conditions it translocates to the nucleus and heterodimerizes with 





HIF-1β to form active HIF-1 protein. The HIF-1 protein, in turn binds and activates 
various hypoxia responsive genes such as vascular endothelial growth factor 
receptor (VEGF), other angiogenic growth factors, glycolytic enzymes and 
cytokines, as an adaptive response.
59, 62
 This will in turn diminish the therapeutic 
responses by triggering angiogenesis and tumor relapse. Several reports have 
documented the upregulation of HIF-1α and VEGF following PDT as a result of 
vascular damage and photochemical consumption of oxygen.
63-66
 Integrating PDT 
with anti-angiogenic agents, such as Avastin (bevacizumab), Celecoxib, Prinomastat 
(AG-3340), PI3-K inhihtors etc. has clearly demonstrated improved therapeutic 
efficacy in preclinical studies.
63
 However, blocking one or two molecular pathways 
at a time might not be sufficient, as multiple pathways might be involved in the 
proliferation of tumor cells. Therefore, combination therapy that targets multiple 
molecular pathways at the same time could be an attractive therapeutic strategy to 
achieve complete and effective tumor response following PDT.  Apart from these 
difficulties, lack of an ideal PS continues to be a major roadblock restricting the 
clinical utility of PDT. In fact, the search for an ideal PS, with majority of the 
characteristics as summarised in Table 2,
45, 67-69
 still continues even after nearly 4 




 generation PSs have been effective in 
establishing the viability and feasibility of this technique, it has not been optimum in 
terms of effectiveness. This is because PSs developed for PDT seems to have been 
driven chemically, rather than clinically. Focus is needed on solving the problems of 
the PS or modifiying the existing PS to overcome the 3 major problems that might 
be the potential impediment to the clinical application of PDT. The areas that 
require improvement in terms of clinical PDT are: 
 





2.2.1. Tumor selectivity  
 
Due to the generalized photosensitivity associated with most of the earlier 
generation PSs, patients find it difficult to make lifestyle changes and stay indoors 
for a prolonged period, which generally prevent them from consenting to PDT. 
Although some PSs are found to be preferential retained by the tumor cells 
compared to the surrounding healthy tissue, the exact mechanisms that drive this 
process are not fully understood. However, the abnormal physiology of tumors such 
as leaky vasculature, poor lymphatic drainage, abnormal stromal composition, 
decreased pH, increased number of low density lipoprotein receptors are often 
considered to contribute to the selectivity of photosensitizers.
29
 Tumor selectivity 
could be improved by targeted delivery agents that can transport the PS from the site 
of administration to the tumor tissue, leading to the selective accumulation of the PS 
in the tumor. In this way, unfavourable biodistribution can be avoided, improving 
bioavailability of the PS. Consequently, undesirable side effects such as prolonged 
skin photosensitivity and damage to surrounding healthy tissues can be prevented. 
Table 2.1. List of properties required in a clinically successful PS 
Chemical purity for regulatory approval 
Ease of synthesis for commercial and  large-scale production 
No degradation upon light activation to form toxic by-products 
Synthesis method with minimal batch variations 
Chemical stability for transport, storage and  reconstitution 
Solubility in injectable solvents and body’s fluids 
Amphilicity for tissue penetration 
Good selectivity towards tumor tissue 





Clinically useful half-life in tissues 
Rapid elimination from non-target tissue, minimizing skin photosensitivity 
Negligible dark toxicity or systemic toxicity 
High quantum yield of singlet oxygen generation 
High molar extinction coefficient 
Good photostability 
Excitable by near infrared wavelengths (700-1300 nm) 
Multiple administration routes (oral, intravenous, intratumoral or inhalational) 
 
2.2.2. Formulation of photosensitizer  
To a large extent, the efficacy of PDT treatment depends on the photochemical, 
photobiological, and pharmacokinetic properties of the PS. In general most of the 
potent PSs have extended delocalised aromatic π electron system, a characteristic 
property that allows them to absorb light efficiently. At the same time due to π-π 
stacking and hydrophobic interactions, they easily form aggregates in aqueous 
media. On the one hand, hydrophobicity could be a desirable characteristic, as 
solubilization of the PS in the lipid bilayer of the cell membrane has been pointed 
out to be one of the main factors of PS efficacy. On the other hand, this feature leads 
to lack of solubility of PS and contributes to its aggregation in aqueous solution.
70, 71
 
This affects the bioavailability of the dye and hampers its ROS generation ability, 
resulting in sub-optimal PDT treatment outcome. Hydrophobicity also complicates 
preparation of pharmaceutical formulations for parenteral administration.
72, 73
 Again 
this could be solved by formulating the PS in suitable carrier systems that can 
transport PS in its stable monomeric form without altering its spectroscopic and 





the PS in a form that can be readily and selectively internalized by hyper-
proliferative cancer cells, in such a way that it facilitates accurate and convenient 
dosing. At the same time, the carrier should be biodegradable, non-toxic or must not 
release toxic degradation products, or must have no immunogenic properties.   
2.2.3. Tissue penetration depth 
  
Clinical application of PDT for the treatment of solid or deep-seated tumors has 
been hampered by the tissue penetration depth limit of the visible light required by 
most of the conventional PSs for its activation. The typical penetration depth of red 
light in living tissue used for PDT is only 1-3 mm. Hence, even if the surface of the 
target area is illuminated evenly, the energy of the incident light will fall 
dramatically at increasing depths below the surface (or at increasing distances 
within tissue from an interstitial fibre). This is because most tissue chromophores 
(haemoglobin, melanin, fat etc.) absorb light strongly in the visible spectrum.
74
 
Thus, effectiveness of PDT greatly decrease with tissue thickness due to strong 
attenuation of visible light with increasing tissue depth, leading to incomplete 
treatment and tumor relapse.
75
 Apparently, for deep penetration of light into tissues, 
wavelength of the irradiated beam should be in the near-infrared (NIR) region 
between 700–1300 nm, which is known as the “optical window” of biological 
tissue.
76
 Although, some efforts have been made to utilize PSs that absorb in the 
NIR range to improve the tissue penetrability,
77, 78
 the low energy associated with 
the NIR light at the single-photon level does not fulfill the energy requirement to 
efficiently excite PSs for sufficient ROS generation. This underscores the need of an 
efficient energy or light transducers that can absorb light in the NIR region and emit 
in the visible region, which could then activate the PS near-by.  





Different strategies have evolved to overcome the current shortcomings with regard 
to the issues associated with the PS, often by means of a delivery vehicle that 
enables a stable dispersion of PS in aqueous systems. Despite of enhanced drug 
loading and improved tumor uptake over free drugs, the traditional delivery systems 
such as oil-based drug formulations (micellar systems) using low molecular weight 
surfactants such as the  polyoxyethylated castor oils (e.g., polysorbate 80 (Tween-
80), Cremophor- EL etc.) have been reported to elicit acute hypersensitivity 
(anaphylactic) reactions in vivo.
79
 Hence, more stable, biocompatible and tumor 
selective carrier systems are required for efficient delivery of PS.  
2.3. NANOPARTICLES IN PHOTODYNAMIC THERAPY  
Nanoparticles represent an emerging technology in the field of PDT that can 
overcome most of the limitations of classic PS.
80-82
 Typically, they are defined as 
sub-microscopic particles between 1 and 100 nm in size. Nanoparticles are designed 
out of a variety of naturally occurring or synthetic materials and can be engineered 
to carry multiple theranostic agents, in a targeted manner. Depending on the type of 
nanocarrier and the mode of attachment or loading of PS in it, the use of 
nanoparticles in conjunction with PDT could have at least some of the following 
advantages: 
a. They have large surface to volume ratios,83 thus could effectively increasing the 
amount of PS that can be delivered to the target cells.
84
 
b. Nanoparticles may prevent the premature release of PS and potential inactivation 
of the drug by plasma components,
85
 thereby preventing its non-specific 
accumulation in normal tissues, and reducing overall photosensitivity. 





c. They bestow amphilicity to PS, a property that some potentially outstanding PS 
agents lack. This allows nanoparticles to travel unhindered through the blood-stream 
carrying the PS payload and localize in the tumor tissue.
86
 
d. They generally take advantage of the enhanced permeability and retention (EPR) 
effect, a phenomenon caused by the abnormal and leaky tumor neovasculature and 
poor lymphatic drainage of the tumor tissue, facilitating both diffusion of PS carriers 
into and their retention within tumor tissue.
87
  
e. Their surface can be further modified with functional groups or targeting agents 
for altering its biological or physical properties thereby improving the 
biodistribution, pharmacokinetics, cell uptake and targeting abilities.
88, 89
 
f. They can be designed as multi-functional nanoplatforms that carry multiple 
components, for example, imaging agents, chemo-drugs, targeting ligands and 
“cloaking” agents (agents that avoid interference with the immune system).16 
Based on the functions or tasks they perform, nanoparticles in PDT can be broadly 
classified into three: Delivery agents of PSs, PSs by itself and energy transducers of 
PS.  
2.3.1. Delivery agents of photosensitizers   
In 1991, Labib et al. was the first to report the use of cyano-acrylic nanospheres 
(150 to 250 nm) or nanocapsules (10 -380 nm) synthesized by interfacial 
polymerization in an oil-in-water emulsion, encapsulating   phthalocyanine or 
naphthalocyanine derivatives.
90
 The immediate and subsequent studies focussed 
mainly on the development of a sensitizer-delivery system based on such 
biodegradable polymeric nanoparticles. Unlike chemotherapeutic drugs, that needs 
to be released from the carrier to exert its effect on the target cells, the PS need not 
be released from the carrier as long as molecular oxygen and 
1
O2, is able to diffuse 





in and out of the carrier. Due to this fact, two different strategies are often adopted 
to develop nanoparticle carriers for PDT. The first type is biodegradable 
nanoparticles (natural or synthetic polymer-based nanoparticles) carrying the PS 
payload, which could undergo enzymatic or hydrolytic degradation and thereby 
excreted out, minimizing long term accumulation of carriers in biological system. 
This includes the extensively investigated polymeric nanoparticles, liposome and 
dendrimers. The second type comprises of non-biodegradable nanoparticles 
(ceramic- or metal-based nanoparticles),which does not readily degrade in the 
biological system, but quite often offer in-built multiple functionalities due to their 
unique characteristics such as optical properties and tunability in its shape, size and 
porosity etc. that makes them valuable as theranostic agents. Thus, these 
nanoplatforms can be considered as modular system that contains thousands of PS 
molecules, bringing them as a single, non-depleting synergistic unit to the tumor 
cells. This class of nanoparticles include silica, gold and magnetic nanoparticles.   
2.3.2. Nanoparticles as photosensitizers 
Certain nanoscale materials have the ability to generate ROS, due its unique optical 
absorption properties, thus allowing them to behave as PSs by itself. This category 
of nanoparticles include fullerenes, a carbon allotrope with extended π-conjugation, 
due to which they absorb light in the UV or blue regions of electromagnetic 
spectrum to form long-lived triplet state and generate ROS upon illumination, 
allowing them to act as PSs. Other examples include TiO2 and ZnO nanoparticles.  
Under irradiation with UV light with energy greater than the band gap energy of 
these materials (i.e. shorter than 385 nm corresponding to a band gap energy of 3.2 
eV for ZnO and anatase polymorph of TiO2; and shorter than 400 nm corresponding 





to 3.06 eV for rutile polymorph of TiO2, respectively), the electrons in the valence 
band are excited to the conduction band, thus resulting in the formation of 
photoinduced hole-electron pairs. These photoinduced electrons and holes possess 
strong reduction and oxidation properties, that can interact with surrounding O2 and 







 and hydrogen peroxide H2O2,
93
 which react with biological 
molecules, such as lipids, proteins and DNA, and eventually kill cancer cells.
94, 95
 
2.3.3. Nanoparticles as energy transducers 
Certain nanoparticles are not just carriers of PS but they also actively participate in 
energy transfer to the attached PS. Generally, the energy harnessed from light is 
then transferred to the PS associated with it, thereby offering the possibility of 
indirectly activating the PS using light at wavelengths that it normally doesn’t 
absorb. These class of nanoparticles includes X-ray activatable nanoparticles 
(scintillation or luminescence nanoparticle), QDs and two-photon absorbing 
nanoparticles. Upon exposure to ionising radiation such as X-rays, scintillation or 





,with attached porphyrin PS, emits luminescence in the 
visible region  of the spectrum that activates the attached PS; resulting in the 
generation of 
1
O2. QDs on the other hand possess large transition dipole moment, 
making them strong light absorbers, ideal for PDT applications. They can act as 
energy donors and transfer the energy to cell molecules like triplet oxygen, reducing 
equivalents or pigments, potentially inducing generation of ROS leading to cell 
death. Lastly, certain nanoparticles (QD, gold nanorods, conjugated polymeric 
nanoparticles etc.) with two photon absorption cross-section can simultaneously 





absorb two low-energy photons and emit higher energy photons. Despite being a 
highly spatially focussed technique, the requirement of high excitation intensities 
and simultaneous absorption of two coherent NIR photons, reduces the probability 
and thus, efficiency of this approach. Furthermore, it excites a tiny tissue volume 
usually resctricted to a few femtolitres,
96
 often resulting in the need of prolonged 
treatment time; thus limiting its clinical use especially in the treatment of large 
tumors.   
2.4. UPCONVERSION NANOPARTICLES  
UCNs are nanometer-sized materials that convert low energy light to high energy 
light through sequential excitation with multiple photons, via an anti-Stokes 
emission process. Materials exhibiting such photon upconversion are usually 
comprised of host lattices of ceramic materials, embedded with transition metal, 








 Such materials possess 
multiple “real” metastable  electronic states which can principally be used to 
















Figure 2.2 Schematic of energy transfer from UCN phosphor to the attached PS and 
corresponding energy diagram. Reproduced with permission from ref
15
. Copyright 
2015 American Chemical Society. 
In general, the lowest metastable state acts as an energy store and absorbs in the 
NIR region to promote electrons to the first metastable state S1.
98
 A subsequent 
absorption of a second NIR photon promotes the electrons from metastable state S1 
to a much higher metastable state S3. Although, some internal conversion and 
multiphonon relaxation of electrons back from S3 to S2 is possible, the electrons 
return to the ground state by emitting a higher energy photon. Due to the uniqueness 
of this material it has found numerous biological applications by virtue of its tunable 
emission, large anti-Stokes shift, sharp emission bandwidth and  high 
photostability
99
. Recently, it has become increasingly necessary to develop new PSs 
that could be excited at NIR range, to augment the scope and applicability of PDT 
especially for the treatment of solid and large tumors. This is where the UCN 
technology may become useful, because UCNs could act both as delivery agent of 
the PS as well as convert the NIR light to visible light, required for the activation of 
associated PS at much deeper levels in the tissues. While, two-photon excitation 
requires simultaneous absorption of two photons using a virtual state with a lifetime 
scale of femtosecond, upconversion process requires sequential absorption using a 
real metastable state with a lifetime in the order of microseconds. Again, the typical 
power densities for upconversion is usually in the range of 1–103 W/cm2 achievable 






. Hence, the efficiency of upconversion process is several orders of 
magnitude higher than that of two-photon emission. In the following sections, we 
will discuss in detail the different strategies adopted to design a UCN-PS system for 
PDT as well as methods utilized to incorporate multiple functionalities to the 





construct, in order to develop it into a multifunctional theranostic probe for 
simultaneous imaging and therapy for a “see and treat” approach. 
2.4.1. Selection of UCNs and photosensitizers 
The UCN constructs used in PDT generally consists of 3 components namely host, 
dopants and PS. In the following section we will review the selection criteria of 
these 3 components, to generate an efficient UCN based PDT system. 
A. Host  
 
The host material provides a crystalline lattice in which the dopant ions are 
accommodated. Hence, there should be a close match between their lattices, to 


















) can be used as host materials.
100  
The optical properties of the UCNs such as 
emission profile and upconversion efficiency depends on the host, and hence 
selection of host material is critical for efficient PDT. In order to reduce energy 
losses during upconversion via multiphonon relaxation and to maximize radiative 
emission, a low phonon energy lattice is essential.
101, 102
 The crystal structure of the 
host material also influences the crystal field around the dopant ions, resulting in 
different optical properties of the UCNs.
103, 104
 The densely packed hexagonal (β-
phase) materials allows efficient energy transfer between the dopant ions, thus 
exhibiting higher upconversion efficiencies than their loosely packed cubic (α-
phase) counterparts.
105-107
 Thus, Jin et al. induced a cubic to hexagonal phase 
transition of the NaYbF4 crystal by Gd
3+
 ion (24%) doping, thereby enhancing the 
emitted blue upconversion luminescence by 30%.
108
 Another important factor is the 





phase-purity of the host where phase-pure hexagonal host materials with an even 
symmetry, exert uniform crystal-field around its dopant ions and minimize the 
energy loss arising from crystal defects, resulting in enhanced upconversion 
efficiency.
105
 Furthermore, the cationic size of the host also influences the 
upconversion efficiency. Generally a host with a smaller unit-cell volume has 
greater crystal-field strength around its dopant ions, resulting in a higher 
upconversion efficiency.
100
 Despite the vast knowledge available on various host 
materials, NaYF4 has been the host material of choice for UCN constructs in PDT. 
Perhaps, this could be due to the low phonon energies (≈360cm-1),109 smaller size 
and high chemical stability of this fluoride based host material. A few studies have 
also reported the use of other host materials containing Gd
110-112
 (NaGdF4) and Yb 
ions
108
 (NaYbF4), that can also function as MR and CT contrast agents, respectively, 
thus imparting additional imaging capabilities to the UCN construct. Recently, 
Wang et al. synthesized tetragonal-phase LiYF4 hosts with good crystallinity and 
high upconversion quantum yield, and further demonstrate that the upconversion 
efficiency improved with the increase in size due to reduced surface quenching 
effects of the UCNs.
112
 To minimize the surface defects and resultant luminescence 
quenching effects, the UCN core may further be coated with an undoped matrix 





B. Dopants  
The dopant ion is the key player in the process of upconversion that actually 
performs the absorption and emission of photons. The emitted upconversion 
luminescence largely depends on the type and the amount of ions doped. Rare earth 
metals, such as lanthanides, are suitable candidates as dopants, as most of them 





(except La, Ce, Yb and Lu) have appropriately spaced, multiple ladder-like 
metastable states necessary for the phenomenon of upconversion.
98, 102
 This class of 
materials have 4f electrons spatially buried by lower energy 5s and 5p electrons 
resulting in a weak electron-phonon coupling.
114
 Thus, multiphonon relaxation 
becomes less efficient due to sufficiently large gap to the next lower energy level 
and thereby resulting in long-lived excited states (up to 0.1 s).
98
 The UCNs used in 
PDT usually consists of at least two dopant ions namely, sensitizer and activator. 
Such a co-doped system enables to enhance the upconversion efficiency. A 
commonly used sensitizer ion is Yb
3+
 that has a relatively large absorption cross-
section and a single metastable state.
115
 Furthermore, it has a reduced tendency of 
concentration-dependant quenching; hence increasing the concentration of Yb
3+
 





 via an energy transfer process. This efficient energy transfer occurs 




 are perfectly in sync that they do not 
undergo phonon relaxation. Nevertheless, to minimize the loss of the excitation 
energy by cross-relaxation process, the doping level of the activator is kept below 2 
mol%, where as that of the sensitizer is around 20 mol% in such a co-doped 
system.
116, 117
 Such Yb-Er based UCNs usually give a bright green emission (around 
550 nm) and a weaker red emission (around 660 nm), the latter which is often 
utilized to activated the attached PS. In order to obtain a single band, dark red 
emission for a higher FRET efficiency to red light absorbing PS, Mn
2+
 ions could be 
doped into the host matrix.
118, 119
 Another strategy involved increasing the Yb
3+
 ion 
concentration from the usual 20% to 25%. This was shown to enhance the emission 
intensity of red upconversion luminescence (UCL) band at 660 nm to about 2.69 
folds higher than the green UCL band.
120
 Strong multicolour UCL could be obtained 


















) instead of homogeneous co-doping.
121
 Such a system can be 
utilized for efficient energy transfer when PS with a broad absorption bands such a 
fullerenes are used. 
C. Photosensitizers  




 UCNs with a thin 
layer of silica doped with a lipophilic PS merocyanine-540 (MC-540), for PDT.
122
 
Since then many PSs, mostly hydrophobic (zinc phthalocyanine (ZnPC), Chlorin-e6 
(Ce6), hematoporphyrin (HP), tetraphenylporphyrin (TPP), hypocrellin A (HA), 
Pheophorbide-A (PpA), silicon phthalocyanine dihydroxide (SPCD) etc.) have been 
used in combination with UCNs for PDT. A few water soluble PS like MB and RB 
have also been chosen to be used in conjunction with UCN technology. The 
selection of PS to be used in combination with a particular UCN type is critical and 
there must be a very close match between the UCN emission and absorption 
maxima of the PS for efficient upconversion to occur. Another important factor to 
be considered is the method of PS loading and the proximity of PS molecule to the 
UCN core. As PS absorbs the upconverted light emitted by the UCN core, it has to 
be placed in close proximity to the UCN core for efficient generation of ROS for 
PDT. PS can be entrapped, non-covalently adsorbed or chemically / electrostatically 
attached on the UCN surface.  
2.4.2. Surface modification of UCN and attachment of photosensitizer 
Following the synthesis of hydrophobic UCNs that usually involves preparation in 
organic solvents; it is transferred to aqueous phase before further utilizing it for 





biological applications. This is often done by surface coating or modifying the core 
to impart hydrophilicity by addition of stabilizers. The surface chemistry of UCN 
ultimately determines its solubility, stability, biocompatibility, pharmacokinetic 
properties and capability of anchoring different functional groups, targeting ligands 
as well as PS or other drugs. Till date the UCN surface chemistry has been 
improved by either polyethyleneimine (PEI),
123
















PEI coating has the advantage of being a one-step “one pot” hydrothermal process, 
whereby amine functionalized UCNs are synthesized that can be utilized for  
covalent conjugation of other ligands via 1-ethyl-3(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC) /N-hydroxysulpho 
succinimide (NHS) reactions.
17
 However, PEI is an inherently toxic polymer. 
PEGylation, a very often used technique to improve water dispersibility of 
nanoparticle and shield it from being removed from the circulation by the immune 
cells, has been frequently used to modify UCNs.
127, 128
 But one drawback of 
PEGylation is that it could be a multistep time consuming process. Several PEG 
block copolymers such as PEG-b-PCL
124
 and PEG-b–PLA133 block copolymer have 
also been employed as polymeric stabilizer. The assembly process is via flash 
nanoprecipitation technique, where all the constituents including the UCNs and the 
hydrophobic PS like TPP are dissolved or suspended in the organic phase, which is 
then mixed at high speed against a large volume of water, yielding the composite 
nanoparticle.
124, 133
 This technique requires thorough optimization of the constituents 
as inadequate PEG coating will lead to UCN aggregation in physiological solution; 





whereas higher amount of the polymer will lead to formation of void polymeric 
micelles. Furthermore, higher polymer concentration may lead to attenuation of the 
UCL. Wang et al. used a PEG-grafted poly (maleic anhydride-alt-1-octadecene) 
(C18PMH-PEG) amphiphilic polymer to transfer hydrophobic UCNs to aqueous 
phase, yielding PEGylated UCNs with excellent water solubility.
125
 Recently, an 
outer layer of charge-reversible polymer containing dimethylmaleic acid (DMMA) 
groups and PEG chains were utilized to coat the UCNs via a layer-by-layer (LbL) 
technique involving electrostatic interactions in which the outer PEG coated surface 
is negatively charged at normal physiological pH 7.4 and switch to a positively 
charged naked surface at pH 6.8, demonstrating enhanced tumor-homing 
properties.
119
 In a different approach polymeric liposomes consisting of amphiphilic 
polymers of octadecyl-quaternized lysine modified chitosan (OQLCS) 
functionalized with FA and transactivating-transduction protein (TAT)  were 
utilized, which displayed multiple functions as carriers of UCN and PS, as well as 
tumor targeting agents while imparting good water dispersibility.
134
 Among 
biodegradable polymers, wrapping of UCNs with positively charged, hydrophilic, 
and non-antigenic polymer chitosan has shown to be very effective in accumulating 
within the negatively charged tumor cell membrane due to electrostatic 
interactions.
127-129
 The amphiphilic nature of chitosan was exploited to harbour 
hydrophobic PSs like Ce6 and PpA, and at the same time they can carry various 
functional groups on the outside for further chemical modifications with other 
targeting moieties. 
Surface coating of UCNs with a thin layer of silica was found to be stable as silica 
was resistant to enzymatic or pH dependant degradation.
122
 Silica encapsulation 
(Figure 2.3A) involves incorporation of PS in the silica shell, and is a widely 





employed strategy to load PS to UCN.
117, 122, 130-132
 The porosity / pore size of the 
silica layer can be tuned such that it can host a wide range of differently sized PS 
molecules. The presence of pores/ channels is advantageous to such PDT system, 
which requires the oxygen and ROS to diffuse in and out of the construct to promote 
effective cell killing during PDT. The silica coating first described by Zhang et al. 
122
 lacked this permeability, which could have resulted in decreased PDT efficiency. 
Secondly, surface modification by silica coating often leads to particle 

















Figure 2.3 Schematic illustrations of various PS loading strategies in UCNs, 
Reproduced with permission from ref 
15
 Copyright 2015 American Chemical 
Society. 





Mesoporous silica coating of UCN was found to have superior properties than a 
simple amorphous silica coating, such as better solubility and greater efficiency of 
energy transfer, due to its porous nature.
130-132 
Furthermore, it had large surface area 
that could be tailored to carry multiple PS and additional tumor homing motifs for 
targeted PDT. It is worth noting that this technique is more suitable for loading 
cationic hydrophilic PSs due to the negatively charged nature of the silica matrix. 
However, with hydrophilic PSs, there is a high chance of its leakage out of the 
uncapped pores during systemic circulation. This could probably lead to 
phototoxicity and reduction in the amount of PS ultimately reaching the tumor. 
Despite of its merits, this method is a slow multistep process and the amount of PS 
loaded was highly variable from batch to batch. Thus accurate dosing of the PS 
becomes a problem, when employing this technique. 
Chemical linkage or covalent conjugation of PS (Figure 2.3B) to the surface of 
UCN offers superior stability, as the PS is chemically attached to UCN surface, and 
thus could prevent leakage of PS during systemic circulation.
110, 111, 121, 128, 135, 136
 
This method is widely adopted to trap PS to the UCNs as unlike chemotherapy 
drugs, PS need not be released from the UCN construct to exert its cell killing 
effect. Often PS with a free carboxyl group (-COOH) was utilized in this method 
and was attached to an amino (-NH2) functionalized UCN surface. Qiao et al. 
utilised a slightly different method and grafted HP and SPCD on mesoporous silica 
shell through the hydrolysis and condensation of the silanol groups to achieve stable 
loading of the PS in the pores of silica layer.
111
  In addition to achieving stable 
binding of the PS, this method also allows attachment of additional functional 
moieties like targeting ligands to the –NH2 group on the UCN surface, enabling 
targeted delivery to cancer cells expressing the receptors to these ligands. PS 





loading by covalent linkage further offers the advantage of having a short distance 
between the UCN surface and attached PS molecule, thus maximizing the energy 
transfer efficiency between the UCN core and attached PS. However, despite of the 
stable binding ability, the PS payload achieved by covalent linkage was 
comparatively low, limiting the application of such constructs to in vitro studies. 
Physical adsorption (Figure 2.3C) of PS to the UCN surface utilizes non-covalent 
hydrophobic forces. Usually a hydrophobic PS is adsorbed on to the hydrophobic 
layer on the UCN layer. While transferring the bare UCNs capped with a 
hydrophobic layer (such as an oleic layer) into an aqueous phase by wrapping it 






 α-cyclodextrin118 or 
Tween-20,
108
 a thin hydrophobic layer is created beneath the polymer on the surface 
of the UCN. The hydrophobic PS attach to this thin hydrophobic layer sandwiched 
between the UCN and polymer, via hydrophobic forces. This also allowed close 
binding of the PS to the UCN core, and hence a better energy transfer from the UCN 
core to the adsorbed PS was achieved. In addition to the superior energy transfer, 
this method of PS loading was found to attain the highest PS payload amongst the 
different strategies proposed till date. However, a higher PS loading does not always 
guarantee a better PDT efficacy, as at high concentrations the PS molecules could 
aggregate or form dimers
137-139
 which could inversely affect its performance as PDT 
agents. Therefore, it becomes essential to determine the optimal amount PS that can 
be loaded on to the UCNs to achieve maximum PDT effect while fabricating UCNs 
for PDT. 
Although not very common, electrostatic interactions between the counter charged 
UCN surface and PS were also utilized to load PS close to the UCN surface (Figure 
2.3D). Wang et al. synthesized oleate ligand free UCN surface by acid treatment, 





which not only imparted hydrophilicity and biocompatibility, but also exposed the 
positively charged Ln
3+
 ions on the surface of the UCNs.
140
 These bare Ln
3+
 ions 
were then utilized for attaching electronegative groups of monosubstituted-β 
carboxyphthalocyanine zinc (ZnPC-COOH) via electrostatic interactions. Such 
interactions allow very close binding of the PS to the UCN surface owing to the 
short distance between the donor and acceptor, resulting in a very efficient energy 
transfer (96.3%, the highest to date), although the drug loading was relatively low 
(1.1 wt%).  
It is to be noted that none of the above mentioned strategies guarantee controllable 
loading or attachment of PS to the UCN, often compromising the repeatability of 
PDT results. It is essential to design robust UCN constructs with controllable and 
stable PS loading, for optimal and reproducible therapeutic efficiency. Studies are 
still underway to optimise the surface properties of UCNs for efficient and stable PS 
loading to achieve maximum 
1
O2 output. 
2.4.3. Application of UCNs in PDT  
This section summarizes the recent developments in the applications of UCNs for 
PDT. A wide range of UCN based nanoconstructs were in developed in less than a 
decade with varying degree of photosensitizer loading and PDT efficiency as 
summarized in Table 2.2. 
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on UCN surface/  
1:15000-S:UCN  
FA 
In vitro PDT/ 
UCL imaging 
















Moderate PS loading (33.33 

















(0.1 wt %) 
- 
In vitro PDT/ 
UCL imaging 
Improved ROS  diffusion but 

















(0.1 wt %) 
- 
In vitro PDT/ 
UCL imaging 
Mechanistic insights into UCN-


















1:9.93-PS:UCN     
(10 wt %) 
- In vivo PDT 
High PS loading; use of high 
laser dose of 134W/cm2 for 15-



















In vitro and in 
vivo PDT / 
UCL imaging 
High PS loading; first in vivo 
study,70% animals show 
disease free survival up to 60 
















on chitosan layer 
(10.8 wt%)  
- 
In vitro and in 
vivo PDT / 
UCL imaging 
High PS loading; in vivo tumor 
inhibition ratio of 76% achieved 
127 
Table 2.2. A list various UCN nanoconstruct synthesized till date for PDT applications.
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Covalent attachment    
(3.3 wt%) 
- 
In vitro PDT /  
UCL / MRI 
First study to report 
multifunctional use and stable 


















surface/             
100:1-PS:UCN 
FA 
In vitro PDT /  
UCL imaging/ 
High PS loading, but PS 
dimerization occurred at high 
concentration; 1000 µg ml -1 
FA-UCN-RB at 980 nm killed 
90% cells using high light dose  




















MB/UCN   
- 
In vitro PDT /  
MRI contrast 
agent 
Minimal PS leakage due to 
electrostatic attraction; 
demonstrated MRI due to the 





















In vitro PDT /  
UCL imaging 
Stable but low PS loading (0.53 
wt%); exhibited selective 
killing of tumor cells. 100ug/ml 

















to mesoporous silica 
shell 
- 
In vitro PDT /  
UCL / MRI 
Multifunctional; stable PS 
loading; high power density of 
2.5 W/cm2 (1500 J/cm2) utilized 
















In vitro PDT 
Demonstrated targeted cell 
destruction via photocatalysis of 
attached  thioglycolic acid 





















In vitro and in 
vivo PDT /  
UCL / MRI   
Stable and high binding of PS 
achieved; exhibited high 
circulation half-life, improved 
survival and 6 fold decrease in 
tumor size in vivo  
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0.25 wt% MC-540, 
0.34 wt%  ZnPc 
FA 
In vitro and 
vivo PDT / 
UCL imaging 
First report using 2 different PS 
co-doped in a single UCN; low 
PS loading (<0.6 wt %). First 
report showing actively targeted 
PDT in vivo; exhibited 



















on chitosan layer/  
(10 wt%) 
FA 
In vitro and in 
vivo PDT /  
UCL imaging 
High PS loading; tumor 
inhibition ratio of up to 50% 
achieved with irradiation at 980 



















on UCN/ 9.3 wt% 
Ce6, 9.54 wt% 
ZnPC  4.13 wt% 
MB 
- 




First demonstration of Mn2+-
doped UCNs for single band, 
dark red emission for higher 
FRET. Combination therapy 














interaction/             
3.4 - 11 % (w/w) 
(optimal 7.7%) 
- 
In vitro and in 
vivo PDT /  
UCL imaging/ 
MRI 
First report demonstrating pH-
responsive PDT using charge-
reversible UCNs; dual-modal 
imaging-guided NIR-PDT; high 





























conjugation/     
 (10.5 wt%) 
FA 
In vitro PDT /  
UCL imaging 
First to employ separately 
doped core and shell UCNs to 






























AlPcS4 Physical adsorption  - 
In vitro PDT/  
UCL/ MRI 






















In vitro PDT /  
UCL imaging 
First to use TAT peptides for 














/ (5.47 wt%) 
- 
In vitro PDT/  
UCL/ MRI/ CT 
Multifunctional agent; 
increased Gd3+ ions (24%) in 























In vitro PDT /  
UCL imaging 
PS is loaded on G4-aptamer 
which is conjugated to UCN; 
exhibits efficient FRET and 

















In vitro PDT/  
UCL/ MR 
imaging 
First report demonstrating 




























In vitro PDT/  
UCL imaging 
TAT-OQLCS and FAOQLCS 
were mixed with OQLCS to 
form the lipid micelle which 
was coated on the surface of 
UCNs, for enhanced cell uptake 

















(optimal 6 wt%) 
FA 
In vitro and in 
vivo PDT /  
UCL imaging 
Yb3+ doping was increased to 
25% to enhance 660 nm 
upconversion emission, led to 
high FRET  efficiency 80.9%; 
moderate PS loading; low 
radiation dose (351 J/cm2) 






































UCN and PS surface stabilizers 
itself used for cancer cell 
targeting, no additional steps 
required to conjugate targeting 
moiety; two-colour 

















(9.3 wt%)  
RGD 
In vitro PDT /  
UCL imaging 
First report using amphiphilic 




















In vitro PDT /  
UCL imaging/ 
Gene therapy 
First study combining PDT and 
gene therapy (siRNA targeting 
Plk1 mRNA). Better loading of 
Ce6 due to electrostatic 
interaction of the PS with the 
cationic PEI, in addition to the 
hydrophobic interactions; 





























In vitro and in 
vivo PDT /  
UCL imaging 
First report using LiYF4 as the 
host material; higher 
upconversion quantum yield 
(0.6%) compared to NaYF4; 
stable attachment of PS directly 
on UCN surface;  low drug 
loading but negligible release; 























In vitro PDT /  
UCL imaging 
Amphiphilic polymeric lipid 
grafted dextran was used to 












TEM- Transmission electron microscopy, DLS – Dynamic light scattering, FA – Folic acid, AlC4Pc - tetra-substituted carboxyl aluminum phthalocyanine, 
c(RGDyK) - cyclic RGD peptide, MRI – Magnetic resonance imaging, CT - Computed tomography, CTAB - Cetyl trimethylammonium bromide,  α-CD - α-
Cyclodextrin,  PAA - Polyacrylic acid, DOX – Doxorubicin, PAAm - Poly(allylamine), APBA – 3-aminophenyl-boronic acid, HYA- Hyaluronic acid, 
PMAO- poly (maleic anhydride-alt-1-octadecene), DOPE - dioleoyl l-α-phosphatidylethanolamine, PVP-Polyvinylpyrrolidone, CPE - conjugated 





















and PDT  
Utilized self-assembling CPEs-
drug (DOX) conjugates 
encapsulating UCNs for NIR 
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First study demonstrating 
bimodal imaging and 
synergistic effect of trimodal 





















In vitro and in 
vivo PDT 
Increase in Yb 3+doping to 80% 
in cubic phase UCN crystals 
increased the red-emission by 
15-folds compared to the 
hexagonal phased counterparts; 
highest  absolute quantum yield  











A. In vitro PDT  




 UCNs coated with a thin 
layer of silica, as delivery agents of hydrophobic PS MC-540.
122
 The UCN construct 
was also functionalized with a tumor targeting anti-MUC1/episialin antibody and thus 
demonstrated superior targeting towards MCF-7/AZ breast cancer cells.
  
Following in 
vitro PDT, cells displayed shrinkage and membrane damage. However, the non-
porous silica layer could have relatively hindered the ROS producing ability of this 
nanoconstruct as PS was physically encapsulated with in the silica layer. Since the 
success of PDT is attributed to the efficient production and diffusion of the ROS, it is 
important to modify the UCN in such a way that the ROS diffused out of the 
nanoparticles effectively. 
Chatterjee et al. demonstrated the ability of PEI-modified NaYF4 nanocrystals loaded 
with ZnPC, for the destruction of HT29 human colonic adenocarcinoma cells.
123
 In 
this work, high PS encapsulation efficiency of 97% was reported by physical 
adsorption of non-polar ZnPC on to the highly non-polar UCN core. Furthermore, the 
effectiveness of these FA conjugated nanoconstructs in selective targeting and 
destruction of folate receptor (FR) overexpressing HT29 cells was demonstrated in 
vitro. However, in addition to being toxic, the positively charged PEI could stick to 
any cells in vivo regardless of whether it over-expresses FR. It was then assumed that 
perhaps the addition of a biocompatible PEG coat could decrease the toxicity and 
increase the availability of the UCNs in circulation. A higher 
1
O2 production using 
TPP co-encapsulated PEGylated UCNs was demonstrated by Ungun et al.
124
 Here, the 
PEG coating improved the biocompatibility and also allowed penetration of oxygen 
and diffusion of the 
1
O2 produced. Yet, this study did not validate the PDT efficacy of 
these particles in cells as well as in vivo models. To enhance the diffusion of 





generated ROS, our group synthesised UCN construct modified with a mesoporous 
silica shell onto which the PS (ZnPC) was loaded by physical entrapment.
132
 In vitro 
studies on MB49-PSA cells demonstrated about 70% cell death following NIR 
irradiation. In a subsequent paper the molecular effects of PDT induced cell death was 
also discussed and the major mode of cell death was confirmed to be apoptosis.
130
 
Despite of its advantages, it is to be noted that PS loading in such a system is highly 
variable, leading to batch variations due to difference in pore size that cannot be 
controlled. Secondly, due to the presence of a double layer of silica (first layer of non-
porous silica to reduce surface defects of UCN core, and a second mesoporous layer), 
the size of the particles were relatively large (∼90 nm). Furthermore, there is an 
increased chance of particle growth and aggregation due to the higher diffusion rate at 
higher temperatures during calcination process. Another group also employed a 
similar technique to load HP and SPCD onto the mesoporous silica coating, over a 
CaF2 shell coated UCN.
111
 However, this time the PS was covalently grafted on the 
surface of the UCN. The CaF2 shell reduced surface defects of the core improving the 
upconversion luminescence as well as its biocompatibility. Nevertheless, a strong 
irradiation dose (2.5 W/cm
2
) was required to transfer energy from UCN core to the PS 
molecule, to generate enough 
1
O2 in order to promote efficient cell death. It was also 
found that the first 5 min of irradiation generated most of the 
1
O2 due to the 
consumption of dissolved oxygen in the medium. Hence, the cell-death is limited by 
the amount of oxygen present in the media, and the linearity of the relationship 
between cell-viability and nanoparticle concentration or light-dose also depends on 
the time-scale up to when the dissolved oxygen in the media is consumed.  Apart from 
its application in PDT, the construct also exhibited potential for fluorescence and 





magnetic resonance imaging (MRI) due to the presence of gadolinium ion (Gd
3+
) in 













Figure 2.4 (A) Schematic diagram of synthesis of chitosan modified ZnPC loaded 
UCN. (B) TEM images of ZnPC loaded Nanoparticles (C) Viability of MCF-7 cells 
incubated with void and ZnPc-loaded UCNs for different irradiation time intervals (0, 
5, 10 and 15 min). Reproduced from ref 
127
 with permission of The Royal Society of 
Chemistry. 
 
Recently, chitosan wrapped UCN loaded with PS showed promising results as PDT 
agents.
127, 128
 Cui et al. reported loading of ZnPC via hydrophobic interactions 
achieving one of the highest PS payload of 10.8% (Figure 2.4).
127
 In vitro PDT using 
chitosan wrapped ZnPC loaded UCN, killed about 80% of MCF-7 breast cancer cells, 
while cells incubated with void-chitosan wrapped UCN demonstrated more than 80% 
viability following NIR irradiation. The mode of cell death was predominantly found 
to be via apoptosis. In a different study, Zhou et al. demonstrated PS loading via 
chemical linkage of PS - Pyropheophorbide A to the amino group of chitosan that was 
also tagged with a cyclic RGD peptide - c(RGDyK).
128
  Such a covalent conjugation 





rendered stable PS loading to the UCN as well as retained the spectroscopic and 
functional properties of the PS. The presence of c(RGDyK) demonstrated targeting 
abilities to integrin αVβ3 expressing U87-MG glioblastoma cancer cells  and selective 
destruction of U87-MG cells upon NIR irradiation. In vitro PDT was performed using 
980 nm at 0.5 W/cm
2
 and different radiation doses from 75 to 300 J/cm
2
. It was 
shown that for optimal PDT cell killing effect, a concentration of 200 ug/ml and 
photoirradiation energy greater than 225 J/cm
2
 was necessary. 
Thereafter, Xu et al. reported synthesis of anti-cAngptl4 antibody conjugated 
nanocomposite consisting of thioglycolic acid functionalized nitrogen-doped-titanium 







 Upon NIR irradiation the UCN core emitted visible light which excited 
the attached photocatalyst N-doped TiO2 to generate highly reactive electron-hole 
pair. It further reacts with water and oxygen to produce ROS leading to cancer cell 
death. However, the synthesized nanocomposites did not seem to have a uniform size, 
as controlling the number of TiO2 nanoparticles attaching to the UCN surface is not 
practically possible. The study only demonstrated in vitro NIR-triggered drug release 
and targeted cancer cell killing of malignant A-5RT3 cells, perhaps due to the non-
uniform size of the nanoconstruct that might have compromised the translatability of 
PDT results in vivo. A few other groups also reported synthesis of multifunctional 
theranostic UCNs for both imaging and therapy. Zhao et al. synthesised small (∼38 
nm), size-controllable silica coated UCN with PS - tetra substituted carboxy 
aluminium phthalocyanine (AlC4Pc) covalently linked to the silica shell.
110
 This 
allowed close proximity of the PS to UCN core, although demonstrating a PDT 
efficiency where only about 40% of the cells treated with 100 ug/ml, where killed 
after 5 min of irradiation using a 980 nm laser at a power density of 0.5 W/cm
2
. The 







 ions in the matrix further facilitated both T1- and T2-weighted MRI. 
Chen et al. demonstrated water in oil strategy to trap positively charged hydrophilic 
PS MB into silica shell.
117
 No leakage of MB was detected from the UCN construct 
due to strong electrostatic attraction between positively charged MB and silica shell. 
The construct also had potential for MRI due to the presence of Gd
3+













Figure 2.5 (A) Schematic illustration of α-CD surface functionalization procedure 
and the preparation of PS@UCN complexes and (B) 980-nm NIR induced PDT using 
PS@UCNs. SEM image of (C) unmodified UCNs and (D) α-CD-UCNs. (D) Room 
temperature upconversion emission of oleic acid capped (OA-UCNs) dispersed in 
cyclohexane (1 mg/mL, solid line) and α-CD-UCNs dispersed in water (1 mg/mL, 
dashed line), respectively (inset: their corresponding luminescent photographs under 
980-nm NIR excitation, power density: 0.5 W/cm
2
). (D) Cell viability of A-549 cells 
treated with Ce6/DOX@UCN complex (980-nm laser density: 1 W/cm
2
; Irradiation 
time: 5 min). Error bars were based on triplicated samples. Reprinted with permission 
from 
118
. Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. 
 
It is to be noted that majority of the hexagonal-phase NaYF4:Yb/Er UCNs developed 
for PDT typically emitted a strong green and a weak red fluorescence. However, most 
of the PSs that were associated with such β–NaYF4:Yb/Er absorbed at the red region 





of the spectrum. Apparently, the dominant green emission has no contribution in the 
excitation of PS, which resulted in relative low efficiency in the FRET process. 
Recognizing this fact, Tian and co-workers synthesised a strong dark red-light 
emitting α-cyclodextrin (α-CD) modified manganese ions (Mn2+) doped UCNs 
(Figure 2.5).
118
 The cube shaped UCNs with a single-band red UCL emission peaked 
at 650 ∼ 670 nm, were further loaded with lipophilic PSs - Ce6 or ZnPc and 
hydrophilic MB. As the loading of the PS on the UCNs employed hydrophobic 
interactions, the more hydrophobic PSs (Ce6 and ZnPC) were more efficiently loaded 
compared to MB. In vitro PDT with Mn
2+
-doped UCNs co-loaded with a 
chemotherapeutic agent DOX and Ce6, induced significantly greater cell death 
compared to treatment using a single modality. Similarly, Wang et al. also utilized 





-doped UCN were further made water soluble, by replacing the 
hydrophobic surface ligands through a ligand exchange reaction using PAA. They, 
then utilized LbL self-assembly approach to load the negatively charged Ce6 
conjugated polymer (Poly(allylamine hydrochloride (PAH)-Ce6-succinic anhydride 
(SA)) (Figure 2.6). The UCN/PAA was first mixed with oppositely charged PAH to 
form positively charged UCN/PAA/PAH, on which the negatively charged PAH-Ce6-
SA was attached via electrostatic interaction, to load up to 3 layers of the Ce6 
conjugated polymer. This technique resulted in achieving a very high loading of PS 
(up to 11.0 wt % for 3 layered Ce6 polymer-UCN composites), however 7.7 wt% 
(two-layer) was found to be optimal. The tight coupling between PS molecules and 
UCNs, prevented Ce6 leakage from UCNs up to 2 d under physiological conditions. 
To further impart UCNs with pH-responsive charge reversibility, PAH was co-grafted 
with PEG and DMMA to obtain negatively charged PAH-DMMA-PEG, which was 





then used to coat UCNs by electrostatic interactions. On incubating the pH-sensitive 
UCNs with HeLa cells grown at pH 6.8 and 7.4, significantly greater UCL signals 
were obtained from HeLa cell at pH 6.8, indicating significantly enhanced cellular 
internalization at slightly acidic pH due to their charge conversion from negative to 
positive. This also led to a correspondingly high cell death following irradiation at 
980 nm light. In addition to the enhanced therapeutic effect, the Mn
2+
 doped 






















Figure 2.6 (A) Schematic showing the fabrication process of pH-sensitive charge-
reversible UCNs with multi-layers of Ce6 loading. (B) TEM micrograph of Mn
2+
-
doped UCNs; inset: high-resolution TEM image of a UCN. (C) UCL emission 
spectrum of Mn
2+
-doped UCNs under  980 nm laser excitation; inset: photo of a UCN 
solution under ambient light and under 980 nm laser excitation. (D) T1-weighted MR 
images of UCN solutions at different concentrations. (E) T1 relaxation rates (r1) of 
UCN solutions at different Mn
2+
 concentrations. (F) Cell viability of HeLa cells after 
various treatments indicated with and without the 980 nm laser irradiation as 
evaluated by the standard MTT assay. Error bars are based on four parallel samples. 
Reprinted with permission from 
119
. Copyright © 2013 WILEY-VCH Verlag GmbH 
& Co. KGaA, Weinheim. 
 
 





 In order to develop a T2-weighted MRI contrast agent, Zeng et al. reported the 
synthesis of multifunctional MRI/UCL/PDT nanocomplexes composed of 10 nm 
Fe3O4 core, coated with a tetragonal NaYF4:Yb/Er shell loaded with AlPcS4.
150
 The 
nanoconstruct exhibited good therapeutic performance which resulted in nearly 70% 
MCF-7 cell death following irradiation at 980 nm at a power density of 0.02 W/cm
2
 
for 5 min. A different approach was adopted by Liu and co-workers where they 




 instead of 
homogeneous co-doping, to achieve strong simultaneous multicolour upconversion 
luminescence around 450, 475, 540, 650 and 808 nm upon 980 nm NIR excitation.
121
 
They then used monomalonic fullerenes (C60MA) covalently conjugated to the core-
shell structured UCNs as energy acceptors and ROS generating agents. The 
nanocomposites were additionally modified with PEG-succinimidyl carbonate, to 
improve biocompatibility and stability in biological solvents and further conjugated 
with FA to bestow targeting abilities to folate receptor expressing HeLa cells. A dose-
dependent decline in the viability of HeLa cells upon NIR irradiation at intensity of 
1.37 W/cm
2
 confirmed the capabilities of this multifunctional UCN–fullerene 
nanoplatform in NIR imaging guided cancer therapy. Recently, Chen and co-workers 
demonstrated for the first time synergistic PDT/PTT photokilling effects of BSA 
modified NaGdY4-based UCNs.
154
 Here, two types of dye molecules, including a PS - 
RB and an NIR-absorbing dye -IR825, were simultaneously loaded into the BSA 
layer via hydrophobic interaction, so that under 980-nm excitation RB absorbs green 
light emitted from UCNs and induced photodynamic cancer cell death, while IR825 
under 808-nm laser irradiation offers a strong photothermal effect. Although the PTT 
effect (808 nm excitation, 0.5 W/cm
2
 for 5 min) caused by the hyperthermia induced 
by IR825 loaded nanocomposites was slightly more effective in killing 4TI cells in 





vitro than the PDT effect (980 nm excitation, 0.4 W/cm
2
 for 10 min), the combination 
of both therapies induced a synergistic effect resulting in significantly greater cell 
death compared to the mono-therapy.  
 
B. In vivo PDT  
One of the biggest challenge in the application of UCNs for PDT in vivo has been the 
delivery of the particles such that it selectively accumulates in the tumor, preventing 
systemic toxicity. Most of the earlier studies reported delivery of UCNs via 
intratumoral injections. This route of administration was chosen as the particles 
synthesised initially were large and aggregated in the physiological milieu. 
Furthermore, it had limited specificity and selectivity to the tumor that most of them 
accumulated in the organs of the MPS leading to toxicity. Thus, to obtain higher PDT 
efficiency and fewer side effects, UCNs were administered intratumorally. The 
various in vivo studies and the parameters used in PDT are summarised in Table 2.3.  
Wang et al. demonstrated in vivo PDT in murine breast tumor using Ce6 loaded 
PEGylated UCNs (Ce6-PEG-UCN) (Figure 2.7).
125
 PEGylation improved the stability 
as well as decreased the toxicity of Ce6-PEG-UCN, where the hydrophobic Ce6 
molecule was simply adsorbed onto the oleic layer of the PEGylated UCN, to achieve 
a very close binding of Ce6 on the UCN. This strategy had an added advantage of 
offering a higher resonance energy transfer between the photon donor and acceptor 
molecule, by virtue of its adjacency. The size of this particle (∼30 nm) was the 
smallest compared to all the previously reported UCNs for PDT. Yet, particles were 
administered intratumorally, rather than intravenously into the animals. Furthermore, 
there was an enhanced retention of the UCNs in the organs such as spleen and the 
liver 15 d post injection, indicating apparent translocation of the UCNs from the 
injected site via the lymphatic circulation. 



























Fluence rate –0.5 W/cm2 
Irradiation time –30 min (1 min 
interval after each min irradiation) 









- ZnPC 33 mg/kg Intratumoral 
Wavelength –980nm 
DLI- 3h, 24h (PDT repeated) 
Fluence rate  –0.4 W/cm2 
Irradiation time –15 min  
(1 min interval after 2 min 
irradiation) 












DLI – 1h 
Fluence rate – ~0.6 W/cm2 
Irradiation time – 5 min (10 s  
interval after every 5 s) 




















DLI- 4 h 
Fluence rate  –0.415 W/cm2 
Irradiation time –1-2 h 









FA ZnPC 50 mg/kg Intravenous 
Wavelength –980nm 
DLI- 24 h 
Fluence rate  –0.4 W/cm2 
Irradiation time –30 min 

















DLI- 24 h 
Fluence rate  –0.5 W/cm2 
Irradiation time –30 min (1 min 
interval after every min) 













Wavelength –980nm nm and 808-
nm 
Fluence rate  – At 808 nm, 0.5  
W/cm2 for 5 min continuous and at 
980 nm 0.4  W/cm2 for 30 min  (1 
min interval for every 2-3 min) 













≈50 mg/kg Intratumoral 
Wavelength – 980 nm 
Fluence rate  –0.39 W/cm2  
Irradiation time -15 min 
(Fractionated with 3 min interval 
after every 3 min irradiation) 





































Wavelength – 980 nm 
DLI – 12 h 
Fluence rate  –0.5 W/cm2  
Irradiation time -20 min 
(Fractionated, 5 min interval after 
every 1 min) 

















Wavelength – 980 nm 
Fluence rate  –1.5 W/cm2 
(intratumoral) and 2.5 W/cm2 
(intravenous) 
Irradiation time -30 min 
(Fractionated, 1 min interval after 
every 1 min) 











Wavelength – 980 nm 
Fluence rate  –0.5 W/cm2  
Irradiation time -40 min 
(Fractionated, 1 min interval after 
every 1 min) 









Figure 2.7. (A)  Schematic drawing of NIR-induced PDT using UCN-Ce6. (B) TEM 
image of PEGylated UCNs. (C) Growth of 4T1 tumors on different groups of mice 
after various treatments indicated; relative tumor volumes were normalized to their 
initial size (n=10). (D) The survival curves of mice in 60 d after various treatments 
indicated; UCN-Ce6 PDT treatment drastically prolonged survival time of mice. (E) 
Schematic of in vivo PDT experiment where tumors were hidden below a slice of pork 
tissue (8 mm) during light treatment. (F) The growth of 4T1 tumors on different 
groups of mice after various treatments indicated. The relative tumor volumes were 
normalized to their initial sizes. (n = 10) *p < 0.05. Error bars represent standard 
errors of the mean. Reprinted with permission from ref 
125
. Copyright © 2011, 
Elsevier. 
 
In vivo PDT using 980nm laser irradiated at a power density of 0.5 W/cm
2
 for 30 min 
(1 min interval after each min of irradiation) appeared quite promising with 70% of 
the tumors disappearing without regrowth in 2 weeks, exhibiting longer morbidity 
free survival. It was clearly shown that NIR light penetrated the 8 mm pork tissue 
placed over the tumor, triggering Ce6-UCN in the tumor leading to significant 
reduction in tumor growth rate. However, direct application of NIR light to the tumor 
did not generate as much 
1
O2 as that generated by free-Ce6 triggered by visible 665 
nm light, thus suggesting that NIR-induced PDT using UCN has potential to be 
developed for the ablation of solid, deep seated tumors. Cui et al. reported in vivo 
PDT using chitosan modified UCN loaded with ZnPC.
127
 PDT at 980 nm NIR laser 
irradiation at 0.4 W/cm
2
 for 15 min, following intratumoral administration of these 
particles produced significant reduction in tumor via necrotic cell death, within 14 d 
compared to the untreated group. In addition, there was no sign of adverse side-effects 
and lethality among PDT treated animals due to the presence of a non-toxic and 
biocompatible chitosan coat. The first study to demonstrate systemic administration of 
a 42 nm UCN carrying Ce6 was by Park et al.
113
 Here, Ce6 was attached both via 
physical adsorption to phospholipid layer as well as covalent conjugation to the amino 
group on UCN, achieving stable and highest PS payload (>1000 Ce6 molecules / 
UCN). Due to the presence of the biocompatible polymer PEG, these UCNs carrying 





Ce6 had better circulation half-life than free-Ce6. Particles mainly accumulated in 
liver and spleen; however the amount dropped considerably 7 d post injection, 
reducing long-term toxic effects. Following, in vivo PDT at 980 nm, there was a 6-
fold decrease in tumor size among the treated group, thus clearly demonstrating its 
potential as PDT agent. Thereafter, Idris et al. reported therapeutic efficiency of 
mesoporous silica coated UCNs co-loaded with two different PS - ZnPC and MC-540 















Figure 2.8 (A) Schematic diagram of ZnPC and MC540 co-loaded with in the 
mesoporous silica shell coated UCN. (B) TEM image of the mesoporous-silica–
coated UCNs  (scale bar, 50 nm).(C) Schematic diagram showing UCN-based 
targeted PDT in a mouse melanoma model intravenously injected with UCNs surface 
modified with FA and PEG. Scale bar, 10 mm. (D) Change in tumor size as a function 
of time following intravenous injection of UCNs with and without targeting agent 
(FA) to assess the effectiveness of UCN-based targeted PDT in tumor-bearing mice. 
Values are means ± SEM (n = 7 mice per group). *P < 0.05 compared to control 
group 3 by Kruskal-Wallis ANOVA. (E) Representative images of mouse 
intravenously injected with FA-PEG-UCNs, unmodified UCNs or PBS showing the 
change in tumor size (highlighted by dashed white circles) before (0 d) and 7 d after 
PDT treatment. Scale bars, 10 mm. Reprinted with permission from ref 
131
. Copyright 
© 2012, Nature Publishing Group.  





Firstly, the melanoma cells were pre-labelled with PS loaded UCNs and then injected 
subcutaneously to develop UCN loaded tumors in mice. This was followed by 
assessment of PDT efficacy by injecting PS loaded UCNs intratumorally into tumor 
bearing mice and subsequently intravenous administration of FA conjugated- 
PEGylated- PS loaded UCNs was performed. This was the first time that 2 different 
PSs absorbing at 2 different wavelengths (660 nm and 540 nm) of the emitted 
upconverted light was being utilised for maximum PDT efficacy. The results were 
quite promising in that all the 3 modes of UCN administration produced significant 
reduction in tumor volume compared to the untreated group. However, a very long 
irradiation time of 1-2 h (at 980 nm, power density of 415 mW/cm
2
), was employed 
for in vivo PDT. This could have been due to the inefficient energy transfer from 
UCNs to the PS probably due to the limited PS loading capacity (< 0.6 wt %) and 
poor stability of the PS that was physically adsorbed onto the mesoporous silica. 
Perhaps, covalent binding of the PS to the surface of UCNs could enhance the 
upconversion efficiency and thus produce a more pronounced PDT effect in vivo. Cui 
et al. again demonstrated remarkable therapeutic efficacy with tumor inhibition ratio 
of up to 50% using FA conjugated chitosan modified ZnPC loaded UCNs in 
comparison with a tumor inhibition ratio of 18% achieved by conventional visible 
light-activated PDT.
129
 Here, PS was loaded via hydrophobic interactions to achieve 
high drug loading capacity of about 10%. The FA conjugated UCNs were 
administered intravenously and exhibited high tumor targeting efficiencies in vivo, 
where it  accumulated as early as 4 h post administration, whereas the unconjugated 
UCNs became visible only after 12 h. The subcutaneous tumor developed on the 
mouse were covered with 1 cm pork tissue to simulate tumors inside the body and 
was irradiated with either 660 or 980 nm light following administration of PS loaded 





UCNs. Survival rates of mice in this deep penetrating PDT experiments reached 88% 
for 980 nm induced PDT compared to 75% using 660 nm light irradiation 
demonstrating the ability of the nanoconstructs in the ablation of deep-seated tumors. 
The results indicated that PDT treatment based on FASOC-UCN-ZnPc could 
effectively improve the survival quality of mice and prolong their lifetime. Using the 
pH-sensitive charge reversible nanoconstruct, Wang et al. demonstrated significantly 
delay in tumor growth following 980 nm NIR PDT at 0.5 W/cm
2
 for 30 min (900 
J/cm
2
), 1 day after intratumoral injection of 0.4 mg UCNs per 4T1 tumor-bearing 
Balb/c mouse.
119
 At the same time, significantly higher uptake of UCNs (6.4 folds) 
were observed in the tumor, 2 h following intravenous administration of same dose of 
UCNs. Despite an increased tumor accumulation of UCNs, the majority of injected 
dose were observed in reticuloendothelial system (RES), such as the liver and spleen, 
following systemic administration. This warrants further improvement of the surface 
modification techniques, to enhance the tumor targeting, and at the same time, reduce 
the accumulation and retention of these smart UCNs in the RES. In their recent 
publication, Chen et al. demonstrated synergistic therapeutic efficacies of the 
combined PTT and PDT in an in vivo mouse model bearing 4T1 tumors, using a 
double dye loaded (RB and IR825) BSA modified UCNs.
154
 The combination therapy 
(PDT at 980-nm excitation for 30 min at 0.4 W/cm
2
 followed by PTT at 808-nm, at 
0.5 W/cm
2
 for 5 min) after intratumoral injection of 10 mg/ml RB:IR825 co-loaded 
UCNs significantly inhibited tumor growth in vivo, while those after mono-therapy 
(PDT only or PTT only) only showed a delayed tumor growth. In addition to the 
therapeutic effect, intrinsic paramagnetic and optical properties of Gd
3+
-doped UCNs 
were utilized for in vivo dual modal imaging, thus proving to be excellent 
multifunctional theranostic agents.  





After successfully developing a positively charged ligand free UCNs on which 
electronegative PS were tighly coupled via electrostatic interactions, to obtain a UCN-
PS complex with highest FRET efficiency (96.3%) till date, Wang et al. studied the in 
vivo therapeutic efficiency of the developed PVP coated UCNs, in a H22 
hepatocarcinoma mouse model.
140
 NIR PDT of the tumor at 980 nm, 12 h post 
intratumoral injection of 20 mg/ml ZnPC-COOH loaded UCNs exhibited significant 
delay in tumor growth (501 mm
3
) compared to untreated control (1282 mm
3
) by 14 d. 
Compared to the animals in the untreated control, the body weight of the mice in the 
treatment group remained unchanged, indicating an overall improvement in their 














Figure 2.9 (A) Emission spectra under 980 nm, 1 W/cm
2
 excitation of α-
NaYF4:Yb,Er@CaF2 UCNs with different Yb-levels. (B) Integrated counts of red-
emission and photographs (inset) of α-NaYF4:Yb,Er@CaF2 UCNs with different Yb-
levels. (C) TEM images of PAA–UCNs (a), hydrazide-functionalized UCNs  (b), and 
ALA–UCNs (c). (D) In vivo volume of tumors exposed to various controls and ALA–





UCNs with red and near-infrared irradiation (0.5 W/cm
2
) in simulated deep tumors. 
Statistical significance was determined from one-way t tests; significance (*) was 
based on P < 0.05 and P > 0.05 for not significant (**) pairs. Reprinted  with 
permission from ref 
164
. Copyright 2014 American Chemical Society. 
 
In order to improve the UCL emission in the red region for further improvement in 
the penetration depth achievable by UCN-based PDT, recently Punjabi et al. 
developed CaF2 coated α-NaYF4:Yb,Er in which the Yb doping was increased from 
20% to 98% (where 80% Yb doping showed optimal results) (Figure 2.9).
164
 They 
reported 15-fold increase in red-emissions compared to their hexagonal phased 
counterparts (β-NaYF4:Yb(20%),Er(2%)@β-NaYF4), with an absolute quantum yield 
of α-NaYF4:Yb(80%),Er(2%)@CaF2 measured to be 3.2%; highest reported value for 
red-emissions. Furthermore, conjugation of ALA to the UCN surface via a hydrazone 
linkage, minimized premature leakage and improved its bioavailability. In vivo PDT 
in mice models of tumors following intratumoral delivery of these ALA loaded 
nanoconstructs demonstrated significant tumor growth delay compared to controls 
even in the presence of 12 mm thick  pork tissue; the greatest depth at which 
significant reduction in tumor growth was achieved with UCN-PDT.  
The first ever attempt that combined bi-modal imaging and trimodal therapy in a 
single UCN-based nanotheranostic system was yet recently reported by Fan et al.
162
 
They synthesized a sub-80 nm rattle structured nanocomposite with Gd
3+
 doped UCN 
in the core (for simultaneous UCL and MR imaging), and a mesoporous silica as the 
outer shell with a cavity in between them (UCMSNs) (Figure 2.10). HP that serves as 
both PS and radiosensitizer, was covalently grafted inside the silica shell with a 
loading efficiency of 7.8%; whereas the chemo-drug docetaxel (Dtxl) was 
encapsulated with in the inner cavity with a loading efficiency of 4.5 wt%. The 





nanoconstruct was found to accumulate in the tumor by passive targeting with a 25% 























Figure 2.10 (A) Schematic illustration of the synthetic procedure of UCMSNs. (B) 
Transmission electron microscopic (TEM) images of (a) Gd-UCNPs 
(NaYF4:Yb/Er/Tm@NaGdF4), (b) Gd-UCNPs@SiO2, (c) Gd-UCNPs@SiO2@mSiO2, 
and (d) UCMSNs (scale bar = 50 nm) (C) In vivo T1–MRI images of a 4T1-tumor 
bearing mouse after intravenous injection of UCMSNs at designated time points: (a) 
0 min; (b) 5 min; (c) 10 min; (d) 15 min. (e) Comparison of MRI signal intensity of 
the corresponding 4T1-tumor at different time points from 0 to 15 min. (f–h) Ex vivo 





NIR–NIR upconversion luminescent imaging (UCL) of dissected organs after the 
intravenous injection of UCMSNs: 1, heart; 2, liver; 3, spleen; 4, lung; 5, kidney; 6, 
tumor (i–k). (D) Tumor growth and relative tumor volumes of different groups post 
intratumoral injection of UCMSNs-HP-Dtxl and corresponding treatment. Control 
groups received PBS. (E) Tumor growth and relative tumor volumes of different 
groups post intravenous injection of UCMSNs-HP-Dtxl and corresponding treatment. 
Reprinted with permission from ref 
162
. Copyright © 2014, Elsevier. 
 
By simultaneously imposing NIR excitation and high energy X-ray irradiation 
following intratumoral administration of UCMSNs-HP-Dtxl, the tumors in mouse 
models were quickly eradicated due to the synergistic effect of PDT/chemo-
/radiotherapy. However, following intratumoral delivery and trimodal therapy, the 
tumors were found to regrow after an initial drop in the volume. It is to be noted that 
most of the in vivo tumor regression studies were short term (10-14 d), where majority 
of the results report a delayed tumor growth and improved overall survival, rather 
than a complete tumor regression. To further improve the therapeutic efficiency of 
UCN based nanoconstruct and fine tune the PDT regimen to achieve complete or 
partial tumor regression, long term tumor regression studies need to be done. 
2.4.4. Toxicity and Biodistribution of UCNs 
Although UCNs have been proposed for various bioimaging and therapeutic 
applications, numerous unresolved issues with respect to its interaction with 
biological system yet remains. Like many other inorganic nanoparticles, UCNs are 
not easily biodegraded in the biological system, causing concerns about its long term 
toxicity and side effects. Although, humans are exposed to lanthanides based 
compounds in the form of therapeutics and diagnostics, they are often considered to 
be moderately to highly toxic. Generally, the toxicity depends on the compound 
(inorganic versus chelated compounds), route of administration, and dose.
165
 Thus, the 
behaviour, biodistribution, degradation, clearance and toxicology profiles of UCN in 
biological systems, is the most critical and fundamental question to be addressed 





presently. Almost all studies highlighted in this section, have evaluated the in vitro 
cytotoxicity of respective UCN constructs by the standard CCK-8, MTT, MTS and 
LDH assays, and have found to be safe to a broad range of tested cell lines within a 
certain concentrations (usually in µg/ml range) and a limited incubation period 
(usually ranging from 30 min to 24 h). A few studies utilized Caenorhabditis elegans 
(C. elegans) as a model organism for evaluating the toxicity of UCNs and reported 
that feeding C.elegans with UCNs did not affect its life span, egg production, egg 
viability or growth rate, indicating that UCNs were not significantly toxic except at 
concentrations above 5 mg/mL or higher.
166, 167
 A list of all the published efforts on 
biodistribution, toxicity and clearance of various UCN constructs in animals are 
summarised in Table 2.4. 
To gain insight into the kinetics of these nanocrystals in rodents, Jalil et al. studied the 
biodistribution of silica coated UCNs following intravenous injection in Wistar rats, 
up to 7 d.
168
 No obvious acute toxic or adverse health effects were observed at the 
dose level of 10 mg/kg for up to 1 week post administration. Quantification of 
Yttrium content in various organs at specfic time-points revealed that lung and the 
heart were the main target organs where the nanocrystals accumulated immediately 
(29.2 and 18.0 mg/L per g of tissue at 10 min) post injection. However, the amount 
dropped significantly by 24 h. The nanoparticles were also detected in spleen, 
reaching the highest concentration at 30 min (6.3 mg/L per g); as well as in kidneys, 
where the concentration of yttrium remained the same up to 24 h. However, the 
concentration in blood and liver remained low throughout.  











































10 min, 30 
min, 24 h, 
7 d 
Highest accumulation in lung and heart 
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In vivo UCL 
imaging 
24 h 
At 1 h mainly in liver, maximum 





ICP-AES 24 h 
Higher accumulation in integrin αVβ3 
expressing U87MG tumors; UCNs 
present in liver and spleen, followed by 






- Mice IV/ 15 mg/kg 115 d 
In vivo UCL 
imaging 
30 min, 6 
h, 12 h, 24 
h, 7 d, 14 
d, 21 d, 
115 d 
At 30 min UCL signals observed in 
liver and spleen at; at day 14 signal 









30 min, 24 
h, 7 d, 115 
d 
Liver and spleen major targets; slight 




for 115 d 
No observable changes 











No changes to ALT, AST, total 
bilirubin, urea, creatinine 
Histology Day 115 
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In vivo UCL 
imaging 
24 h 
Unmodified UCNs: mainly in liver and 
spleen; FA conjugated UCN: detected 




ICP-AES 24 h 
Unmodified UCN : mainly in spleen, 
followed by liver, lung; FA modified 











IT / ≈ 40 
mg/kg 
60 d 
In vivo UCL 
imaging 
Day 1, 2, 
3, 6, 10, 14 
Signals only in the tumors, lasts upto 14 
days 




Day 1, 15, 
40, 60 
Observed in Skin and muscle near the 
site of injection on Day 1; by day 15 




for 16 d 
No obvious changes 











- Mice IV/ 20 mg/kg 90 d 
In vivo UCL 
imaging 
5 min, 30 
min, 1 d, 3 
d, 7 d 
UCN-PAA accumulated in liver within 
5 min, but UCN-PEG uptake was 
slower and observed in liver at 30 min. 
Ex vivo imaging revealed accumulation 
of UCNs in the liver, spleen, lung and 















ICP-AES -Inductively coupled plasma atomic emission spectroscopy 
ICP-AES 
1, 3, 7, 20, 
40 and 90 
d 
Observed in liver spleen and bone 
marrow up to 90 days 
Body weight 
Once in 6 
days 





3, 7, 20, 40 
and 90 d 
No appreciable toxicity, except slight 
increase in AST level but within control 
range 
Histology 
3, 7, 20, 40 
and 90 d 











doses 36 - 220 
mg/kg 
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In vivo NIR 
imaging (ICG- 
Der-01) 
Up to 96 h 
Rapid accumulation in liver and cleared 
through intestine by 48h 
Cleared 









for 7 d 
No change in body weight for animal 




High AST and ALT levels in 150 
mg/kg group 
Histology 7 d 
Mild edema and few chronic 
inflammatory cells were observed in 




100% death in 220 mg/kg group within 
7 days, LD50 = 149 mg/kg 








The nanocrystals were mostly cleared from all major organs by day 7 post-injection 
indicating that they were not retained for a long period of time. On studying the long 
term fate of 11.5 nm sized PAA coated UCNs in nude mice, Xiong et al. reported that 
the major organs where the nanoparticles were retained was liver and spleen (Figure 
2.11).
170
 Although, no major toxic effects were observed, the study reported a very 
slow clearance of the nanoconstructs from the system via hepatobiliary route. 
However, the study only included a small number of animals (n=3) and the blood 
biochemical and histology results were collected only at the end of the experimental 













Figure 2.11 (A) Real-time in vivo UCL imaging of athymic nude mice after 
intravenous injection of PAA-UCNs (15 mg/kg) at different time points. Column 3: 
overlays of UCL and brightfield images of mice. Column 6: overlays of UCL and 
brightfield images of dissected mice. (B) Biodistribution of particles in organs of 
mice. Error bars were based on triplet measurements. (C) H& E-stained tissue 
sections from mice 115 d post-injection with PAA-UCNs (a, c, e, g, i and k) and mice 
receiving no injection (b, d, f, h, j and l).Tissues were harvested from heart (a, b), 





spleen (c, d), liver (e, f), lung (g, h), kidney (i, j) and blood smear (k, l). Reprinted 
with permission from ref 
170
. Copyright © 2010, Elsevier. 
 
Later, Cheng et al. conducted a thorough assessment of the pharmacokinetics, long 
term biodistribution and toxicity of 30 nm sized PEG or PAA modified UCNs.
172
 
Although, the blood circulation curves of UCN-PEG and UCN-PAA followed a two-
compartmental model, the blood circulation half-life of UCN-PEG was significantly 
greater than UCN-PAA, which was attributed to the biocompatible PEG coating on 
the UCN surface and its improved stability in physiological solutions. In vivo UCL 
imaging showed that UCN-PAA accumulated in liver within 5 min, but UCN-PEG 
uptake was slower and observed in liver at 30 min. Ex vivo UCL imaging revealed 
accumulation of UCNs in the liver, spleen, lung and bone at 1 d, but no signal was 
detected by day 7. However, the yttrium ion levels in these organs did not drop much 
over a course of 90 d, except in the lung, which showed a rapid decrease of yttrium 
ion concentration after 3 d.  
The presence of nanoparticle aggregates in the TEM of liver slices from mice 7 d post 
injection, indicates partially decomposition of UCNs inside the macrophage cells after 
RES uptake and loss of their UCL emission signals over time. Thus, the study 
concluded that nanoparticle residues would stay inside the mouse body for more than 
90 d, which is in stark contrast to the previous reports. Perhaps the size difference of 
UCNs in these two studies could have led to the observed difference in the excretion 
routes and clearance of the nanoparticles. But it is to be noted that, although the 
nanoparticles remained in the animal for over 90 d, no appreciable variations were 
observed in the blood biochemical, haematological or histopathological analysis. 
Presence of targeting ligands, were found to channel the UCNs to the tumor and 
reduce the percentage of injected dose that accumulated in other organs such as the 
liver and spleen. Cui et al. administered FA conjugated UCNs intravenously, that 





exhibited high tumor targeting efficiencies and accumulated in the tumor as early as 4 
h post administration; whereas the unconjugated UCNs became visible only after 12 
h.
129
 The particles first accumulated in the liver, following which they were gradually 
excreted into the intestines by 24 h and the absence of fluorescence signals from the 
loaded NIR dye (ICG-Der-01) at 48 h indicated complete clearance of the UCNs from 
the system via enterohepatic route. A significant variation in the biodistribution was 
observed in the presence of a targeting moiety FA at 24 h in a tumor bearing mice, 
where FA-conjugated UCN levels were much higher in tumor but lower in organs like 
lung, liver and kidney, compared to the level of unmodified UCNs. Due to the huge 
diversity in the nature, size, composition, charge, surface properties and presence or 
absence of additional functional moieties on the surface of UCNs, it becomes very 
hard to even speculate the biodistribution and toxicity of these nanomaterials, with the 
limited knowledge available from the literature till date. Several questions regarding 
the ultimate fate of these nanomaterials in the system, the possibility of their 
degradation into toxic by-products and their effects following prolonged residence in 
a particular organ, still remain unanswered. Long term comparative studies on the 
biodistribution, metabolism, degradation and toxicity profiles of various UCNs of 
different size, charge and surface functionalities are necessary to evaluate the 
usefulness of this class of nanomaterials before its further development and 
application in the clinics. 





2.5.  RESEARCH OBJECTIVE  
The main objective of this Ph.D. work is to design a UCN based PDT system with 
stable and precise loading of PS, such that there is no leakage of the PS during 
circulation in the blood stream following systemic administration of the 
nanoconstructs. This property is essential for the efficiency and reproducibility of the 
PDT effect in vivo, which is not addressed in the studies till date. In order to achieve 
this, experiments were conducted in a step-wise manner, to understand the 
characteristics and behaviour of the developed nanoconstructs in physiologically 
relevant conditions first, using solution based and cell based assays,  before 
progressing into in vivo tumor models. At every step stringent checks were done to 
assess and optimize the surface properties of the developed nanoparticles to achieve 
specific biological functions.   
Hypothesis: Direct surface coating of the photocatalyst TiO2 on the surface of 
UCNs enables stable loading of the PS  resulting in effective NIR-PDT of solid 
tumors.   
Objective 1: To synthesize NIR to UV light upconverting UCN core that is stably 
surface coated with a thin layer of TiO2 and evaluate its characteristics, ROS 
generation and cell killing abilities in vitro. 
Significance: Large sized nanoparticles and agglomerates, as well as high probability 
of PS leakage from the UCN based nanoconstructs, are the major reasons for reduced 
bioavailability, ultimately resulting in ineffective PDT. Direct surface coating of the 
photocatalyst TiO2 on the UCN surface will completely eliminate any possibility of 
PS leakage, offering superior stability and precise control over PS loading. Here, TiO2 
was chosen as a photocatalyst as it has been previously shown to have photokilling 










irradiation with UV light. Furthermore, it is known to be physiologically inert, with a 
well-characterized surface and photocatalytic activity.
176-179
 However, direct 
excitation of TiO2 nanoparticles by UV light suffer from limited penetration ability of 
UV light in the tissue, making this technique only suitable for the treatment of 
superficial tumors.
177
  By employing UCNs, tissue penetrating NIR light can be 
utilized to photoexcite the UCNs that upconverts the incident NIR light to UV light, 
which subsequently excites the TiO2 on the shell; thereby expanding the applicability 
of this promising photocatalyst in the treatment of a variety of solid and deep-seated 
tumors. 
Objective 2: To surface modify the developed nanoparticles to impart stability in 
physiological conditions, stealth properties and make them biocompatible for in vitro 
and in vivo PDT applications. 
Significance: Nanoparticles toxicity depends on physiochemical parameters such as 
particle size, shape, surface charge and chemistry, composition, and its subsequent 
stability. However, nanoparticles in physiological solutions with high ionic strength, 
form micrometer-sized coarse aggregates.
180, 181
 Aggregated nanoparticles have been 
shown to exert different biological effects as compared to well-dispersed 
nanoparticles
182, 183
 and can affect the degree of uptake and as well as result in size- 
and surface area dependent toxicity.  On the other hand, adsorption of proteins to the 
surface of nanoparticles also alters its properties such as surface charge, interfacial 
properties and bioreactivity.
184
 In addition to that, such proteins might also trigger 
opsonization resulting in rapid recognition and removal of the nanoparticles from the 
circulation by the macrophage cells. Hence, appropriate surface modification strategy 
must be adopted to render the developed nanoparticles suitable for biological 





applications. At the same time, it is important to ascertain that the ROS generation 
ability is not compromised. Thorough in vitro biocompatibility and mechanistic 
studies and “proof of concept” in vivo PDT following intratumoral administration of 
these nanoconstructs will provide useful insights on its ROS generation and tumor 
ablation capabilities, for its further development. 
Objective 3: Addition of a tumor targeting agent and to evaluate the targeting 
abilities of the nanoconstruct in vitro. 
Significance: Presence of a surface modifying/stabilizing agent might reduce the bio-
interaction of nanoparticles and hinder its uptake by cells.
185, 186
 The addition of tumor 
targeting ligands aim to increase selective binding and internalization of the 
nanoparticles in tumor cells through receptor-mediated endocytosis, minimising its 
undesired effects elsewhere. Herein, addition of the tumor targeting ligand to the 
developed nanoconstruct is expected to allow targeted delivery and internalization 
with in the tumor cells following systemic administration. Hence, detailed study on 
the dynamics of its uptake, targeting ability, toxicity and PDT efficiency in vitro is 
necessary to validate the role and advantage of the presence of targeting agent.  
Objective 4: To evaluate the blood contact properties, long term dose-dependent 
toxicity, single-dose sub-acute toxicity and biodistribution of the developed targeted 
nanoconstruct following systemic administration in vivo. 
Significance: When administered intravenously, nanoparticles immediately come in to 
contact with blood components initiating a myriad of biological responses.
187
 In order 
to better understand the factors that influence the distribution of the nanoparticles in 
vivo, it is imperative to study the interactions that exist between intravenously injected 
nanoparticles and blood, as this could alter the targeting and transport capabilities of 





nanoparticles. Dose-dependent long-term (120 d) toxicity profiling of the 
nanoconstruct, will facilitate the selection of an appropriate tolerable dose, with 
minimal long-term effects. Sub-acute (28 d) haematological, biochemical and 
histopathological toxicity as well as biodistribution studies will further confirm the 
safety of the fabricated nanoparticles for systemic administration in vivo. 
Objective 5: To determine the PDT treatment efficacy and survival of the developed 
NIR excitable targeted nanoconstruct following systemic administration in a 
xenograft mouse tumor model. 
Significance: The ultimate aim of this work is to develop a NIR excitable UCN based 
construct with stable loading of PS, for PDT of solid tumors. Hence, efficiency of the 
developed nanoconstruct in combating and controlling the growth of solid tumors is to 
be determined. Furthermore, the comparison of the PDT efficiency using NIR light 
excitable agents over red-light excitable conventional PS will further highlight the 
advantage of developing these nanoparticles. 
2.6. THESIS OUTLINE  
In this thesis, a brief introduction to cancer, the pros and cons of the different 
conventional and alternative therapeutic options that are currently available, and the 
need for development of new nanoparticle based therapeutic systems are briefly 
outlined in Chapter 1. Chapter 2 is a detailed literature review on PDT and its current 
limitations, and further discusses how the application of nanoparticles could tackle 
some of the issues associated with conventional PDT. The application and 
development of UCNs in PDT is briefly discussed, summarizing the current issues 
associated with such nanoconstructs. Chapter 3 investigates the development of a 
UCN construct stably and uniformly surface coated with a thin layer of photocatalyst 





TiO2, and further evaluates its characteristics and ROS production capabilities in 
physiologically relevant conditions, and assess the need for further surface 
modification of the nanoconstructs so as to develop it for PDT application in 
biological systems. Chapter 4 examines the performance of surface modified 
nanoconstructs (PEGylated TiO2-UCNs referred to as Mal-PEG-TiO2-UCNs) in vitro 
and also demonstrates proof of concept in vivo PDT efficiency following intratumoral 
administration of the nanoconstructs. Chapter 5 describes further modification of the 
nanoconstruct by decorating it with a tumor specific targeting moiety for systemic 
delivery and further explores its biocompatibility, targeting efficiency and PDT 
efficacy in vitro. Chapter 6 evaluates the toxicity and biodistribution of the targeted 
nanoconstruct in animal models following systemic administration, and also 
determines an optimal therapeutic dose. Chapter 7 demonstrates the therapeutic 
efficiency of the developed nanoconstructs following systemic administration and 
further compares it with conventional PDT. Finally, Chapter 8 and 9 highlights the 
conclusions and future directions for the work documented in this thesis. 
  







Titania coated core-shell structured UCN as NIR 




PDT is a highly localized and minimally invasive therapeutic approach against cancer, 
with low systemic toxicity and fewer side effects as compared with chemo- and 
radiation therapy. However, at present it is not suitable for the treatment of solid 
tumors that are at a thickness greater than a few millimetres as most of the available 
PSs are activated by visible light (400-700 nm), which has limited penetration depth 
in tissues. Apparently, for deep penetration of light into tissues, wavelength of the 
irradiated beam should be in the NIR window (700–1100 nm).74 Recently, the 
application of UCNs has opened a new avenue for tackling the shortcomings in this 
field. UCNs are “nanotransducers” that has the ability to convert low-energy NIR 
light to high energy visible or UV light, via an anti-Stokes emission process. In the 
recent years, there have been few studies on such UCN based PDT systems, in which 
an appropriate PS is closely attached to the UCN that act both as a “delivery agent” as 
well as NIR to visible/UV light “transducer”, required for the activation of PS at 
much deeper levels in the tissues. The selection and attachment of PS to the UCN is 
of prime importance for the success of this technology.  While a good overlap 
between the UCN emission and absorption maxima of the PS is required for efficient 
upconversion, sufficient amount of PS in close proximity to the UCN is necessary for 
efficient ROS generation. Previously, the three common strategies of PS loading on 
UCNs have been silica encapsulation, covalent conjugation and physical adsorption. 





While the widely adopted silica encapsulation (incorporation of PS in the silica or 
mesopororus silica shell) technique generally leads to relatively large sized particles 
with unstable PS loading,
117, 130-132, 188
 covalent conjugation of PS is often associated 
with low PS loading efficiency.
110, 111, 128, 136
 On the other hand, physical adsorption 
method makes use of non-covalent hydrophobic forces allowing close binding of PS 
to the UCN core achieving the highest PS payload among the different constructs 
proposed till date.
125, 127, 129, 189
 However, none of these strategies guarantee controlled 
loading or stable attachment of PS to the UCN, often compromising the repeatability 
of PDT results. Therefore, it becomes essential to design robust UCN constructs with 
controllable and stable PS loading, for optimal and reproducible therapeutic 
efficiency. 
In this study, we report a different approach of uniformly surface coating a 
photocatalyst –TiO2 on a NaYF4: Yb,Tm UCN core (TiO2-UCN) and demonstrate the 
ability of the synthesized nanoconstruct in achieving cancer cell destruction in vitro. 
TiO2, a well-studied photocatalyst, has been previously shown to have photokilling 
ability in variety of cancer cells in vitro 
95, 173-176
 and in vivo
173, 175, 177
 upon irradiation 
with UV light. However, direct excitation of TiO2 nanoparticles by UV light suffer 
from limited penetration ability of UV light in the tissue (less than 1 mm), making this 
technique only suitable for the treatment of superficial tumors.
177
 Some effort to 
improve the penetration depth and thereby the PDT effect of TiO2 has been recently 
reported by employing UCNs and fabricating non-uniform composite nanostructures 
with a few UCNs embedded in TiO2 matrix.
135
 However, the study mainly reported 
experiments conducted in solution and cell-based assays, perhaps due to the non-
uniform size of the nanoconstruct that might have compromised repeatability and 
translatability of PDT results in vivo. Our design allows controllable and uniform PS 





(TiO2) loading on individual UCN core and completely eliminates the possibility of 
PS leakage. As illustrated in Scheme 1, the UCN core upconverts NIR light to UV 
light, which further photoexcites the electrons in the valence band (VB) of TiO2 shell 
to conduction band (CB). This results in the formation of electron-hole pair eliciting 
further redox reactions for the generation of ROS.  
 
Figure 3.1 Schemetic illustration of the concept behind NIR-PDT using TiO2-UCNs. 
Upon NIR irradiation, upconverted UV light emitted from NaYF4:Yb,Tm UCN core 
photoexcites electrons in the valence band (VB) of the TiO2 shell to the conduction 
band (CB), thus resulting in the formation of photoinduced hole-electron pairs. 
Interaction of electrons and holes with surrounding O2 and H2O molecules generate 
various ROS, eventually leading to cancer cell death. 
 
. 
3.2. MATERIALS AND METHODS 
3.2.1. Synthesis of NaYF4: Yb,Tm @SiO2 nanoparticles 
The NaYF4:Yb, Tm UCN core was synthesized as previously reported.
143
 Briefly, 0.8 
mmol YCl3, 0.2 mmol YbCl3 and 0.005 mmol TmCl3 were mixed with 6 mL oleic 
acid and 15 mL octadecene in a 50 mL flask and heated to 160 °C to form a 
homogeneous solution. After cooling it down to RT, 10 mL of methanol solution 
containing 2.5 mmol NaOH and 4 mmol NH4F was slowly added into the flask and 
stirred for 30 min. The solution was subsequently heated to remove methanol, 
degassed at 100 °C for 10 min, followed by heating to 300 °C and was finally 





maintained under Argon protection for 1h. When the solution cooled down to RT, 
nanocrystals were precipitated from the solution with ethanol, and washed three times 
with 1:1 ethanol/water (v/v). Subsequent silica coating on the UCN core (NaYF4: 
Yb,Tm @SiO2) was done following previous published methods.
190
 Briefly, 0.1 mL 
CO-520 and 6 mL cyclohexane were mixed with 4 mL 0.01 M NaYF4 nanosphere 
solution in cyclohexane and stirred for 10 min. 0.4 mL CO-520 and 0.08 mL 
ammonia (30 wt%) were then added and the container was sealed and sonicated for 20 
min until a transparent emulsion was formed. 0.04 mL tetraethyl orthosilicate (TEOS) 
was added and the solution was rotated for two days at a speed of 600 rpm. NaYF4: 
Yb,Tm @SiO2 nanospheres were then precipitated by adding acetone, and the 
nanospheres were washed two times with 1:1 ethanol/water (v/v) and then stored in 
water. 
3.2.2. Coating of TiO2 on NaYF4: Yb,Tm @SiO2  
Amino groups were first modified on the silica surface by grafting (3-aminopropyl)-
trimethoxysilane (APS) on the NaYF4:Yb,Tm@SiO2 by adding 0.008mmol APS into 
the solution containing 0.02 mmol NaYF4:Yb,Tm@SiO2 during the silica coating 
procedure. In a typical synthesis, 0.02 mmol APS grafted NaYF4: Yb,Tm @SiO2 was 
dispersed in 10 mL isopropanol, 0.3 mL ammonia (28 wt%) and 2.5 mL water. Then, 
2 mL of 0.001 M titanium diisopropoxide bis(acetylacetonate) solution in isopropanol 
was slowly added and stirred for 24 h at RT. Amorphous TiO2-UCNs were then 
collected by centrifugation and washed two times with isopropanol. To achieve a 
crystallized TiO2 shell, the TiO2-UCNs were treated with anhydrous ethanol in a 
sealed autoclave at 180 ºC for 24 h under an air atmosphere.  
 





3.2.3. Characterization of synthesized nanoparticles  
Size, morphology and energy-dispersive X-ray spectroscopy (EDX) of the 
synthesized nanoparticles were characterized using a JEOL 2010F TEM (Jeol Ltd., 
Tokyo, Japan) operating at an acceleration voltage of 200 kV. Powder X-ray 
diffraction (XRD) was carried out on a Philips X' Pert Pro X-ray diffractometer 
equipped with a Cu K radiation. Fluorescence spectra was recorded on a SpectroPro 
2150i spectrophotometer (Roper Scientific Acton Research, MA) equipped with a 
1200 g/mm grating and  980-nm VA-II diode pumped solid-state (DPSS) laser. 
Dynamic light scattering (DLS) was conducted with the Zetasizer (Nano ZS, Malvern 
Instruments Ltd., UK) to measure the hydrodynamic diameter, polydispersity index 
(PDI) and zeta-potential. Nanoparticles at a concentration of 1 mg/ml in deionised 
water were sonicated for 20 min before further diluting (100 µg/ml) it in water, 
phosphate-buffered saline (PBS), Roswell Park Memorial Institute 1640 medium 
(RPMI) and RPMI with 10% fetal bovine serum (FBS) to determine the average 
aggregate size with time. 
3.2.4. Detection of ROS production from TiO2-UCN 
In a typical experiment 1 mg of the TiO2-UCN was suspended in 1 mL of water 
containing 10 µM of aminophenyl fluorescein (APF) dye. In the scavenging 
experiment, 20 mM sodium pyruvate, or 2% dimethyl sulphoxide (DMSO) – the 
respective scavengers for hydrogen peroxide (H2O2) and hydroxyl radical (
·
OH) - was 
additionally included in the solution. The mixture was then placed in a cuvette and the 
solution was irradiated with a 980 nm laser (EINST Technology Pte Ltd, Singapore) 
at 2.1 W/cm
2
 for 20 min time intervals beginning from time (t) = 0 to 60 min, with the 
fluorescence emission of APF at 520 nm (upon excitation at 485 nm) being measured 





between intervals using a Tecan Safire2 fluorescence plate reader (Männedorf, 
Switzerland).  
3.2.5. Cell culture  
Human oral squamous cell carcinoma (CAL-27) (OSCC) and normal human lung 
fibroblasts (IMR-90) (NHF) cells were obtained from American Type Culture 
Collection (ATCC, Manassas, VA, USA) and grown in RPMI and Dulbecco's 
Modified Eagle's medium (DMEM), respectively supplemented with 10 % FBS, 100 
units/mL of penicillin and 100 g/mL of streptomycin, and maintained in a 
humidified, 5 % CO2 atmosphere at 37 °C. 
3.2.6. Cell imaging study 
Cells were plated onto a 8 well chambered slide at a density of 8,000 cells per well 
and incubated overnight at 37 °C in a humidified, 5 % CO2 atmosphere. They were 
then treated with 54 µg/mL (0.2 mM) TiO2-UCN for 6 h at 37 C. After which the old 
culture medium containing unbound and non-internalized nanoparticles were 
discarded and the cells were washed three times with PBS before they were fixed in 
ice-cold methanol for 10 min. The cell membrane and nuclei were counterstained with 
Wheat Germ Agglutinin, Alexa Fluor® 488 Conjugate and propidium iodide (PI), 
respectively. Stained cells were  imaged under a 40X objective of a Nikon 80i 
Fluorescence Microscope (Nikon, Tokyo, Japan) equipped with a 980 nm Laser 
Wide-field Fluorescence add-on (EINST Technology Pte Ltd, Singapore). The plasma 
membrane and nuclei of the cells were visualized under excitation with Hg arc lamp 
light and a standard FITC and TRITC filter set, respectively. 





3.2.7. Dark-toxicity test  
a. MTS assay: Cells were seeded on a 96-well plate at a density of 8 X 103 cells 
per well and incubated overnight at 37 °C in a humidified, 5 % CO2 atmosphere, to 
allow it to adhere to the bottom of the plate. 1 mg/mL TiO2-UCN stock solution was 
prepared in PBS and dispersed by sonication for 20 min before diluting it in 
respective culture medium to achieve a concentration ranging from 10 μM (2.7 
µg/mL) to 8 mM (2160 µg/mL). The cells were treated with the different 
concentration of nanoparticles for 6 h at 37 C followed by washing three times with 
PBS to remove unbound and non-internalized nanoparticles. Fresh culture medium 
was then added into each well and the plate was returned to 5 % CO2 atmosphere at 
37 °C for another 24 h round of incubation. The number of cells that remained viable 
was then assessed by CellTiter 96
®
 AQueous One solution cell proliferation assay 
(Promega, Madison, WI, USA) as per manufacturer’s instructions. Absorbance was 
measured at 490 nm using a microplate reader (Tecan Safire, Männedorf, 
Switzerland). Cell viability is expressed as a percentage of control cells without 
exposure to TiO2-UCN.  
b. LDH assay: Cell seeding and nanoparticle incubation was performed similar 
to that of MTS assay.  Cell viability was determined using CytoTox-ONE™ 
homogeneous membrane integrity assay kit purchased from Promega (Madison, WI, 
USA), according to the manufacturer’s instructions. Release of the cytosolic enzyme, 
lactate dehydrogenase (LDH) from lysed cells were quantitated by measuring the 
fluorescence (560 nm excitation and 590nm emission wavelengths) using a microplate 
reader (Tecan Safire, Männedorf, Switzerland). 
 





3.2.8. In vitro PDT  
Cells were plated and treated with TiO2-UCN at a concentration ranging from 10 μM 
(2.7 µg/mL) to 1 mM (270 µg/mL), as described in the dark-toxicity test above. After 
washing off the nanoparticles three times with PBS and replacing it with fresh culture 
medium, the cells were exposed to 980 nm NIR light at a power of 1.2 W for 5 min 20 
sec delivering a total fluence of 675 J/cm
2
. For scavenging experiments, 2% DMSO 
or 20 mM sodium pyruvate were added to the cell culture medium along with the 
nanoparticles at a concentration of 1 mM, before exposure to NIR light.  The cells 
were incubated for additional 24 h before percentage of cell viability relative to the 
control untreated cells was determined using CellTiter 96® AQueous One Solution 
Cell Proliferation Assay (Promega, Madison, WI, USA) as per manufacturer’s 
instructions.  
3.2.9. Statistical Analysis 
In all figures, data points represent mean ± standard deviation (SD). Statistical 
analyses were performed using the GraphPad Prism version 6.0 software (GraphPad 
Software, San Diego California USA). Differences in means were compared with 
two-tailed unpaired Student’s t–test, one-way or two-way ANOVA followed by 
Bonferroni's post-hoc test. P values less than 0.05 (P<0.05) were considered 
significant. 
3.3. RESULTS AND DISCUSSION 
3.3.1. Synthesis and characterization of TiO2-UCNs  
A hydrophobic NaYF4: 20%Yb, 0.5%Tm UCN core was synthesized by solvent-
thermal process. To impart hydrophilicity, UCN core was further coated with a thin 
layer of silica (NaYF4:Yb,Tm @SiO2) (Figure 3.2A). Subsequent grafting of APS 
provided positively charged amino groups for the binding of titanium precursor, 





followed by gradual epitaxial growth of the titanium precursor resulting in 











Figure 3.2 (A) Schematic of synthesis of TiO2-UCN; TEM images of (B) UCN core 
(NaYF4:Yb,Tm), (C) silica coated UCN (NaYF4:Yb,Tm@SiO2), and TiO2-UCN (D) 
before and (E) after annealing (TiO2 coated NaYF4:Yb,Tm@SiO2), scale bar: 20 nm. 
 
 
TEM images of the UCN core (NaYF4:Yb,Tm) revealed a spherical shape with an 
average diameter of ∼25 nm (Figure 3.2B), that was surrounded by a silica layer with 
an average thickness of about ∼6 nm (Figure 3.2C). TEM of TiO2-UCNs (Figure 3.2 
D and E) revealed a uniform spherical shape with a well-defined core-shell structure 
and average primary particle size of ∼50 nm. To further confirm the presence of TiO2 
on the UCN core, powder XRD and EDX spectroscopy analysis were performed. As 
seen in Figure 3.2A, the peaks from the XRD pattern of the core particles can be 
indexed to the NaYF4 nanocrystal while those of core–shell particles can be indexed 
to both the NaYF4 nanocrystal and anatase phase TiO2 (JCPDS standard card no. 21-





















Figure 3.3 (A) XRD patterns of core UCN and core-shell TiO2-UCN. (B) EDX 
spectrum of the TiO2-UCNs supported on a carbon-film coated copper grid. (C) 
Absorption spectra of TiO2-UCNs. (D) Fluorescence emission spectra of 100 μg/ml 
silica coated UCN (NaYF4:Yb,Tm@SiO2) and TiO2-UCN in PBS under 980 nm NIR 
excitation, inset shows blue fluorescence emission from TiO2-UCNs upon NIR 
excitation at 90 W/cm
2
. (E) Fluorescence emission spectra of 100 μg/ml TiO2-UCN in 
PBS under NIR excitation at different power densities (photon multiplier tube (PMT) 
voltage at 500V). 
 
The composition of these core–shell particles was further confirmed by their EDX 
spectrum as displayed in Figure 3.3B. The peaks labeled Na, Y, F, Yb and Tm 
originate from the core nanocrystals, while that of Ti, Si and O come from the shells. 
The elements C and Cu are from the carbon-film coated copper grid used in the EDX 
characterizations. Absoprtion spectra of TiO2-UCNs confirm that the nanoparticles 
absorb light in the UV regions (Figure 3.3 D). Upon 980 nm NIR light irradiation, 
both NaYF4:Yb,Tm@SiO2 and TiO2-UCNs emitted upconverted light in UV, visible 
and NIR regions of the spectrum (Figure 3.3C and D). However there is an obvious 





quenching of fluorescence in the UV region for TiO2-UCNs (Figure 3.3C), which 
confirms the absorption of the UV light by the TiO2 layer due to the spectral overlap 
between the emitted UV and absorption wavelength of the TiO2. This activates the 
TiO2 layer to generate several cytotoxic ROS that could eventually lead to cell death. 
The UCN’s blue emission (peaks at 450 and 475 nm) could be used to track the 
nanoparticle uptake by cells, whereas for in vivo imaging its emission at the NIR 

















Figure 3.4 (A) Average hydrodynamic size of 100 μg/ml TiO2-UCN soaked in 
different media at RT plotted as a function of time the nanoparticles were soaked, 
*P<0.0001 versus size of TiO2-UCNs in RPMI without FBS. (B) Average PDI of 100 
μg/ml TiO2-UCN soaked in different media at RT, plotted as a function of time the 
nanoparticles were soaked. (C) Average hydrodynamic size of TiO2-UCN soaked in 





different physiological solutions at 37°C monitored up to 24 h and plotted as a 
function of time. Data are mean (n>2) ± SD. (D) Effect of addition of 10% FBS on 
hydrodynamic size of 100 μg/ml TiO2-UCN soaked in PBS, *P<0.0001 compared to 
size of TiO2-UCNs at 24 h. (E) Effect of addition of 10% FBS on PDI of 100 μg/ml 
TiO2-UCN soaked in PBS. (F) Photograph of 100 µg/ml TiO2-UCN suspension 
showing difference in aggregate formation following soaking in PBS for 6 h, 24 h as 
well as PBS with 10% serum at 24 h. 
 
3.3.2. Stability of TiO2-UCNs in physiological solutions. 
Initial studies with TiO2-UCNs revealed formation of large aggregates (in the range of 
micrometres) in water and various physiological solutions at room temperature (RT) 
(Figure 3.4A and B).  While it is known that hydrodynamic size of nanoparticles 
dispersed in liquid is often larger than its primary particles size as measured by TEM, 
here they seemed to increase substantially as a function of time and temperature 
(Figure 3.4C) leading to rapid sedimentation of the aggregates.  However, in RPMI 
with 10% FBS, TiO2-UCNs formed a stable dispersion. To check, if this was due to 
the presence of serum proteins, the aggregation characteristic of TiO2-UCNs in PBS 
and PBS with 10% FBS were compared, and found that there was over 10 time 
increase in particle size in the absence of FBS (Figure 3.4D - F). 
 
To better understand the process of aggregation, the surface charge of these 
nanoparticles were studied by measuring the zeta-potential. When TiO2 nanoparticles 
are dispersed in water, the surface of the nanoparticle is generally covered by 
hydroxyl group (Ti
IV






, which imparts a negative charge to 
it. As expected, although TiO2-UCNs had a negative zeta-potential (Table 3.1), its 











Table 3.1 Zeta-potential and PDI of 100 μg/ml TiO2-UCN and Mal-PEG-TiO2-UCNs, 
immediately after dispersing in various solutions 
 
 
Generally, zeta-potential of more than +30mV or less than −30mV is required to 
provide enough repulsive forces to counterweigh the van der Waals force of attraction 
that leads to particle aggregation. Presumably, the low zeta potential (in the range of -
25.5 ± 6.8), could be the reason for the observed increase in the hydrodynamic sizes 
of TiO2-UCNs in water. On the other hand, in a high ionic strength dispersing media 
(like PBS and RPMI), the hydrodynamic size of nanoparticles are affected by both the 
zeta potential and electrical double layer thickness. It is well known that electrical 
double layer thickness around the nanoparticles becomes smaller when dispersed in 
high ionic strength solutions,
192
 which correspondingly leads to a weaker electrostatic 
repulsive force resulting in large sized aggregates. It is worth noting that the zeta-
potential of TiO2-UCNs in PBS is in the range of -24.0 ± 2.3 mV and that in RPMI 
without FBS is -9.6 ± 1.3 mV. Thus, both a weak zeta-potential and smaller electrical 
double layer could have resulted in the formation of large aggregates in PBS and 
RPMI. On the contrary, binding of serum proteins to the surface of TiO2-UCNs 
forming a “protein corona”, helped to maintain dispersion stability when 
nanoparticles were suspended in media containing serum.
194
 The presence of proteins 
on the surface of TiO2-UCNs creates a physical steric barrier, preventing the 
nanoparticles from approaching one another.
195
 Although serum protein binding might 
 Zeta-potential (mV) PDI 
Water -25.5 ± 6.8 0.216 ± 0.012 
PBS -24.0 ± 2.3 0.284 ± 0.005 
RPMI without FBS -9.6 ± 1.3 0.217 ± 0.002 
RPMI with 10% FBS -7.5 ± 0.9 0.204 ± 0.005 





momentarily seem to solve the problem of aggregation, it has some serious negative 
implications as certain components of the protein corona may act as opsonins.
196, 197
 
Opsonization can eventually lead to the recognition and removal of these 
nanoparticles from circulation by the macrophages of the mononuclear phagocytic 
















Figure 3.5 (A) ROS production from irradiated and non- irradiated TiO2-UCNs in 
PBS at various conditions; data are mean (n=2) ± SD. (B) Comparison of ROS 
production irradiated immediately after 20 min sonication, soaked overnight and 
irradiated without and with 20 min sonication to study the effect of aggregation on 
ROS production; data are mean (n=2) ± SD. *P<0.05 versus ROS production at 60 
min from monodisperse TiO2-UCNs irradiated immediately after sonication, ns stands 
for ‘not significant’. (C) Comparison of ROS production from TiO2-UCNs in the 
presence of ROS scavengers like 10% FBS, DMSO and sodium pyruvate. Data are 
mean (n=2) ± SD. 
#
P<0.0001, *P<0.05 versus ROS production at 60 min from TiO2-
UCNs in PBS irradiated immediately after sonication. 





3.3.3. ROS generation ability of TiO2-UCNs in physiological conditions 
Upon NIR irradiation, monodisperse TiO2-UCNs (with an average hydrodynamic size 
of 184.5 ± 11.31 nm) generated significant amount of ROS in PBS compared to the 
corresponding non-irradiated nanoparticles (P< 0.0001) (Figure 3.5A).To check the 
effect of aggregation on the ROS production ability of TiO2-UCNs, the nanoparticles 
were soaked in PBS overnight, and the aggregated nanoparticles with an average 
hydrodynamic size of 2793 ± 55.15 nm, were then irradiated without sonication prior 
to exposure to NIR. Aggregation was found to reduce the ROS generation ability of 
TiO2-UCNs by 30% (Figure 3.5A and B), probably due to the reduced accessibility of 
oxygen and water with in the interior surface of the aggregated nanoparticles, to 
effectively react with electron and hole pairs formed within the aggregates. On 
redispersing the aggregated nanoparticles by sonicating them for 20 min prior to NIR 
irradiation, the ROS production of TiO2-UCNs (now with an average size of 199 ± 
8.45 nm) were found to be reversed. To further evaluate the ROS generation ability of 
TiO2-UCNs in physiologically relevant conditions, 10% FBS was added to the 
suspension prior to irradiation. Serum is known to be a scavenger of ROS, and as 
expected there was a 36% drop in the ROS production (Figure 3.5C). Furthermore, 
addition of DMSO – a hydroxyl radical scavenger and sodium pyruvate - hydrogen 
peroxide scavenger, revealed significant quenching of APF fluorescence. 
3.3.4. In vitro uptake and dark toxicity of TiO2-UCNs 
We chose human OSCC cells as a model as these cells overexpressed epithelial 
growth factor receptors on its cell surface,
198
 that can be utilized to specifically target 
the developed nanoparticles to these cancer cells in the next phase of our study. On 
incubating the nanoparticles with OSCC cells for 6 h, TiO2–UCN were taken up with 
in the cells and were observed mainly in the cytoplasm (Figure 3.6A), which is 





important for subsequent PDT treatment. It was found that there was no significant 
reduction in the viability of OSCC cells and normal NHF cells treated with TiO2-
UCNs up to a concentration of 1 mM (Figure 3.6B). At 2 mM, though the cell 
viability is still above 80%, it is significantly lower than the viability of untreated 
control cell and drops below 50% at very high concentration of 8 mM. As the 
standard MTS ([3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) proliferation assay only reflects the mitochondrial 
enzyme activity, the dark-toxicity of the nanoparticles was also evaluated using the 
LDH assay which determines the quantity of the cytosolic enzyme, lactate 
dehydrogenase that is released when the cell wall is lysed, which in turn indicates the 
toxicity of the nanoparticles. Again there was no significant difference between 
viability of OSCC and NHF cells and viability of the cells treated with TiO2-UCNs, 

















Figure 3.6 (A) Fluorescence microscopic images showing uptake TiO2-UCN into 
OSCC. Blue fluorescence indicates upconversion emission from the TiO2-UCN under 
980 nm excitation, green fluorescence indicates cell membrane counterstaining with 
Wheat Germ Agglutinin, Alexa Fluor® 488 Conjugate while red fluorescence is 
nuclear counterstaining with PI (scale bar: 50 μm). In vitro dark toxicity of 
nanoparticles incubated with OSCC and NHF cells using (B) MTT,  and (C) LDH 
assay; data are mean (n=3) ± SD. 
 
3.3.5. In vitro PDT 
Before evaluating the efficiency of the synthesized nanoparticles for PDT, it is 
essential to optimize the PDT parameters like the light dose and time of irradiation 
such that the NIR light itself does not kill the cells. To achieve this, OSCC cells were 
subjected to a range of NIR laser dose at 980 nm, to determine a light dosage that can 
be well tolerated by the cell, but is detrimental to the cells in the presence of 
nanoparticles. Since, here the photocatalyst TiO2 is excited indirectly by an 
upconverted UV light (anti-Stokes scheme) and not by direct excitation with UV as in 
a typical PDT regime, the excitation power density that is required will be relatively 
higher due to the low efficiency of the upconversion process.
136
  It was found that a 
NIR laser power of 1.2 W under continuous irradiation for 5 min 20 sec (at power 
density of ∼2.1 W/cm2) delivering a light fluence of 675 J/cm2 was well tolerated by 
OSCC cells (Figure 3.7A), with >95% cell viability. At the same time, in the presence 
of 1 mM TiO2-UCNs, irradiation using this optimized light dose killed about 50% of 
the cells. Any further decrease in laser power and increase in time of irradiation did 
not hit such a right balance. Under NIR irradiation using the optimized light dose 
following 6h incubation with TiO2–UCN, there was a significant drop in the viability 
of both OSCC and NHF cells to about 60% of control untreated cells (Figure 3.7B), 
indicating the effectiveness of the developed nanoparticles for PDT. However, it is to 
be noted that cell killing ability of TiO2-UCNs saturated, such that the photocatalytic 
killing effficiency of the nanoparticles did not increase much with increase in 





concentration, and the maximum cell death achieved was 50-60% under the best 
conditions. This could perhaps been due to the formation of large aggregates in the 













Figure 3.7 (A) Optimization of NIR laser dose for in vitro PDT. OSCC cells treated 
with 1 mM TiO2-UCN were irradiated with varying power and fluences using 980 nm 
NIR laser. Light alone control was also run alongside by irradiating the cells that were 
not treated with any nanoparticles, with the same power and light fluence. Response 
of the cells to the PDT treatment was then quantified by measuring their viability by 
MTT assay. Data are mean (n=4) ± SD, *P<0.0001, ns stands for not significant 
compared to control. (B) In vitro PDT using TiO2-UCN on OSCC and NHF cells. 
Values are means (n= 3) ± SD. (C) Comparison of cell killing efficiency of TiO2-
UCNs in the presence of ROS scavengers, DMSO and sodium pyruvate;
 #
P<0.0001, 
*P<0.05. Data are mean (n=3) ± SD.  





To further confirm that the cell death was indeed brought about by ROS, scavengers 
of ROS such as DMSO and sodium pyruvate were added to the culture media prior to 
the irradiation. The presence of DMSO and sodium pyruvate protected OSCC cells 
from hydroxyl radicals and hydrogen peroxide and reduced cell death significantly 
even in the presence of NIR light (Figure 3.7C). From these observations it can be 
concluded that the cell death was primarily caused by hydroxyl radicals generated 
during the photocatalytic reaction, which were scavenged by DMSO, thereby 
reducing the cell-death. However the presence of other ROS agents like hydrogen 
peroxide or superoxide that are not scavenged by DMSO, could still have caused the 
death of a fraction of cells. 
3.4. CONCLUSION 
Controlling the amount of PS loaded in UCN constructs and achieving stable loading 
of sufficient amount of PS, has been one of the major bottleneck in the design of UCN 
based PDT nanoplatform impeding its translation to even distantly comparable 
advances in the clinics. In the present study, a different method of “direct surface 
coating” of a photocatalyst TiO2 is achieved on the UCN core, resulting in stable and 
precisely controllable PS loading in the UCNs. Here, the photocatalyst TiO2 was 
individually coated on each UCN core to give rise to a well-defined core–shell 
structure with uniform size and shape. However, the developed nanoparticles were 
found to form huge aggregates in physiological solution in the absence of serum due 
to their weak zeta potential and high ionic strength of the media, and the formation of 
large aggregates reduced its ROS production ability. Although, serum protein binding 
to these nanoparticles might momentarily seem to solve the problem of aggregation, it 
might lead to other obstacles such as reduced circulation time leading to decreased 
bio-availability especially during their application in-vivo.  While, the nanoparticles 





were found to be quite biocompatible at concentration of up to 1 mM and resulted in 
significant cell death when irradiated with NIR light, thus indicating the effectiveness 




























CHAPTER 4  




It is well known that when nanomaterials are dispersed in aqueous systems there 
occur a dramatic change in their physicochemical properties like aggregation state and 
surface charge.
199, 200
  Aggregation could lead to size- and surface area- dependent 
toxicity. Thus, thorough and accurate characterization of nanoparticle dispersion 
properties in physiologically relevant system is necessary to provide key information 
towards the understanding of its behaviour, reactivity and toxicity in biological 
systems. Although, the synthesized TiO2-UCNs demonstrated fairly good 
performance as a PDT agent producing significant amount of ROS and inducing 
reasonable reduction in viability in cell based assays, in depth characterization studies 
in physiological solution revealed formation of large aggregates as well as attachment 
of serum proteins to the surface of the nanoparticles. Aggregation of TiO2-UCNs in 
physiologically relevant media could be detrimental to its intended use as a NIR 
excitable photocatalytic agent, as formation of large aggregates was found to reduce 
the ROS generation ability of these nanoparticles. Furthermore, this could also 
hamper the uptake of the nanoparticles by the cells. Both these factors could have led 
to the observed saturation in the PDT effect, resulting in a dose-independent PDT 
response in vitro. On the other hand, although attachment of serum proteins to the 
nanoparticle surface was found to favor the formation of a stable dispersion by 
creating a physical steric barrier, they could also act as opsonin proteins and tag the 





nanoparticles for recognition and uptake by the cells of the mononuclear phagocytic 
system (MPS). This could again lead to quick removal of the nanoparticles from the 
circulation when administered systemically, reducing their bioavailability at the target 
site.  Hence, it was necessary to surface modify TiO2-UCNs to: (a) improve its 
dispersion stability in physiological solution without compromising its ROS 
producing ability, as well as (b) prevent the attachment of opsonins and camouflage 
the nanoparticles from the MPS. 
In this chapter, the synthesized titania coated core-shell structured UCNs (TiO2-
UCNs) were furthered surface modified to impart stability and stealth properties, 
towards making it more conducive for biological applications. PEGylation or addition 
of PEG chains to the surface of nanoparticles, constitutes the most efficient and 
widely used anti-opsonization and steric stabilization strategy.
201
 Typically, a PEG 
chain with molecular weight of 2000Da or greater is required to achieve stealth 
characteristics,
202
 such that it remains invisible to the phagocytic cells. Hence, a 
maleimide-PEG-silane with a molecular weight of 2000Da was chosen to surface-
modify TiO2-UCNs. The maleimide group served as a reactive functional group for 
further conjugation of tumor targeting moieties, for targeted delivery of nanoparticles 
in the future. The PEGylated nanoconstruct was again subjected to rigorous testing at 
physiological conditions to check for their stability and anti-opsonisation ability, 
before evaluating their PDT performance in vitro and in vivo. 
4.2. MATERIALS AND METHODS 
4.2.1. Surface modification of TiO2-UCNs with Maleimide-PEG-silane 
4 mg maleimide-PEG-silane (Nanocs Inc., New York, USA) was dissolved in 4 ml of 
water, to which 4 mg of TiO2-UCN dispersed in 4 ml ethanol was added. 
Subsequently, 10 µl of TEOS was added and the solution was stirred at RT for 30 





min. At the end of stirring, 150 µl of ammonia (28 wt%) was added drop wise to the 
solution and stirred for another 3 h at RT. Mal-PEG-TiO2-UCNs were then collected 
by centrifuging solution at 8000 rpm for 10 min at 10°C, washed two times with 
ethanol and then stored at 4°C. For comparison, PEG-silane without maleimide group 
(methoxy-PEG-silane -2000Da, Nanocs Inc., New York, USA) was also used to 
surface modify TiO2-UCNs using the same protocol. 
4.2.2. Characterization of synthesized nanoparticles.  
Size and morphology of the synthesized nanoparticles were characterized using a 
JEOL 2010 TEM operating at an acceleration voltage of 200 kV. Fluorescence spectra 
was recorded on a SpectroPro 2150i spectrophotometer (Roper Scientific Acton 
Research, MA) equipped with a 1200 g/mm grating and  980-nm VA-II diode pumped 
solid-state (DPSS) laser. FT-IR spectra were recorded on a Shimadzu IRPrestige-21 
model spectrometer (Shimadzu Corporation, Kyoto, Japan).  DLS was conducted with 
the Zetasizer (Nano ZS, Malvern Instruments Ltd., UK) to measure the hydrodynamic 
diameter, PDI and zeta-potential. Nanoparticles at a concentration of 1 mg/ml in 
deionised water were sonicated for 20 min before further diluting (100 µg/ml) it in 
water, PBS, RPMI and RPMI with 10% FBS to determine the average aggregate size 
with time.  
4.2.3. Measurement of ROS production in solution  
UCNs at a concentration of 1 mg/ml in PBS were sonicated for 20 min and APF dye 
at a final concentration of 10 µM was added to the UCN suspension. The fluorescence 
of suspension was measured before irradiation at 515 nm by a UV-Vis 
spectrophotometer (Photonitech, Singapore) under excitation at 490 nm, which is 
denoted as fluorescence intensity at time 0 h (t=0). The suspension was then irradiated 
using 980 nm NIR light at a power of 1.2 W for up to 60 min, measuring the 





fluorescence at every 20 min of irradiation. As the amount of generated ROS is 
proportional to the fluorescence intensity of APF, the fluorescence intensity is plotted 
as a function of exposure time. 
To demonstrate the tissue penetration abilities, the same experiment was performed 
by placing tissue phantoms of varying thickness (6 - 10 mm), in the path of the 
incident NIR or UV light. Briefly, the tissue phantoms were prepared using 0.5% 
(w/v) ultrapure agarose (Invitrogen, USA), 1% (v/v) of intralipid-10% (KabiVitrum 
Inc., USA) as the scatterer and 0.1% (v/v) Nigrosin, as the absorber. The tissue 
penetration and ROS generation abilities of NIR and UV light was expressed as 
percentage drop in ROS generation from 1 mg/ml Mal-PEG-TiO2-UCNs following 
irradiation in the presence of tissue phantoms as compared to direct irradiation of the 
sample with NIR or UV light without the tissue phantom. 
4.2.4. Gel electrophoresis and silver staining 
The nanoparticles (TiO2-UCNs and Mal-PEG-TiO2-UCNs) at a concentration of 1 
mg/ml were soaked in RPMI with 10% FBS or 100% FBS for 24 h. The suspension 
was then carefully layered over 10% glycerol and centrifuged at 15000 rpm for 15 
min. The pellet was collected and resuspended in 200 µl of deionized water. Equal 
volume of this sample was treated with 2 X Laemmli sample buffer (Bio-Rad, USA) 
and heated for 5 min at 95°C to reduce the di-sulfide bonds. The samples were then 
loaded on a 5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) gel to separate SDS-denatured proteins at 120 V for 2.5 h. The protein bands 
were silver stained using the Pierce Silver Stain Kit (Thermo Scientific, USA), 
following manufacturer’s instructions.  
 
 





4.2.5. Cell-lines   
OSCC (CAL-27), mouse leukemic monocyte macrophage cell line (RAW 264.7) and 
NHF cells (IMR-90) were purchased from ATCC, USA. The cells were cultured in 
RPMI (OSCC cells) and DMEM (Macrophages and NHF cells). The media were 
supplemented with 10% FBS and 1% penicillin-streptomycin. Cells were maintained 
at 37°C in a humidified atmosphere containing 5% CO2. 
4.2.6. In vitro macrophage uptake assay 
RAW 264.7 mouse macrophages were seeded in 8-well chambered slide at a cell 
density of 25 x 10
3
 cells per well and incubated overnight to allow the cells to adhere 
to the floor of the wells. The medium in the wells were replaced with a nanoparticle 
suspension (TiO2-UCN or Mal-PEG-TiO2-UCN) at a concentration of 1 mM (270 
µg/ml) in DMEM supplemented with 10% FBS and incubated for 1 h at 37°C. The 
macrophage cells were then rinsed three times with 1 × PBS to wash away the excess 
non-ingested nanoparticles and fixed in ice-cold methanol for 10 min. The plasma 
membrane was stained with Wheat Germ Agglutinin, Alexa Fluor® 488 Conjugate 
(Molecular Probes, Inc., USA) at a concentration of 5 µg/ml for 10 min. The nucleus 
was further counterstained with PI (Molecular Probes, Inc., USA) at a concentration 
of 500 nM for 5 min. The cells were gently washed three times with PBS and 
mounted using Vectashield mounting medium (Vector Laboratories, USA). The 
uptake of unmodified and modified TiO2-UCNs by the macrophages was imaged 
using an upright Nikon 80i Fluorescence Microscope (Nikon, Japan) equipped with a 
980 nm Laser Wide-field Fluorescence add-on (EINST Technology Pte Ltd, 
Singapore) using a 20X objective (200X magnification).  The plasma membrane and 
nuclei of the cells were visualized under excitation with Hg arc lamp and a standard 
FITC and TRITC filter set, respectively. The uptake of unmodified and modified 





TiO2-UCNs by macrophages was also compared by measuring the total fluorescence 
intensities of UCNs using the Image J 1.47v software (National Institute of Health, 
USA). 
4.2.7. In vitro dark-toxicity measurement.  
OSCC and NHF cells were seeded at a cell density of 8 X 10
3
 per well in a 96-well 
plate and incubated overnight to allow it to adhere to the bottom of the plate. The 
nanoparticles (TiO2-UCNs or Mal-PEG-TiO2-UCNs) were prepared at a concentration 
of 1 mg/ml in sterile PBS, sonicated for 20 min and then diluted in RPMI with 10% 
FBS at varying concentrations ranging from 10 µM (2.7 µg/ml) to 4 mM (1.08 
mg/ml) before adding to the cells.  Cells were further incubated for 6 h at 37 °C after 
which they were gently washed 3 times with 1 X PBS  to remove the nanoparticles 
and replaced with fresh culture media. Following 24 h incubation at 37°C, the number 
of viable cells was determined by MTS assay using CellTiter 96® AQueous One 
Solution Cell Proliferation Assay (Promega, Madison, WI, USA) kit as per 
manufacturer’s instructions. The percent cell viability values are reported relative to 
those of untreated control cells. 
For trypan blue staining, 8 X 10
4 
OSCC cells were seeded in a 12 well plate and 
treated with nanoparticles as mentioned above. The cells in each of the wells were 
harvested and collected by centrifugation at 1200 rpm for 5 min. The cells were then 
stained with 0.4% trypan blue solution in PBS for 5 min before counting using a dual-
chamber hemocytometer and a light microscope. Total number of cells and dead (blue 
coloured) cells were recorded, and the mean of three independent cell counts were 
pooled for analysis. The percentage of viable cells was determined by according to the 
following formula. Percent of viable cells = 100 x [(Total number of cells – Number 
of dead cells)/ (Average number cell in the control untreated well)]. 





4.2.8. Hemolysis assay 
Female Balb/c nude mice, 6–8 weeks of age, weighing an average of 17 g were 
obtained from BioLasco, Taiwan. Fresh blood (≈1 ml) was obtained from mice via 
cardiac puncture. All procedures carried out in this study were approved by the 
Institutional Animal Care and Use Committee, SingHealth, Singapore and were 
conducted in accordance with international standards. Red blood cells (RBCs) were 
separated from plasma by centrifuging at 1500 rpm for 15 min at 4°C. The isolated 
RBCs were further washed three times with sterile PBS by centrifugation until the 
supernatant was clear, and resuspended in 2 ml PBS. Then 100 µl of the nanoparticle 
(both TiO2-UCN and Mal-PEG-TiO2-UCN) suspension in PBS at concentrations 
ranging from 50 µM to 4 mM were added to 100 µl of the RBCs suspension. 
Following 2 h incubation at 37°C under constant shaking, the suspensions were 
centrifuged at 1500 rpm for 15 min. Subsequently, 100 µl of supernatant from each 
centrifuge tube was used to analyse hemoglobin release by microplate reader at the 
wavelength of 576 nm. Control experiments were performed under the same 
experimental conditions, where 100 µl of the RBCs suspension was added to 100 µl 
of PBS as a negative control and to 100 µl of 0.5% Triton X-100 as a positive control. 
The percentage hemolysis was calculated using the following equation: 
Hemolysis(%) = (OD576 sample − OD576 negative control)/(OD576 positive control 
− OD576 negative control) ×100% 
4.2.9. In vitro uptake of nanoparticles  
OSCC cells were seeded in a 145 cm
2
 cell-culture dish at a density of 3 x 10
6
 cells per 
dish and incubated at 37°C overnight. Cells were treated with UCNs at a 
concentration of 1 mM for 3, 6 or 24 h; following which the culture medium 
containing non-internalized nanoparticles were discarded, and the cells were washed 





three times with phosphate-buffered saline. The cells were then harvested and the 
intracellular uptake of nanoparticles was determined by measuring the titanium, 
yttrium and ytterbium content using inductively coupled plasma atomic emission 
spectroscopy (ICP-AES). 
For imaging uptake of nanoparticles, OSCC and NHF cells were seeded in 8 well 
chambered slide and incubated overnight; following which the cells were treated with 
Mal-PEG-TiO2-UCNs at a concentration of 1 mM for 6 h. The cells were then fixed 
with ice-cold methanol for 10 min; plasma membrane and nuclei were stained with 
Wheat Germ Agglutinin, Alexa Fluor® 488 Conjugate and PI, washed, coverslipped 
and imaged using a Nikon 80i Fluorescence Microscope (Nikon, Tokyo, Japan) using 
a 40X objective (400X magnification) under excitation with Hg arc lamp and a 
standard FITC and TRITC filter set. Furthermore, the uptake of Mal-PEG-TiO2-UCNs 
and Met-PEG-TiO2-UCNs in OSCC cells at various incubation conditions was 
quantified by measuring the total fluorescence intensities of UCNs using the Image J 
1.47v software (National institute of Health, USA). To check the influence of N-
ethylmaleimide (NEM) on the cellular uptake of Mal-PEG-TiO2-UCNs, OSCC cells 
were pre-blocked with 1 nM NEM in serum free RPMI for 15 min, followed by 6 hr 
incubation with 1 mM Mal-PEG-TiO2-UCNs.  
4.2.10. In vitro PDT  
OSCC cells were seeded into 96-well cell culture plate at a cell density of 8 X 10
3 
cells per well. Following overnight incubation at 37°C, the cell were treated with 
various concentrations of unmodified and surface modified TiO2-UCNs ranging from 
10 µM to 1 mM for 6 h. The medium containing non-internalized nanoparticles were 
removed and the cells were washed three times with PBS, and replaced with fresh 
culture medium. The cells were then irradiated using 980 nm NIR light at a power of 





1.2 W for 5 min 20 sec delivering a total fluence of 675 J/cm
2
.The cells were 
incubated for additional 24 h before percentage of cell viability relative to the control 
untreated cells was determined using CellTiter 96® AQueous One Solution Cell 
Proliferation Assay (Promega, Madison, WI, USA) as per manufacturer’s instructions.  
4.2.11. Measurement of ROS production in vitro 
The amount of ROS generated following in vitro PDT using TiO2-UCNs or Mal-PEG-
TiO2-UCNs was measured using OxiSelect™ In vitro ROS/RNS Assay Kit 
(CellBiolabs Inc. USA) following the manufacturer's instruction. Briefly, OSCC cells 
were seeded into 96-well cell culture plate at a cell density of 8 X 10
3 
cells per well. 
Following overnight incubation at 37°C, the cells were then treated with TiO2-UCNs 
or Mal-PEG-TiO2-UCNs for 6 h, following which the medium was removed and 
replaced with 100 µL of the non-fluorescent 2’,7’-dichlorofluorescein (DCFH) for 1 
h. The cells were then gently washed three times with 1X PBS and fresh medium was 
added to each well followed by 980 nm NIR light irradiation using same light dose as 
mentioned above. The ROS generated in the cells was determined fluorometrically by 
measuring the amount of 2’, 7’-dichlorodihydrofluorescein (DCF) produced and 
comparing it with predetermined DCF standard curve. 
4.2.12. Assessment of mode of cell-death 
To study the mode of cell death following in vitro PDT, OSCC cells were lightly 
counterstained with 0.1% trypan blue in PBS for 5 min at different time intervals after 
treatment (30 min and 6 h). The cells were then gently washed once with 1 X PBS and 
coverslipped with Hank’s balanced salt solution (HBSS) and immediately visualised 
using a bright field microscope fitted with a Nikon DS-Ri1 camera. 
To further assess the mechanism of cell death following PDT, Promokine 
apoptotic/necrotic/healthy cells detection kit (PromoCell GmbH, Germany) was used 





according to manufacturer’s instruction. Briefly, OSCC cells adhering to the bottom 
of 8-well chambered slide were subjected to PDT following which the slides were 
returned to 37°C incubator for the PDT effect to take place. The cells were then 
washed two times with 1X binding buffer and stained with staining solution 
containing 5 µl of FITC-Annexin V, 5 µl of Ethidium Homodimer III and 5 µl of 
Hoechst 33342 in 100 µl 1X binding buffer for 15 min at RT. The cells were further 
washed two times with 1X binding buffer and coverslipped with 1X binding buffer. 
Images were acquired on a Nikon 80i Fluorescence Microscope (Nikon, Tokyo, 
Japan) using a 20X objective (200X magnification) under excitation with Hg arc lamp 
and a standard FITC, TRITC and DAPI filter set.  
4.2.13. In vivo imaging 
In vivo imaging following intratumoral administration of 0.1mg Mal-PEG-TiO2-
UCNs was performed using the uFluor-980 small animal fluorescence upconversion 
imaging system (Einst Technology Pte Ltd, Singapore). Briefly, 0.1 mg Mal-PEG-
TiO2-UCN in 40 µl saline was intratumorally injected at 2 or more sites. Imaging was 
performed before as well as 30 min and 6 h after administration of particles under 980 
nm laser excitation delivering a fluence rate equivalent to 250 mW/cm
2
. Similarly, 
UCL images from tumor tissues excised from mouse at 4 h post injection of 0.1 mg 
TiO2-UCNs or Mal-PEG-TiO2-UCNs, were also captured using 810 nm emission 
filter. To determine the localization of the nanoparticles with in the tumor, tumor 
tissue was harvested 4 h post intratumoral administration of Mal-PEG-TiO2-UCNs. 
The tissues were cryosectioned and fixed in 4% paraformaldehyde for 15 min. The 
sections were washed 3 X 5 min in PBS, and stained with Wheat Germ Agglutinin, 
Alexa Fluor® 488 Conjugate for 2 h followed by PI for 30 min. The sections were 
again washed 3 X 5 min, coverslipped and imaged using a Nikon 80i Fluorescence 





Microscope (Nikon, Tokyo, Japan) under excitation with Hg arc lamp and a standard 
FITC and TRITC filter set. 
4.2.14. In vivo PDT treatment 
Animals were assigned to six different groups: (i) control (untreated tumor), (ii) NIR-
light alone control (1000 J/cm
2
) (iii) TiO2-UCN alone (0.1 mg/tumor)  (iv) Mal-PEG-
TiO2-UCN alone (0.1 mg/tumor) (v) TiO2-UCN (0.1 mg/tumor) + PDT (1000 J/cm
2
) 
and (vi) Mal-PEG-TiO2-UCN (0.1 mg/tumor) + PDT (1000 J/cm
2
), and each group 
comprised of 5 animals. Tumor volume was measured when tumors reached a size of 
about 120 mm
3
. For group (ii), tumors were irradiated with 980 nm NIR light at a 
fluence rate of 500 mW/cm
2
 for 33 min 20 sec. For group (iii) and (iv), tumors were 
intratumorally injected with 40 μl of respective UCNs. For group (v) and (vi), 4 h post 
intratumoral administration of 40 μl of respective UCNs, the tumors were irradiated 
with NIR light. For all groups, tumor volume was measured on at least 3 alternate 
days a week, for up to 35 d. The tumor volume was calculated using the following 
formula: Volume = (π/6 × d1 × d2 × d3), where d1, d2 and d3 are tumor dimensions 
in 3 orthogonal directions. For Evan’s blue staining, 400 μl of 1% Evan’s blue dye in 
saline was injected intraperitoneally into the animals 48 h post treatment and 6 h later 
the animals were sacrificed to excise the tumors. 2 – 3 mm thick cross-section slices 
of tumors were cut and imaged under a stereoscopic microscope (Stemi 2000C, Zeiss, 
Germany). For H&E staining, tumors were excised 48 h post treatment and snap-
frozen in liquid nitrogen. Serial 8 μm thick cryosections were fixed in acetone, stained 
with H&E and imaged by a Nikon 80i digital microscope (Nikon, Tokyo, Japan) 
using a 20X objective (200X magnification). 
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In all figures, data points represent mean ± SD. Statistical analyses were performed 
using the GraphPad Prism version 6.0 software (GraphPad Software, San Diego 
California USA). Differences in means were compared with two-tailed unpaired 
Student’s t -test or using two-way ANOVA followed by Bonferroni's post-hoc test. P 
values less than 0.05 (P<0.05) were considered significant. 
4.3. RESULTS AND DISCUSSION 
4.3.1. Synthesis and characterization of Mal-PEG-TiO2-UCNs 
 
In order to surface modify TiO2-UCNs with maleimide-PEG-silane, TEOS was added 
which conferred hydroxyl (OH) groups on the TiO2 shell for the attachment of silane 
group of maleimide-PEG-silane, resulting in the formation of Mal-PEG-TiO2-UCNs 























Figure 4.1 (A) Schematic of synthesis of Mal-PEG-TiO2-UCN; TEM images of (B) 
TiO2-UCNs and (C) Mal-PEG-TiO2-UCN, (scale bar: 50 nm). 





TEM of both TiO2-UCNs and Mal-PEG-TiO2-UCNs revealed a uniform spherical 
shape with a well-defined core-shell structure and average primary particle size of 
∼50 nm for both nanoparticles, before and after surface modification (Figure 4.1B 
and C). This is because the TEM images only reflects the inorganic core size, without 
taking into account the surrounding soft capping/polymeric layer and solvation layer. 
Upon 980 nm NIR light irradiation, Mal-PEG-TiO2-UCNs also emitted upconverted 
light in UV, visible and NIR regions of the spectrum (Figure 4.2A). Fourier transform 
infrared (FT-IR) absorption spectra confirmed successful grafting of maleimide-PEG-
silane on the surface of TiO2-UCN, with characteristic peaks of PEG appearing at 
~2885 cm
-1
 and ~1470-1350 cm
-1
 corresponding to C-H stretching and C-H bending, 







Figure 4.2 (A) Fluorescence emission spectra of 100 μg/ml TiO2-UCN in PBS under 
NIR excitation. (B) FT-IR absorption spectra of TiO2-UCN, Maleimide-PEG-silane 
and Mal-PEG-TiO2-UCN 
 
4.3.2. Stability Mal-PEG-TiO2-UCNs in physiological solutions 
 
PEGylation of TiO2-UCNs conferred dispersion stability up to 24 h, with smaller 
hydrodynamic sizes (∼300 nm) and PDI, even in the absence of FBS (Figure 4.3A -
C). As PEGylation further reduced the negative zeta-potential of TiO2-UCNs (Table 
4.1), the dispersion stability observed in the case of Mal-PEG-TiO2-UCNs is assured 





not by the electrostatic repulsion but by the steric repulsion between the PEG chains. 
Furthermore, while the PDI of TiO2-UCN was slightly greater than 0.2 in the different 
solutions except in RPMI with 10% FBS, PDI of Mal-PEG-TiO2-UCN was less than 
0.2, again indicating formation of a stable dispersion (Table 4.1).  
Table 4.1 Zeta-potential and PDI of 100 μg/ml Mal-PEG-TiO2-UCNs, immediately 













Figure 4.3 (A) Average hydrodynamic size of 100 μg/ml Mal-PEG-TiO2-UCN in 
different solutions at RT plotted as a function of time. (B) Average PDI of 100 μg/ml 
Mal-PEG-TiO2-UCN in different solutions at RT plotted as a function of time and (C) 
Photograph of stable dispersion of 100 µg/ml Mal-PEG-TiO2-UCNs soaked in PBS at 
0, 6 and 24 h. (D) Image of a silver stained gel to detect adsorption of serum proteins 
on the surface of nanoparticles suspended in either RPMI with 10% FBS or in 100% 
FBS. Unmodified TiO2-UCN in water and 100% FBS were run as negative and 
positive controls, respectively. 
 Zeta-potential (mV) PDI 
Water -15.3 ± 5.3 0.154 ± 0.004 
PBS -8.09 ± 0.5 0.183 ± 0.002 
RPMI without FBS -8.16 ± 0.3 0.188 ± 0.004 
RPMI with 10% FBS -10.4 ± 0.3 0.155 ± 0.008 





To check if PEGylation was successful in reducing protein adsorption, nanoparticles 
soaked in RPMI with 10% and 100% FBS were centrifuged to separate out the 
nanoparticles with attached serum proteins. Gel electrophoresis and silver staining 
revealed that PEGylation significantly reduced, but did not completely exclude, 
adsorption of serum proteins to the surface of TiO2-UCNs (Figure 4.3D). 
4.3.3. ROS generation ability of Mal-PEG-TiO2-UCNs 
Upon NIR irradiation, both TiO2-UCNs and Mal-PEG-TiO2-UCNs generated 
significant amount of ROS in PBS compared to the corresponding non-irradiated 
nanoparticles (Figure 4.4A). In addition to this, we determined the tissue penetration 
ability of NIR light  as well as its ROS production ability following indirect excitation 
of TiO2 shell by the upconverted UV light and further compared it with direct 
excitation of TiO2 shell with UV light, by utilizing tissue phantoms of varying 









Figure 4.4 (A) Comparison of ROS production from non-irradiated and irradiated 
nanoparticles in PBS, *
,#
P<0.0001 versus ROS production from non-irradiated TiO2-
UCNs and Mal-PEG-TiO2-UCNs, respectively after 60 min. Data are mean (n>2) ± 
SD. (B) Comparison of ROS production from 1mg/ml Mal-PEG-TiO2-UCNs 
irradiated with NIR or UV light in the presence of tissue phantoms of different 
thickness, *P<0.05 versus ROS production from NIR irradiated Mal-PEG-TiO2-
UCNs. Data are mean (n=3) ± SD. 





It was found that while there was only about 36% drop in ROS production when 
irradiated with NIR light in the presence of a 10 mm tissue phantom, there was over 
90% drop in ROS generation when irradiated with UV light. Thus, when compared to 
direct excitation of TiO2 shell with UV light, indirect excitation with NIR light has the 
advantage of penetrating thick tissues, which further highlights the suitability of our 
nanoconstruct in the treatment of solid or deep-seared tumors. 
4.3.4. Uptake of nanoparticles in macrophage and cancer cells 
 
The presence of PEG also reduced the recognition and uptake of nanoparticles by 
mouse macrophage cells. TiO2-UCNs were taken up about 4 times more than Mal-







Figure 4.5 (A) Representative fluorescence microscope images showing blue 
upconversion fluorescence indicating nanoparticle uptake by macrophages following 
1 h incubation with 1 mM of respective nanoparticles; green and red fluorescence 
indicate cell membrane and nucleus, respectively (scale bar: 50 μm). (B) Comparison 
of fluorescence intensities of nanoparticles at a concentration of 1 mM taken up by 
macrophages following 1 h incubation; *P=0.0004. Data are mean fluorescence 
intensities (n>3) ± SD. 
 
To optimize the treatment time it is important to determine the time required for 
maximum number of nanoparticles to bind and be taken up by the target cells. Both 
TiO2-UCNs and Mal-PEG-TiO2-UCNs were incubated with OSCC cells for different 
time-points, and washed to remove the unbound nanoparticles. Subsequently, the cells 
were digested and the lysate was quantitatively analysed for titanium content by ICP-





AES. It was found that while PEGylation reduced uptake of nanoparticles by 
macrophage cells, it significantly enhanced the uptake of nanoparticles into OSCC 
cells (Figure 4.6A) compared to TiO2-UCNs. Moreover, there was significantly 
greater uptake at 6 h post incubation compared to 3 h incubation. At the end of 6 h 
incubation, the nanoparticles were mostly observed in the cytoplasm (Figure 4.6B and 
C). However, following 24 h incubation there was a drop in titanium content 
compared to the 6 h time point, suggesting the realease of some of the ingested 















Figure 4.6 (A) Comparison of titanium content by ICP-AES analysis following 
uptake of 1mM TiO2-UCN or Mal-PEG-TiO2-UCN in OSCC cells; *P<0.0001. Data 
are mean concentration of titanium (n=2) ± SD. Confocal fluorescence microscopic 
image showing localization of PEG-TiO2-UCNs in the cytoplasm of OSCC cells. 
Cells were incubated with 1 mM PEG-TiO2-UCN for 6 h. (B) Volume rendered xy 
image of z-stacks of an adherent OSCC cell with blue fluorescence indicating the 
uptake of PEG-TiO2-UCN. Green fluorescence indicates cell membrane stained with 
wheat germ agglutinin, Alexa Fluor® 488 conjugate and red fluorescence indicates of 
nuclear counterstaining with PI.  (C) Volume rendered xy image of z-stacks rotated at 
an angle to show persistence of fluorescence across the optical sections. (D) 
Representative fluorescence microscope images of OSCC cells incubated with 1 mM 
Met-PEG-TiO2-UCN or Mal-PEG-TiO2-UCN for 3 h (Scale bar: 20 μm). (E) 
Comparison of fluorescence intensities of 1mM TiO2-UCNs surface modified with 





methoxy-PEG-silane (Met-PEG-TiO2-UCN) or maleimide-PEG-silane (Mal-PEG-
TiO2-UCN) incubated with OSCC cells; *P<0.05. Data are mean fluorescence 
intensities (n>3) ± SD. 
 
It is often argued that while PEGylation reduced macrophage recognition and uptake, 
it could in turn lead to reduced cellular uptake, decreasing the therapeutic potential of 
such nano-delivery systems. However, we observed an increased uptake of Mal-PEG-
TiO2-UCNs by the cancer cells compared to TiO2-UCNs. As maleimide group rapidly 
and specifically binds to the thiol group, it is possible that PEG-maleimide-modified 















Figure 4.7 (A) Relative UCN fluorescence intensity showing influence of N-





ethylmaleimide (NEM) on the cellular uptake of Mal-PEG-TiO2-UCNs, OSCC cells 
were pre-incubated with or without 1 nM NEM in serum-free RPMI for 15 min, 
followed by 6 h incubation with 1 mM Mal-PEG-TiO2-UCNs (Data are mean (n<6) ± 
SD, *P= 0.0464) and (B) Representative fluorescence microscope images of OSCC 
cells incubated with 1 mM Mal-PEG-TiO2-UCN with and without NEM (Scale bar: 
20 μm). (C) Representative fluorescence microscope images of OSCC cells incubated 
with 1 mM Mal-PEG-TiO2-UCN for 3 h in RPMI media with no FBS, 10% FBS or 
50% FBS. Blue upconversion fluorescence indicates nanoparticle uptake by OSCC 
cells; green and red fluorescence indicate cell membrane and nucleus, respectively 
(Scale bar: 20 μm). (D) Influence of serum proteins in the binding and internalization 
of 1 mM Mal-PEG-TiO2-UCNs in OSCC cells following 3h incubation; *P=0.0091. 
Data are mean fluorescence intensities (n>3) ± SD. 
 
To further investigate whether the presence of maleimide has indeed favoured the 
binding and uptake of TiO2-UCNs in cancer cells, we utilized PEG-silane with 
(maleimide-PEG-silane) and without malemide group (methoxy-PEG-silane, 2000Da) 
to surface modify TiO2-UCNs, and compare its cell-binding and internalization 
efficiency in OSCC cell. The results revealed a significant increase in the uptake of 
Mal-PEG-TiO2-UCNs into the OSCC cells as early as 3 h (Figure 4.6D and E), which 
could be due to the interaction of maleimide group on the nanoparticle with the cell-
surface thiols. As a further confirmation, when cell surface thiols were pre-blocked 
with NEM, we observed 5 fold reduction in the internalization of Mal-PEG-TiO2-
UCNs in cancer cells (Figure 4.7A and B). Apparently, if such interactions existed, 
the maleimide group could also interact with thiols groups on various serum 
components before reacting with cell surface thiols, leading to suppression of the 
nanoparticle uptake. Nevertheless, the uptake of Mal-PEG-TiO2-UCNs was not 
significantly affected by the presence of 10% FBS compared to the uptake in medium 
without FBS, but dropped about 4 folds in the presence of 50% FBS (Figure 4.7C and 
D). Similar results were recently reported using maleimide functionalized liposomes, 
in which the enhanced uptake in the presence of serum proteins were attributed to the 
binding of malemide functionalized nanoparticles to certain serum proteins like albu-
min, that express reductive cysteine residues and tend to be taken by cells via 







 Although, a higher FBS concentration could be 
detrimental, 10% FBS was still optimal for the cell internalization process of 
maleimide functionalized nanoparticles. Apart from the absence of a reactive 
maleimide group, other possible reasons for the relatively lower uptake of bare TiO2-
UCNs in cancer cells could be the higher surface negative charge compared to Mal-
PEG-TiO2-UCNs that could have reduced its attachment to the negatively charged 
cell membrane, and perhaps due to aggregate formation in complex biological 







Figure 4.8 In vitro dark toxicity of nanoparticles incubated with OSCC cells for 6 h 
using (A) MTT, *P=0.0082  and (B) trypan blue assay; data are mean (n=3) ± SD. 
 
4.3.5. Dark-toxicity of nanoparticles. 
We chose human OSCC cells as a model for both in vitro and in vivo studies as these 
cells overexpressed epithelial growth factor receptors on its cell surface,
198
 that can be 
utilized to specifically target the developed nanoparticles to these cancer cells in the 
next phase of our study. It was found that there was no significant difference between 
cell-viability of untreated OSCC cells and cells treated with TiO2-UCNs or Mal-PEG-
TiO2-UCN up to a concentration of 1 mM (Figure 4.8).  
 
 

















Figure 4.9 (A) Representative fluorescence microscope images showing various 
nanoparticle uptake (1mM concentration) by NHF and OSCC cells following 6 h 
incubation. Blue upconversion fluorescence indicates nanoparticles internalized by 
the cells, green and red fluorescence indicates cell membrane and nucleus, 
respectively (Scale bar: 20 μm). (B) In vitro dark toxicity of nanoparticles incubated 
with NHF cells using MTT assay; data are mean (n=3) ± SD. 
 
At 2 mM, though the cell viability is still above 80%, it is significantly lower than the 
viability of untreated control cell and drops below 50% at very high concentration of 
4 mM. Again, there was no significant difference between the toxicity of unmodified 
and surface modified TiO2-UCNs except at high concentration above 2 mM, where 
the PEGylated TiO2-UCNs seemed to be significantly less toxic than the unmodified 
version (P=0.0082). As the standard MTS ([3-(4,5-dimethylthiazol-2-yl)-5-(3-





carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) proliferation assay only 
reflects the mitochondrial enzyme activity, the dark-toxicity of the nanoparticles was 
also evaluated using the trypan-blue dye exclusion method which is based on the fact 
that dead cells lose their membrane integrity and becomes permeable to the dye. As 
expected, this time the viability of OSCC cells dropped slightly more, but again there 
was no significant difference between cell-viability of untreated OSCC cells and cells 
treated with TiO2-UCNs or Mal-PEG-TiO2-UCN up to a concentration of 1 mM and 
cell-viability remained above 80% (Figure 4.8B). Thereafter, it reduced to 60% at a 
concentration of 2 mM. Hence, for all subsequent in vitro work, the maximum 
concentration of nanoparticles used was fixed at 1 mM. Although, the cell uptake and 
dark-toxicity of OSCC cells cannot be compared with normal human fibroblast (NHF) 
cells, owing to the difference in cell sizes and growth patterns (Figure 4.9A), a  
similar trend in dark-toxicity was also observed when the nanoparticles were 
incubated with NHF cells (Figure 4.9B). 
4.3.6. Hemolysis assay 
 
The hemocompatibility of the nanoparticles at a concentration range of 50 µM – 4 
mM were evaluated with RBC lysis assay. As shown in Figure 4.10A and B, both 
TiO2-UCNs and Mal-PEG-TiO2-UCNs displayed a dose-dependent increase in 
hemoglobin release. However, the RBC lysis caused by TiO2-UCNs at concentrations 
greater than 50 µM were significantly greater than Mal-PEG-TiO2-UCNs. Percent 
hemolysis levels in 4 mM TiO2-UCN treated RBCs were 21.7%. On the other hand, 
the hemoglobin release caused by Mal-PEG-TiO2-UCNs was well below 5% across 
the range of concentrations investigated. This indicates that PEG modified TiO2-
UCNs exhibit excellent hemocompatibility and is suitable for in vivo application. 
 












Figure 4.10 (A) Photographs of hemolysis of mouse RBCs in the presence of 
nanoparticles; Triton-X 100 and PBS are used as positive and negative controls, 
respectively. (B) Rate of hemolysis in RBCs upon 2 h incubation with nanoparticles at 
incremental concentrations, *P<0.05, **P<0.0001; data are expressed as mean ± SD 
and n=4.  
 
4.3.7. In vitro PDT and cell death. 
 
In vitro PDT on OSCC cells using the previously  optimized light parameters, showed 
that Mal-PEG-TiO2-UCNs produced significantly more cell death (78%) compared to 
TiO2-UCNs (56%) at a concentration of 1 mM (Figure 4.11A). Thus, surface 
modification of TiO2-UCNs significantly improved the PDT efficacy of TiO2-UCNs 
in vitro. As a further proof that the cell-death is indeed bought about by ROS that is 
generated by the photoactivation of TiO2 shell on the UCNs, the ROS generation was 
quantitatively evaluated within 30 min after irradiation of the cells. At a concentration 
of 1 mM, the Mal-PEG-TiO2-UCNs in the presence of 980 nm light produces 
significant amount of ROS compared to TiO2-UCNs, resulting in better PDT efficacy 
probably due to the higher uptake of the nanoparticles by the cancer cells (Figure 
4.11B). Additionally, it was observed that in the case of Mal-PEG-TiO2-UCN, there 
was a considerable dose-dependence in the production of ROS. In contrast, TiO2-
UCNs did not display such a trend. In addition to quantitative analysis, the generated 
ROS was also imaged using carboxy-2′,7′-dichlorodihydrofluorescein (carboxy-





H2DCHF), a fluorogenic marker for ROS. Here, the non-fluorescent carboxy-
H2DCHF is oxidised to fluorescent carboxy-DCF (bright green fluorescence) in the 
presence of ROS. As a result of the photocatalytic damage induced by modified and 
unmodified TiO2-UCNs upon NIR irradiation, there were a significant number of cells 
exhibiting bright green fluorescence representing oxidative stress in the presence of 
ROS (Figure 4.11C). Again, the fluorescence from the cells treated with Mal-PEG-
TiO2-UCNs was visibly much stronger than that treated with the unmodified version, 















Figure 4.11 (A) OSCC cell viability 24 h following in vitro PDT in the presence of 
nanoparticles; Control cells are untreated cells assumed to have 100% viability, Light 
alone control are cells treated with NIR light alone. Data are mean cell viability % 
(n=3) ± SD. The extent of ROS generated was (B) quantified based on the 
fluorescence intensity of carboxy-DCF (Data are mean relative fluorescence 
intensities (n=3) ± SD) and (C) visualized by fluorescence microscopy, images 





showing green fluorescence indicating positive staining for carboxy-DCF, blue 
fluorescence indicate nucleus. 
 
Furthermore, it was found that when Mal-PEG-TiO2-UCNs were incubated for a 
shorter duration of 1 h, the particles were mostly seen attaching to the cell membrane, 
with very minimal uptake of the particles into the cells (Figure 4.12A). However, after 















Figure 4.12 Variation in the cell uptake, cell viability and in vitro ROS generation 
ability of 1 mM Mal-PEG-TiO2-UCN incubated with OSCC cell for either 1 h or 6 h. 
(A) Fluorescence microscopy images showing blue upconversion fluorescence 
indicating the presence of Mal-PEG-TiO2-UCNs. Mal-PEG-TiO2-UCNs were 
predominantly localized in the cell membrane (arrows) when they are incubated for a 
shorter period (1 h) with OSCC cells (Scale bar: 20 μm). (B) Comparison of cell 
viability post NIR-PDT at 675 J/cm
2
 following incubation of 1 mM Mal-PEG-TiO2-
UCNs at 1h and 6h; *P<0.5 (Data are mean (n=3) ± SD.). (C) Comparison of in vitro 
ROS generation following PDT in the presence of 1 mM Mal-PEG-TiO2-UCNs that 
were incubated for 1 h and 6 h. Images showing green fluorescence indicating 
positive staining for the fluorogenic marker for ROS, carboxy-DCF (Scale bar: 25 
μm). 
 





Although, a longer incubation time was required for the uptake of nanoparticles 
within the cytoplasm, we expected that a short DLI could likely be sufficient to 
produce enough cell death by disruption of the membrane integrity by the ROS. On 
comparing the cell-viability, it was observed that there was about 50% cell death 
following PDT after a mere 1 h incubation of Mal-PEG-TiO2-UCN (Figure 4.12B). 
Nevertheless, cell death was more pronounced (>70%) following PDT after 6 h 
incubation. This observation is consistent with our in vitro nanoparticle uptake data, 
that there is a higher uptake of nanoparticles after a 6 h incubation period, due to 
which there was greater reduction in cell vibility following PDT. But the significance 
of this observation is that the mere attachment of the nanoparticles to the cell-
membrane itself could kill a significant number of cells. In an in vivo setting, this 
could imply that it might not be essential for the nanoparticles to enter the cells to 
achieve a reasonable amount of tumor cell destruction following PDT. However, for a 
more rounded and effective PDT outcome perhaps the uptake of the nanoparticles into 
the cell will be desirable as an incomplete treatment would often lead to a rapid 
relapse of the tumor. Having established that ROS is the major causative agent for cell 
death following NIR mediated photocatalytic activation of TiO2, the next step was to 
determine the mechanism of cell death. PDT is known to induce cell-death by 
apoptosis, necrosis or autophagy depending on the cell type, the nature and 
localisation of the PSs and the light dose.
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 When untreated OSCC cells and cells 
irradiated with NIR light alone were stained with trypan blue, very few cells seemed 
to take up the blue dye within 30 min of light irradiation (Figure 4.13A). However, 
when the cells were incubated with Mal-PEG-TiO2-UCNs for 6 h and then irradiated 
with NIR light, majority of the cells stained blue within 30 min of treatment, 
indicating loss of membrane integrity although the cells appeared to maintain its 





shape. 6 h after NIR light irradiation, there was cell membrane blebbing and complete 




















Figure 4.13 (A) Bright-field live cell images showing mechanism of cell death in 
OSCC cells counterstained with trypan blue, inset shows cells undergoing necrosis 
(scale bar:10μm). (B) Representative fluorescence microscopy images showing mode 
of cell death post PDT in OSCC treated with 1mM TiO2-UCN or Mal-PEG-TiO2-
UCN. Necrotic and apoptotic cells were stained with Ethidium Homodimer III (red 
fluorescence) and annexin V-FITC (green fluorescence), respectively. Positions of the 
cells are indicated by nuclear staining with Hoechst 33342 (blue fluorescence), scale 
bar: 50 µm. 
 





To further confirm this, the cells were stained 30 min after treatment with FITC-
Annexin V, Ethidium Homodimer III and Hoechst 33342 that stains apoptotic cells 
green, ncrotic cells red and nuclei blue, respectively. It was found that majority of the 
cells incubated with Mal-PEG-TiO2-UCNs and TiO2-UCNs underwent necrosis, 
staining red and blue (Figure 4.13B). 
4.3.8. In vivo imaging following intratumoral administration of the UCNs 
 
In order to determine the time of homogenous distribution of UCNs in the tumor 
following intratumoral injection of Mal-PEG-TiO2-UCNs, animals were imaged by an 
in vivo optical imaging system using an external 980 nm laser excitation source. 
Bright UCL emission was captured using an 810 nm emission filter, 30 min and 6 h 




















Figure 4.14 (A) In vivo imaging of upconversion luminescence in live mouse upon 
excitation with 980 nm laser using a 810 nm emission filter before (time= 0 h) as well 
as 0.5 h and 6 h after intratumoral administration of 0.1 mg Mal-PEG-TiO2-UCN. (B) 
Representative UCL images from excised tumor tissues (from the top and bottom) 4 h 
post intratumoral administration of 0.1 mg TiO2-UCNs (i and iii) and Mal-PEG-TiO2-
UCNs (ii and iv). (C) Representative fluorescence microscopy image showing the 
localization of Mal-PEG-TiO2-UCNs (blue fluorescence) in the tumor tissue excised 
4h post intratumoral administration, green and red fluorescence indicates cell 
membrane and nucleus, respectively (Magnification: 200X, scale bar: 50 μm). Inset 
shows higher magnification (400X) of the field (scale bar: 50 μm). 
 
However, the UCL from the tumor at 6 h was better distributed across the tumor 
compared to that at 30 min. To better understand the distribution of particles within 
the tumor, we studied the UCL emission from the tumor tissue excised 4 h post 
intratumoral administration of the nanoparticles. It was found that TiO2-UCNs and 
Mal-PEG-TiO2-UCNs diffused out from the site of injection and distributed 
throughout the tissue (Figure 4.14B). To further find out the localization of the 
nanoparticles with in the tumor, the tumor were excised at 4 h post injection with 
Mal-PEG-TiO2-UCNs and sections were imaged using fluorescence microscope. The 
Mal-PEG-TiO2-UCNs were found in the extracellular space as well as entered the 
tumor cell by 4 h post administration (Figure 4.14C). 
4.3.9. In vivo PDT and treatment efficacy 
Following NIR irradiation of the tumor, an eschar tissue was formed within 48 h in 
animals treated with Mal-PEG-TiO2-UCNs (Figure 4.15B). However, in animals 
irradiated with NIR-light alone no skin discolouration was observed (Figure 4.15A). 
Evan’s blue vital staining was done to compare the effect of NIR light alone and NIR 
light irradiation following intratumoral administration of Mal-PEG-TiO2-UCN. It was 
found that the NIR light alone did not cause any tumor tissue necrosis where as in 
tumors that were irradiated 4 h post intratumoral administration of nanoparticles, a 
clear unstained necrotic area was observed 48 h post PDT (Figure 4.15A and B). This 





confirmed that a 4 h DLI allowed sufficient distribution of nanoparticles within the 










Figure 4.15 Representative images of mouse 48 h post-PDT treated with (A) NIR 
light alone (1000 J/cm
2
), (B) intratumorally injected with Mal-PEG-TiO2-UCN + NIR 
light (1000 J/cm
2
) and sections of tumor tissue excised from the respective mouse 6 h 
after intraperitoneal injection of Evan’s blue vital stain. (C) H&E stained sections of 
tumor tissue excised from untreated control, NIR alone control, Mal-PEG-TiO2-UCN 
alone and Mal-PEG-TiO2-UCN + NIR light treated mouse (48 h after treatment), 
Scale bar – 100 µm. (D) Change in body weight of mice in different groups following 
treatment for up to 35 d. 
 
H&E staining of tumor slices from animals that were treated with Mal-PEG-TiO2-
UCN + 980nm, revealed severe destruction of tumor cells in marked contrast to the 
tumor slices from control animals (untreated control, NIR light alone and Mal-PEG-
TiO2-UCN alone) (Figure 4.15C). As the body weight of the animal reflects its overall 
health condition, the weight of the animals in different groups were measured and 
plotted as a function of time for up to 35 d. There was no significant decrease in body 





weight in any of the animals (Figure 4.15D). Our preliminary findings reveal that 












Figure 4.16 (A) In vivo OSCC tumor growth up to 35 d on different groups of mice 
after various treatments indicated, n=5 per group. Error bars represent standard error 
of the mean (SEM). Representative images of animals with tumors that were (B) not 
treated (untreated control animals) and (C) intratumorally injected with 0.1 mg Mal-
PEG-TiO2-UCN and irradiated with 980 nm light, at designated time-points. (D) 
Survival rates of mice in different treatment groups within 60 d. 
 
The PDT treatment efficacy of the developed nanoconstruct was then explored by 
recording the tumor volume and survival rates of the animals. The untreated control 
animals and animals that were treated with NIR light alone, TiO2-UCN alone or Mal-
PEG-TiO2-UCN alone with no light irradiation did not show any therapeutic effect 
(Figure 4.16A-C). For animals with tumors that were intratumorally injected with 
TiO2-UCNs or Mal-PEG-TiO2-UCNs and exposed to NIR light, there was significant 





delay in tumor growth compared to the control groups. Although there was a clear 
reduction in the tumor size in both TiO2-UCN and Mal-PEG-TiO2-UCN injected 
groups post NIR-PDT with in the first 5 d, a complete tumor inhibition was not 
observed in these groups with a single PDT regimen. Perhaps a second round of PDT 
about 2 weeks after the first dose, when the residual tumor starts to regrow, could 
result in a better control of tumor growth and prevent tumor relapse. Survival rates of 
mice in untreated control, NIR alone control, TiO2-UCN alone and Mal-PEG-TiO2-
UCN alone treated groups reduced to 40% at day 29, 31, 33 and 36, respectively 
(Figure 4.16D). On the other hand, there was a 40% reduction in survival rate of mice 
treated with TiO2-UCNs + 980 nm by day 60, whereas no mice died in the group that 
was treated with Mal-PEG-TiO2-UCN + 980 nm. As a matter of fact, the PDT 
outcome in vivo ultimately depends on various factors such as the location, type, 
aggressiveness and oxygenation of the tumor, the type, concentration and localization 
of the photosensitizing molecule within the tumor microenvironment at the time of 
irradiation, the DLI, and the light parameters such as the total light dose, light fluence 
rate and time of irradiation 
29, 208-210
. Hence, it is critical to customize the treatment 
parameters and regimen, depending on these factors for an optimal PDT outcome.  
4.4. CONCLUSION 
Our in vitro and in vivo results clearly indicate the potential application of this 
biocompatible nanoconstruct in NIR-triggered deep-tissue PDT. On comparing with 
previous reports on direct excitation of TiO2 nanoparticles with UV light that has little 
or no tissue penetrating abilities, our method of indirectly exciting TiO2 shell via NIR 
light has the potential to significantly improve the treatment, transforming it into a 
“minimally invasive” procedure from being an “invasive” technique. Our proof-of-
concept demonstration strongly motivates further development and testing of in vivo 





toxicity and biodistribution of these nanoconstructs following systemic 
administration, as well as fine tuning of the treatment parameters. Carrying out these 
future studies will undoubtedly improve the performance and therapeutic efficacy of 
this technology, which may indeed encourage its application in clinics in the near 
future. 





CHAPTER 5  
Conjugation of PEGylated TiO2-UCN with anti-
EGFR affibody for targeted delivery to oral cancer: 




Oral cancer is the sixth leading cancer by incidence worldwide with one of the poorest 
clinical outcomes.
211
 Surgical management of oral cancer often leads to severe 
morbidity due to disfiguration and functional impairment. Although, surgery 
combined with chemotherapy and radiotherapy can improve the overall survival of 
patients with advanced oral cancers, approximately one-third experience loco-regional 
recurrences and/or distant metastasis,
212
 accounting for poor prognosis and low 
survival rate.
213, 214
 The primary tumor site, nodal involvement, tumor thickness, and 
the status of the surgical margins dictates the prognosis of the disease.
215
 The median 
thickness for T1 and T2 tumors ranges from 4.3 and 8 mm, respectively and the 
prognosis significantly changed with thickness where tumors <4 mm had 100% 
survival rates compared to 74% for those 4 mm or more thick.
216
 PDT of oral cancers 
has been garnering significant interest as an alternative therapeutic modality to treat 
head and neck cancer and the results from phase I/II trials conducted on head and 
neck tumors strongly suggest that PDT could be an effective treatment for patients 
presenting with early head and neck tumors.
217
 Clearly, new and improved therapeutic 
options are urgently needed for selective destruction of thick, solid, advanced and 
recurrent oral cancers.  





It is known that the increased expression of EGFR plays a critical role in the 
aggressive behaviour of OSCC including proliferation, invasion, metastasis, 
angiogenesis as well as therapeutic resistance.
218
 It is overexpressed in up to 90% of 
head and neck squamous cell carcinoma,
219, 220
 making it an attractive therapeutic 
target. Hence developing a targeted approach utilizing the EGFR receptor will be 
worthwhile in the treatment of solid, advanced and recurrent oral cancers.  
The previous chapter highlighted the efficiency of PEGylated TiO2-UCNs in 
generating ROS and effectively killing tumor cells in vitro, as well as in vivo 
following intratumoral administration. The present study aims to further modify the 
PEGylated TiO2-UCNs with a targeting moiety against EGFR receptors, such that it 
can specifically target EGFR expressing cancer cells when administered systemically 
in vivo. To achieve this, non-immunoglobulin-derived affinity protein known as 
Affibody
®
 was chosen due to their small size and low immunogenicity.
221, 222
 Since 
the OSCC cells (CAL 27) were previously reported to express high levels of 
EGFR,
223, 224
 anti-EGFR affibodies were utilized to conjugate the PEGylated TiO2-
UCNs. The presence of a targeting moiety on the surface of nanoparticles intends to 
enhance cellular binding and internalization through receptor-mediated endocytosis; 
the rate of which is dependent on the type of receptor-ligand interaction.
225
 In general, 
these molecules are strategically situated on the outmost exterior of the nanoparticle 
delivery system and have high affinity to their cognate receptors, as well as possess 
innate abilities to induce receptor-mediated endocytosis.
226
 Here, the fabricated anti-
EGFR-affibody conjugated PEGylated TiO2-UCNs (anti-EGFR-PEG-TiO2-UCNs) 
were again subjected to rigorous characterization and its selective cell targeting, 
uptake dynamics, ROS generation, dark toxicity and PDT efficiency were studied.  
 





5.2. MATERIALS AND METHODS 
5.2.1. Cell-lines 
All cell-lines were purchased from ATCC. OSCC (CAL-27), H596 (HTB-178) and 
H460 (HTB-177) were cultured in RPMI medium containing 10% FBS and 1% 
penicillin-streptomycin (Gibco, USA). A549 (CCL-185), MCF-7 (HTB-22), Hep-G2 
(HB-8065), and NHF cells (IMR-90) were cultured in DMEM supplemented with 
10% FBS and 1% penicillin-streptomycin. All cells were maintained at 37°C in a 
humidified atmosphere containing 5% CO2. 
5.2.2. Detection of EGFR expression in OSCC cells and tumor 
Immunofluorescence: Cells were seeded in 8-well chambered slide at a cell density of 
25 x 10
3
 cells per well and incubated overnight. The cells were then fixed in ice-cold 
methanol, followed by blocking with a blocking buffer (2 % goat serum, 2% BSA, 
0.1% Tween 20) for 1 h at 37°C. Subsequently, the cells were incubated with primary 
anti-EGFR antibody (clone EP38Y) diluted 1:100 in blocking buffer (Abcam, 
Cambridge, UK), at RT for 2h. The sections were washed 3 X 5 min with PBS and 
then incubated with Texas red (TR) labelled secondary antibody (goat polyclonal 
antibody (Abcam, UK), diluted 1:1000 in blocking buffer for 1 h at RT in dark. 
Following a 3 X 5 min washing with PBS, the plasma membrane of the cells were 
stained with Wheat Germ Agglutinin, Alexa Fluor® 488 Conjugate (Molecular 
Probes, Inc., USA) at a concentration of 5 µg/ml for 10 min at RT. The nucleus was 
further counterstained with Hoechst 33342 stain (Molecular Probes, Inc., USA) at a 
concentration of 1 μM for 5 min. The cells were gently washed three times with PBS 
and mounted using Vectashield mounting medium (Vector Laboratories, CA, USA). 
EGFR expressing human epidermoid cancer cells A431 was used as the internal 
positive control, while human breast adenocarcinoma MCF-7 cells served as the 





negative control. The cells were imaged using an upright Nikon 80i Fluorescence 
Microscope (Nikon, Tokyo, Japan) equipped with a 980 nm Laser Wide-field 
Fluorescence add-on (EINST Technology Pte Ltd, Singapore) using a 20X objective 
(200X magnification).  The EGFR statining, plasma membrane and nuclei were 
visualized under excitation with Hg arc lamp and a standard DAPI, FITC and TRITC 
filter set, respectively. 
Western blotting: The cells were grown in 175 mm
3
 flask and once confluent they 
were lysed by adding cell lysis buffer (M-PER, Pierce, USA) along with protease 
inhibitor (Complete Mini, Roche, Germany). The lysate was centrifuged at 14,000 g 
for 15 min at 4°C and the supernatnant was carefully aliquoted and stored at -80°C. 
To prepare tumor lysates, OSCC xenograft tumors were excised and immediately 
frozen in liquid nitrogen. The tumors were then crushed into powder in liquid nitrogen 
and ice-cold lysis buffer (TPER, Pierce, IL, USA) with protease inhibitor and kept on 
ice for 30 min. After subsequent centrifugation, the supernatant (total tumor cell 
lysates) were stored at -70°C. The protein concentration was estimated by Bradford’s 
assay using Bio-Rad protein assay reagent in accordance with the manufacturer’s 
protocol. 100 μg of protein were resolved on 10% SDS-PAGE gel before transferring 
to a nitrocellulose membrane. The membrane was then probed with 1:200 anti-EGFR 
monoclonal antibody (Cell Signaling Technology, USA) or anti-β actin polyclonal 
antibody (Abcam, USA) and 1:400 horseradish peroxidase-conjugated antibody (Cell 
Signaling Technology, USA) using the iBind Western System (Life Technologies, 
USA). The membrane was then incubated with chemiluminescent substrate (Thermo 
Fisher Scientific, USA) followed by detection on traditional ECL film (Amersham 
Hyperfilm ECL, GE Healthcare, USA). The intensity of the band was quantified using 





NIH Image J 1.49p software (National Institute of Health, USA). The ratio of EGFR 
band intensity was plotted against actin bands. 
5.2.3. Conjugation of affibody to Maleimide-PEG-COOH 
Anti-EGFR affibody (13.9 kDa) was purchased from Affibody AB (Sweden). Prior to 
the conjugation step, 1mg/ml lyophilized unconjugated anti-EGFR affibody in PBS 
was mixed with 20 mM dithiothreitol (DTT) at pH above 7.5 and incubated at RT for 
4 h under constant stirring at 14000 rpm. The excess DTT was then removed by 
passing the mixture through Zeba Spin desalting columns, molecular weight cut-off 
(MWCO) 7K (Pierce, USA), using PBS  (pH 7.2) with 5mM ethylenediamine 
tetraacetic acid (EDTA) as the exchange buffer. 1.2 mg of reduced anti-EGFR 
affibody was subsequently added to 48 mg maleimide-PEG-COOH (MW3000, 
Sigma, USA) in 15 ml of PBS with 5mM EDTA, and incubated at 4°C for 3 h under 
constant shaking at 285 rpm. The mixture was once again passed through Zeba Spin 
desalting columns (7K MWCO) to remove unconjugated PEG as well as exchange of 
the buffer to water. The anti-EGFR affibody conjugated PEG chains (anti-EGFR-
PEG-COOH) were subsequently freeze dried, weighed and stored at -20°C until 
further use. 
5.2.4. Grafting of anti-EGFR-PEG-COOH to TiO2-UCNs 
Under constant stirring at RT, 10 μl of APS was added to 8 mg of anti-EGFR-PEG-
COOH in 4 ml ethanol along with 8 mg of N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (EDC) in 200 ul ethanol and 8 mg of N-
hydroxysuccinimide (NHS) in 200 ul ethanol, and allowed to react overnight. 2 mg 
unmodified TiO2-UCNs well dispersed in 4 ml ethanol and 10 ul TEOS, was then 
added to the above mixture while stirring. After 30 min, 75 ul ammonia (28 wt%) was 
added drop wise to the reaction mixture and continued to stir for another 3 h at RT. At  





the end of the reaction, the affibody conjugated nanoparticles (anti-EFGR-PEG-TiO2-
UCNs) were washed three times with ethanol, air-dried and stored at 4°C. 
5.2.5. Characterization of anti-EGFR-PEG-TiO2-UCNs 
Size and morphology of the synthesized nanoparticles were characterized using TEM, 
fluorescence spectra of 100 µg/ml anti-EFGR-PEG-TiO2-UCNs in PBS at various 
time-points under NIR excitation was recorded using spectrophotometer and DLS was 
conducted to measure the hydrodynamic diameter and zeta-potential as described 
elsewhere. FT-IR spectra were recorded on a Shimadzu IRPrestige-21 model 
spectrometer (Shimadzu Corporation, Kyoto, Japan). 
5.2.6. Comparison of ROS production ability before and after affibody 
conjugation 
To measure the ROS generation ability, 1 mg of the TiO2-UCN or anti-EFGR-PEG-
TiO2-UCN was suspended in 1 mL of PBS containing 10 µM of APF dye. The 
mixture was then placed in a cuvette and the solution was irradiated with a 980 nm 
laser (EINST Technology Pte Ltd, Singapore) at 2.1 W/cm
2
 for 20 min time intervals 
beginning from time (t) = 0 to 60 min. The fluorescence emission of APF at 520 nm 
(upon excitation at 485 nm) was measured using a Tecan Safire 2 fluorescence plate 
reader (Männedorf, Switzerland).  
5.2.7. Comparison of in vitro targeting and uptake of Anti-EGFR-PEG-TiO2-
UCNs 
To compare the internalization efficiency of anti-EGFR affibody conjugated 
nanoparticles, OSCC cells were seeded in a 8 well chambered slide at a density of 25 
x 10
3
 cells per well and incubated at 37°C overnight and subsequently treated with 
TiO2-UCN or anti-EGFR-PEG-TiO2-UCN at a concentration of 1 mM for 3 h. The  





culture medium containing non-internalized nanoparticles were discarded, and the 
cells were washed three times with PBS. The cells were then fixed with ice-cold 
methanol for 10 min; plasma membrane and nuclei were stained with Wheat Germ 
Agglutinin, Alexa Fluor® 488 Conjugate and PI respectively, washed with PBS and 
coverslipped. The uptake of unmodified and modified TiO2-UCN was imaged using 
an upright Nikon 80i Fluorescence Microscope (Nikon, Tokyo, Japan) equipped with 
a 980 nm Laser Wide-field Fluorescence add-on (EINST Technology Pte Ltd, 
Singapore) using a 20X objective (200X magnification).  The plasma membrane and 
nuclei of the cells were visualized under excitation with Hg arc lamp and a standard 
FITC and TRITC filter set respectively. The uptake was quantified by measuring the 
total fluorescence intensities of UCNs with Image J 1.49p software (National Institute 
of Health, USA).  
To compare the targeting efficiency of anti-EGFR-PEG-TiO2-UCN, nanoparticles 
were incubated with various EGFR overexpressing cell-lines such as OSCC, A431, 
H596 and H460 and low EGFR expressing MCF-7 and HepG2 cells. Cells were 
seeded in 8 well chambered slide and incubated overnight; following which the cells 
were treated with anti-EGFR-PEG-TiO2-UCNs at a concentration of 1 mM for 3 h. 
Thereafter the cells were washed, fixed and stained as mentioned above. The UCN 
uptake was quantified by taking the blue (UCN fluorescence) to red (nuclei) 
intensities of the images. Furthermore, the uptake dynamics of anti-EGFR-PEG-TiO2-
UCNs in OSCC and MCF-7 cells was determined by incubating the nanoparticles 
with the cells at various time-points. To evaluate the effect of low temperature on the 
energy dependent activities of the cells such as endocytosis, OSCC cells were pre-
cooled at 4°C for 45 min prior to the addition of 1 mM anti-EGFR-PEG-TiO2-UCNs, 
which were further incubated for another 3 h. Lastly, for competition assay OSCC 





cells were pre-blocked with 20 µM human epithelial growth factor (EGF) ligand  
(R&D Systems, Inc., USA) 2 h prior to the addition of 1mM anti-EGFR-PEG-TiO2-
UCNs, which was incubated for another 3 h, before the cells were washed, fixed, 
stained and quantified as mentioned above. 
5.2.8. In vitro dark toxicity assay 
OSCC cells were seeded at a density of 8 X 10
3
 cells per well in a 96-well plate and 
incubated overnight at 37 °C, to allow it to adhere to the bottom of the plate. 1 mg/mL 
stock solution of TiO2-UCN and anti-EGFR-PEG-TiO2-UCNs was prepared in PBS 
and dispersed by sonication for 20 min before adding it in the respective culture 
medium to obtain concentration ranging from 10 μM to 5 mM. The cells were then 
treated with the different concentration of nanoparticles for 6 h at 37°C followed by 
washing it three times in PBS to remove unbound and non-internalized nanoparticles. 
Fresh culture medium was then added into each well and the cells were returned to 5 
% CO2 atmosphere at 37 °C for another 24 h round of incubation. The number of 
cells that remained viable was then assessed by MTS assay as mentioned elsewhere. 
5.2.9. In vitro PDT assay 
OSCC cells were seeded into 96-well cell culture plate at a cell density of 8 X 10
3
 
cells per well. Following overnight incubation at 37°C, the cell were treated with 
various concentrations of unmodified TiO2-UCNs and anti-EGFR-PEG-TiO2-UCNs 
ranging from 100 µM to 1 mM for 6 h. The medium containing non-internalized 
nanoparticles were removed and the cells were washed three times with PBS, and 
replaced with fresh culture medium. The cells were then irradiated using 980 nm NIR 
light at a power of 1.2 W for 5 min 20 sec delivering a total fluence of 675 J/cm
2
.The 
cells were incubated for additional 24 h before percentage of cell viability relative to 
the control untreated cells was determined by MTS assay. In order to study the 





selective killing ability of the anti-EGFR affibody conjugated nanoparticles, 1mM of 
anti-EGFR-PEG-TiO2-UCNs were incubated with cells that displayed different levels 
of EGFR overexpression for just an hour. The cells were then washed three times with 
PBS, and irradiated with NIR light using the same light parameters as mentioned 
above and further incubated 24h before proceeding to determine the viability using 
MTS assay. 
5.2.10. Statistical analysis 
Statistical analysis was performed using GraphPad Prism version 4.0 (GraphPad 
Software, Inc., San Diego, CA, USA). One-way ANOVA was used to analyze the 
variance and Bonferroni's multiple comparison tests was used to compare the 
significance between all the groups for the various experiments. A p value of <0.05 
was considered to be significant. 
 
5.3. RESULTS AND DISCUSSION 
5.3.1.  Determination EGFR expression in oral cancer cells 
To ascertain the level of EGFR expression in OSCC, the cells were 
immunofluorescently stained with anti-EGFR antibodies and the expression levels 
were compared with EGFR overexpressing human epidermoid A431 cells (positive 
control) and low EGFR expressing human breast adenocarcinoma MCF-7 cells 
(negative control). The OSCC cells revealed significant red fluorescence particularly 
on the surface of the cells (Figure 5.1A), confirming high cell surface expression of 
EGFR. In order to further confirm and quantify the level of EGFR in both OSCC cell 
and xenograft tumor, western blotting was performed (Figure 5.1B). The ratio of 
EGFR intensity plotted against actin was higher for A431 cell lysate (2.0) compared 
to OSCC cell lysate (1.7), however the difference was not statistically significant 





(Figure 5.1C). OSCC tumor lysate had the highest EGFR expression (2.4), whereas 
the MCF-7 and normal lung fibroblast NHF cells showed low expression of EGFR 
levels (0.6). This observation reconfirms that both the OSCC cells and xenograft 
tumor induced by inoculating OSCC cells in mouse models expressed high levels of 
EGFR and was suitable for further studies involving nanoparticles carrying targeting 








Figure 5.1. (A) Representative immunofluorescence images showing the expression 
of EGFR in A431 (positive control), MCF-7 (negative control) and OSCC. Red 
fluorescence represents EGFR staining and the blue fluorescence depicts nuclei, 
stained by Hoechst 33342. (B) Western blot image showing EGFR and actin 
expression in various cell and tumor lysate. (C) The ratio of EGFR band intensity 
plotted against actin. Error bars represents SD of the mean; ns stands for ‘not 
significant’. 
 
5.3.2. Synthesis of anti-EGFR-PEG-TiO2-UCNs 
The next step was to conjugate the anti-EGFR affibodies to TiO2-UCNs, and to 
achieve this dimerized anti-EGFR affibody molecules were reduced with DTT to 
expose the thiol (-SH) group on reactive cysteine residue (Figure 5.2). The thiol group 
then reacts with the maleimide group of the maleimide-PEG-COOH, to generate the 
anti-EGFR-PEG-COOH. Further addition of APS results in the reaction between 





amino group (-NH2) on the APS with COOH group on the PEG, resulting in the 
functionalization of the PEG chain with a silane group. In the final step, TEOS was 
added which conferred hydroxyl (OH) groups on the surface of unmodified TiO2-
UCNs for the attachment of the silane group of PEG-affibody conjugates resulting in 





Figure 5.2. Schematic illustration of conjugation of anti-EGFR affibodies to TiO2-
UCNs.  
 
5.3.3.  Characterization and ROS generation ability of anti-EGFR-PEG-TiO2-
UCNs 
The TEM of anti-EGFR-PEG-TiO2-UCNs revealed spherical shape with ∼50 nm 
diameter and a well-defined core-shell structure (Figure 5.3A). The nanoconstructs 
demonstrated good dispersion stability in water, PBS and RPMI with 10% FBS 
(Figure 5.3B). The hydrodynamic sizes were found to be relatively stable up to 6 h. 
The zeta-potential of the nanoparticles were found to be negative (Table 5.1) and PDI 
was less than 0.2, indicating formation of a stable dispersion. Upon NIR irradiation 
the nanoparticles dispersed in PBS, emitted mainly in the UV and blue regions of the 
spectrum. However, there was a slight drop (<1.5 times) in the fluorescence emission 
following 24 h soaking of the nanoparticles in PBS. This could probably be due to 
aggregate formation, hence all the studies were performed before 24 h. FT-IR 
absorption spectra confirmed successful grafting of PEGylated affibody conjugates on 





the surface of TiO2-UCN, with characteristic peaks of PEG appearing at ≈2885 and 
≈1470-1350 cm_1 corresponding to C-H stretching and C-H bending, and N-H stretch 
and C=O stretch pertaining to the amide linkage observed at ≈3500 and ≈1690 cm_1, 









Figure 5.3. (A) TEM image of anti-EGFR-PEG-TiO2-UCN. (B) Average 
hydrodynamic size of 100 μg/ml anti-EGFR-PEG-TiO2-UCN soaked in different 
media at RT plotted as a function of time the nanoparticles were soaked. (C) 
Fluorescence emission spectra of 100 μg/ml anti-EGFR-PEG-TiO2-UCN in PBS and 
immediately irradiated by NIR light and irradiated 24 h after soaking in PBS. (D) FT-
IR absorption spectra of TiO2-UCN and anti-EGFR-PEG-TiO2-UCN. 
  
 
Table 5.1. Zeta-potential and PDI of 100 μg/ml anti-EGFR-PEG-TiO2-UCN, 
immediately after dispersing in various solutions. 
 
Zeta potential (mV) PDI 
Water -16.5 ± 1.01 0.14 ± 0.01 
PBS -7.82 ± 0.44 0.16 ± 0.02 
RPMI with 10% FBS -7.62 ± 0.517 1.70 ± 0.02 





Upon NIR irradiation, anti-EGFR-PEG-TiO2-UCNs generated significant amount of 
ROS in PBS compared to the corresponding non-irradiated anti-EGFR-PEG-TiO2-
UCNs (Figure 5.4A). In addition to that, in comparison with unmodified TiO2-UCNs 
there no significant drop in the ROS generation after conjugation of the nanoparticles 







Figure 5.4. (A) ROS production from irradiated and non- irradiated anti-EGFR-PEG-
TiO2-UCNs in PBS and corresponding un-modified TiO2-UCNs; *P<0.0001, Data are 
mean (n=2) ± SD. (B) Comparison of ROS production from TiO2-UCNs before and 







Figure 5.5. (A) Representative images of nanoparticle uptake (blue fluorescence) in 
OSCC cells post 3 h incubation; green and red fluorescence indicate cell membrane 
and nucleus, respectively (Magnification 200X, Scale bar: 20 μm). (B) Comparison of 
fluorescence intensities of 1 mM unmodified and anti-EGFR-affibody conjugated 
TiO2-UCNs internalized by OSCC cells. Data are mean fluorescence intensities (n=5) 
± SD. 





5.3.4.  In vitro uptake and targeting efficiency of anti-EGFR-PEG-TiO2-UCNs 
When compared to unmodified TiO2-UCNs, the anti-EGFR-PEG-TiO2-UCNs were 
internalized much more rapidly and efficiently (∼3.8 folds) by OSCC cells within 3 h 
(P<0.0001) (Figure 5.5A and B). This could mostly likely be due to the presence of 
the targeting agents that could have initiated immediate attachment of anti-EGFR-
PEG-TiO2-UCNs to the EGFR receptor triggering receptor mediated endocytosis of 
these nanoparticles. To compare the internalization efficiency of anti-EGFR-PEG-
TiO2-UCNs in vitro, various cell-lines with high copy number of EGFR genes such as 
A431 and human lung adenosquamous carcinoma H596, EGFR wild type large cell 
lung cancer cell-line H460 and low EGFR expressing MCF-7 and HepG2 cell lines 
were chosen. The cell lines with EGFR amplification, A431 and H596, displayed 
greater uptake of anti-EGFR-PEG-TiO2-UCNs (Figure 5.6A and B). At the same 
time, OSCC cells also showed no significant difference in the uptake of anti-EGFR-
PEG-TiO2-UCNs compared to A431 or H596. On the other hand, EFGR wild type 
H460 cells, and low EGFR expressing MCF-7 and HepG2 cells revealed significant 
reduction in the uptake of anti-EGFR-PEG-TiO2-UCNs compared to A431 cells. This 
observation further reconfirms the advantage of having the targeting moiety on the 
surface of the nanoparticle that initiates the immediate attachment and internalization 
of the nanoparticles in cells that expressed the surface receptor against it. Furthermore 
to study the uptake dynamics of the nanoparticles with in the cells, anti-EGFR-PEG-
TiO2-UCNs were incubated with OSCC and MCF-7 cells at different time-points 
ranging from 30 min to 24 h. The highest uptake of nanoparticles was found to occur 
at 6 h post incubation in OSCC cells (Figure 5.7A). At the same time, the uptake of 
nanoparticles by MCF-7 cells at 6 h was about 2 times lower that that taken up by 
OSCC cells (P<0.0001) (Figure 5.7B and C).  


























Figure 5.6. (A) Representative images of anti-EGFR-PEG-TiO2-UCN  uptake (blue 
fluorescence) in various cells expressing different levels of EGFR receptors post 3 h 
incubation; green and red fluorescence indicate cell membrane and nucleus, 
respectively (Magnification 200X, Scale bar: 20 μm). (B) Comparison of fluorescence 
intensities of 1 mM anti-EGFR-PEG-TiO2-UCNs internalized by various cells; 





*P<0.05, #P<0.0001 compared with the uptake of anti-EGFR-PEG-TiO2-UCN by 
A431 cells, ns denotes no significant difference between the groups compared; data 































Figure 5.7 (A) Representative images of anti-EGFR-PEG-TiO2-UCN uptake at a 
concentration of 1mM, as a function of time in OSCC and MCF-7 cells; green and red 
fluorescence indicate cell membrane and nucleus, respectively (Magnification 400X, 
Scale bar: 20 μm). (B) Comparison of fluorescence intensities of anti-EGFR-PEG-
TiO2-UCN internalized by OSCC and MCF-7 cells as a function of time; *P<0.0001 
data are mean fluorescence intensities (n>4) ± SD. 
 
To check whether the uptake of anti-EGFR-PEG-TiO2-UCNs within the cells 
occurred via receptor mediated endocytosis, the cells were pre-incubated at 4°C when 
most of the energy-dependent activities such as endocytosis were suppressed. 
Consequently, the nanoparticle uptake was significantly reduced by ∼90% compared 





to the cells that were incubated at 37°C (P<0.0001) (Figure 5.8A and B), indicating 
that the internalization of the nanoparticles occurred via an energy dependent 
pathway. Finally, pre-blocking of the EGFR receptors by treating with EGF ligands 
also resulted in significant drop (∼85%) in the uptake of anti-EGFR-PEG-TiO2-UCNs  
(P<0.0001) (Figure 5.8C and D). This observation suggests that an interaction 
between anti-EGFR affibodies on the nanoparticles and the cell-surface EGFR 











Figure 5.8 (A) Representative images of anti-EGFR-PEG-TiO2-UCN uptake in 
OSCC cells that were either pre-incubated at 4°C or 37°C, (Magnification 400X, 
Scale bar: 20 μm) (B) Comparison of UCN fluorescence intensities showing uptake of 
anti-EGFR-PEG-TiO2-UCN in OSCC cells pre-incubated at different temperature, 
*P<0.0001, data are mean fluorescence intensities (n=5) ± SD. (C) Representative 
images of anti-EGFR-PEG-TiO2-UCN uptake in OSCC cells that were either not 
treated or pre-blocked with EGF. (D) Comparison of UCN fluorescence intensities 
showing uptake of anti-EGFR-PEG-TiO2-UCN in OSCC cells that were either not 
treated or pre-treated with EGF to block the EGFR receptors; *P<0.0001, data are 
mean fluorescence intensities (n=5) ± SD. 
 





5.3.5.  In vitro dark toxicity and PDT using anti-EGFR-PEG-TiO2-UCNs 
On comparing the toxicity of the nanoparticles post incubation with OSCC cells, both 
anti-EGFR-affibody conjugated nanoparticles were found to be less toxic and were 
not significantly lower than the untreated control cells up to a concentration of 1 mM 
(Figure 5.9A). Whereas, unmodified TiO2-UCNs where found to cause significant 
decrease in cell viability from a concentration of 50 μM, compared to the viability of 
the untreated control cells. Again, up to a concentration of 2 mM the viability of the 
cells treated with anti-EGFR-PEG-TiO2-UCN was still above 80%. However, the cell 
viability drops below 50% at very high concentration of 5 mM.  These results suggest 
that the PEG chains might have contributed to the biocompatibility of the anti-EGFR-
PEG-TiO2-UCNs and that the conjugation of anti-EGFR affibody do not have any 
significant negative effect on the viability of the cells. In vitro PDT in OSCC cells 
post 6h incubation using the previously optimized light dose parameters demonstrated 
significant cell death in a dose dependent manner when treated with anti-EGFR-PEG-
TiO2-UCNs (Figure 5.9B). It was found that at a concentration of 1 mM about 80% of 
the OSCC cells were killed, which was equivalent to the cell-death brought about by 
Mal-PEG-TiO2-UCNs in the previous chapter. Finally to demonstrate selective killing 
of EGFR expressing cells, anti-EGFR-PEG-TiO2-UCNs were briefly incubated (1h) 
with OSCC, A431 or MCF-7 cells. On irradiating the cells with 980 nm NIR light, 
similar amount of cell death (∼35%) was achieved in A431 and OSCC cells (Figure 
5.9C). On the other hand, there was merely any cell death in the case of MCF-7 cells. 
This again reiterates the fact that due to the presence of the targeting agent, anti-
EGFR-PEG-TiO2-UCNs quickly attaches to the EGFR receptors expressed on the 
OSCC and A431 cells, within a short span of time and triggering internalization 
through receptor mediated endocytosis. As expected, the enhanced uptake of the 





targeted nanoparticles by the EGFR positive cells resulted in the higher cell death 













Figure 5.9 (A) In vitro dark toxicity of nanoparticles incubated with OSCC cells for 6 
h using MTT assay. (B) OSCC cell viability 24 h following in vitro PDT; control cells 
are untreated cells assumed to have 100% viability, light alone control are cells 
treated with NIR light alone. (C) In vitro PDT following incubation of anti-EGFR-
PEG-TiO2-UCNs with various cells for a brief period of 1 h, to demonstrate selective 
cell killing; *P<0.0001, data are mean cell viability % (n=3) ± SD. 
 
5.4. CONCLUSION 
Advanced and recurrent oral cancer is often associated with poor prognosis, hence 
alternative targeted therapies to selectively destroy thick and solid lesions need to be 
developed. In view of this, anti-EGFR affibody conjugated PEGylated TiO2-UCNs 
were developed for targeted delivery of nanoparticles specifically to the tumor cells so 
that they can then be excited by deep tissue penetrating NIR light to achieve cancer 
cell destruction at much deeper levels in the tissue.  The developed anti-EGFR-PEG-
TiO2-UCNs were found to specifically target EGFR expressing cells, leading to their 





enhanced uptake by these cells probably by an energy dependent receptor mediated 
endocytosis process. Pre-blocking of the receptors using EGF, endogenous ligand of 
EGFR receptor, resulted in significant reduction in the uptake of the nanoparticles, 
suggesting the critical role of EGFR receptors in the attachment and internalization of 
these targeted nanoparticles. The in vitro PDT results also indicate the ability of the 
anti-EGFR affibody tagged TiO2-UCNs in not only bringing about significant cell 
death, but also in causing selective destruction of EGFR expressing cells. Further in-
depth investigation of the biodistribution and toxicity profile of these nanoparticles is 
essential and is performed in the next part of the study. 
  





CHAPTER 6  
Targeted delivery of TiO2-UCN to oral cancer: 
Biocompatibility, biodistribution and toxicity studies   
 
6.1. INTRODUCTION 
Intratumoral delivery of drugs by direct injection into the tumor mass could result in 
extremely high doses of drug with in the tumor with minimal systemic toxicity.
227
 
However, this technique is often discouraged in clinical practice and the rationale for 
this reluctance stems from three notions: (1) the tumor can simply be resected instead 
of injecting it with drugs, (2) disturbing the tumor could stimulate metastasis along 
the needle track, and (3) in case of metastatic disease local chemotherapy may not be 
helpful. On the other hand accumulation of anti-cancer agents at non-intended sites 
causing toxicity and unwanted side effects is the major limitation of systemic 
administration. To overcome this critical issue and deliver the drugs directly to the 
tumor site, active targeted drug delivery could be exploited where tumor site-specific 
delivery of the anti-cancer agent is achieved through incorporation of a “targeting 
moiety” against a cell-surface receptor or antigen that is usually overexpressed on 
tumor cells.
225, 228, 229
 A number of cell surface receptors such as folate receptor, 
EGFR, HER-2 receptor, αvβ3 integrin receptor, transferrin receptor, prostrate specific 
antigen receptor, urokinase plasminogen activator receptor etc. have been explored as 
targets for tumor specific delivery of various nanoparticles.
229, 230
 While PEGylated 
nanoparticles are known to confer stealth properties and long circulation time, they 
primarily rely on passive targeting via EPR effect to accumulate in the tumor site, 
consequently resulting in insufficient drug concentration. In addition to that, the 





interaction of PEGylated nanoparticles with the cell membrane can be low due to the 
steric hindrance between grafted polymer chains and the cell membrane.
231
 Thus, 
intravenous administration of Mal-PEG-TiO2-UCNs was not carried out due to the 
skepticism surrounding the targeting and cell internalization ability of polymer grafted 
nanoparticles (Chapter 4). In the previous chapter, the presence of a targeting moiety, 
“anti-EGFR-affibody”, on the surface of PEGylated TiO2-UCNs was found to trigger 
rapid cellular binding and internalization through receptor-mediated endocytosis in 
the in vitro studies (Chapter 5). However, before studying the therapeutic effect of 
these nanoparticles following systemic administration in vivo, it is essential to analyse 
its biodistribution and long term toxicity profiles, as well as determine a single safe 
dose for its systemic administration in vivo. Although, UCNs have been deemed safe 





 their long term effects and potential bioaccumulation 
remain largely unexplored.  
Thus, in this Chapter, in vivo intravenous delivery of anti-EGFR-PEG-TiO2-UCN is 
performed to: (1) assess the immediate effect of the nanoparticles with components of 
the blood (hemocompatibility and blood contact properties), (2) evaluate dose 
dependent long term (120 d) toxicity to determine a single dose that is tolerable with 
minimal side effects, (3) conduct a sub-acute toxicity study (28 d) (hematology, blood 
biochemistry and histopathology) using the selected single dose and finally (4) 









6.2. MATERIALS AND METHODS 
6.2.1.  Blood and tissue collection from animals 
Female balb/c nude mice, 6–8 weeks of age, weighing an average of 17 g were 
obtained from Animal Research Centre, Australia. All procedures were approved by 
the Institutional Animal Care and Use Committee, SingHealth, Singapore, and 
performed in accordance with international standards. Before any terminal blood 
collection procedure, the animal was anaesthetized by intraperitoneal injection of 200 
µl of an anaesthetic cocktail (Ketamine: diazepam: saline 6: 9: 10).  For collection of 
blood plasma, fresh blood (≈600 µl) obtained via cardiac puncture was collected in a 
BD Microtainer PST™ tube (Becton-Dickinson Co.,USA). The tubes were 
subsequently centrifuged at 1300 g for 15 min at RT. The separated plasma was 
frozen at −80°C until analysis. For collection of mouse blood serum, fresh blood (≈1 
ml) was collected in a 2 ml centrifuge tube, and allowed to clot for about 1 h at RT. 
The tubes were then centrifuged at 1500 g for 15 min. The separated serum was 
frozen at −80°C until analysis. For harvesting tissues, the anaesthetized animals 
were sacrificed by cervical dislocation, the tissues were excised and either 
immediately snap frozen in liquid nitrogen or were fixed in 10% formalin solution. 
6.2.2. Hemolysis assay 
RBCs were separated from fresh blood (≈600 µl) obtained via cardiac puncture by 
centrifuging at 1500 rpm for 15 min at 4°C. The isolated RBCs were further washed 
three times with sterile PBS by centrifugation until the supernatant was clear, and 
resuspended in 2 ml PBS. Then 100 µl of the nanoparticle (both Mal-PEG-TiO2-UCN 
and Anti-EGFR-PEG-TiO2-UCN) suspension in PBS at concentrations ranging from 
0.0625 to 1 mg /ml were added to 100 µl of the RBCs suspension. Following 2 h 





incubation at 37°C under constant shaking, the suspensions were centrifuged at 1500 
rpm for 15 min at RT. Subsequently, 100 µl of supernatant from each centrifuge tube 
was used to analyse hemoglobin release by microplate reader at the wavelength of 
576 nm. Control experiments were performed under the same experimental 
conditions, where 100 µl of the RBCs suspension was added to 100 µl of PBS as a 
negative control and to 100 µl of 0.5% Triton X-100 as a positive control. The 
percentage hemolysis was calculated using the following equation: 
Hemolysis(%) = (OD576 sample − OD576 negative control)/(OD576 positive control 
− OD576 negative control) ×100% 
6.2.3. Platelet aggregation assay 
Anti-EGFR-PEG-TiO2-UCNs in sterile saline, at various concentrations ranging from 
10 to 100 mg/kg were thoroughly sonicated for 20 min, before intravenous 
administration (injection volume = 100 μl) through the tail vein. Plasma was then 
collected at various time-points (10, 30 and 60 min) from the animals and expression 
of mouse platelet factor 4 (PF4) in the collected mouse serum was quantified using an 
ELISA assay kit (PF4 (CXCL4) Mouse ELISA Kit, Abcam, USA) according to 
manufacturer’s instruction. 
6.2.4. Thrombin/Prothrombin determination 
Mouse blood plasma collected at 10, 30 and 60 min post systemic administration of 
different concentration of anti-EGFR-PEG-TiO2-UCN ranging from 10 to 100 mg/kg, 
was quantified for the presence of total prothrombin and thrombin using an ELISA kit 
(Prothrombin/Thrombin Mouse ELISA kit, Abcam, USA) as per manufacturer’s 
protocol. 





6.2.5.  Complement activation assay 
Determination of mouse complement protein C3 in blood sera collected at 10, 30 and 
60 min post systemic administration of different concentration of anti-EGFR-PEG-
TiO2-UCN ranging from 10 to 100 mg/kg, was done using an ELISA kit 
(Complement C3 Mouse ELISA Kit, Abcam, USA) according to manufacturer’s 
instruction. 
6.2.6.  Long term toxicity study 
A. Weight measurements: Twenty five animals were used in this study. Animals were 
randomly grouped in to 5 groups of 5 animals and each group was housed separately.  
All animals were weighed before treatment (Day 1). Animals in the control group 
received no treatment. Group 2 to 5 received intravenous injection of different doses 
of anti-EGFR-PEG-TiO2-UCN ranging from 10 -200 mg/kg (volume of injection= 
100 ul). Following systemic administration of the nanoparticles, the animals were 
closely monitored for the first 48 h, and then daily once for 28 d, during when they 
were observed for any physiological or behavioral changes as well as mortality. The 
animals were weighed individually every day and the food and water intake of each 
group were also recorded daily up to 28 d. 
B. Histopathology: At 120 d post systemic administration of different doses of anti-
EGFR-PEG-TiO2-UCNs, the animals were sacrificed; major organs were harvested 
and immediately fixed in 10% formalin, and processed using a tissue processor (Leica 
TP 1020, Germany). Briefly, the tissue samples were treated in an ascending series of 
ethanol and subsequently cleared with xylene and embedded in paraffin. The paraffin 
embedded tissue samples were cut at a thickness of 5 μm using a microtome (Leica 
RM 2135, Germany). The sections were mounted on superfrost/plus slides (Fischer 
Scientific, USA), air-dried and subsequently stained with H&E. Imaging of the tissue 





section was done using a Nikon 80i digital microscope (Nikon, Tokyo, Japan) using a 
20X objective (200X magnification). 
6.2.7 Single dose sub-acute toxicity study 
A. Cytokine release profiling: Mouse blood plasma was collected at 10, 30 and 60 
min post systemic administration of anti-EGFR-PEG-TiO2-UCN at a dose of 50 
mg/kg. Cytokines were quantified using a 64 target antibody array (Cytokine Mouse 
Membrane Antibody Array, Abcam, USA) strictly following the manufacturer’s 
protocol. Briefly, the protein array membranes were blocked with blocking buffer, 
after which the sample (blood plasma) was added to the membrane and incubated 
overnight at 4°C. After extensive washing with the wash buffers provided in the kit, 
the membrane was incubated with Biotin-Conjugated Anti-Cytokines. Following 
another round of washing, HRP conjugated streptavidin was added to the membranes 
and incubated for 2 h. After adding the detection buffer the membrane was exposed to 
X-ray film (Hyperfilm ECL, Amersham Biosciences, UK) and signal was detected 
using a film developer (Kodak M35, OMAT Processor, USA). The intensities of the 
signal were quantified by Image J 1.49p software (National institute of Health, USA). 
Normalized signal intensity of a spot in Array A “X(A)” was calculated by the 
formula: X(NA) = X(A) * P1/P(A);  where,  
X(A) is the mean signal density of a spot in array A 
P1 is the mean signal density of positive control spots on reference array 
P(A) is the mean signal density of positive control spots on array A 
By comparing the intensity of signals with the control (plasma collected from 
untreated animals), the relative expression levels of the angiogenic proteins were 
analyzed.  





B. Determination of organ weight variations: At different time-points (4 h to 28 d) 
post systemic administration of 50 mg/kg anti-EGFR-PEG-TiO2-UCN, the animals 
were weighed, sacrificed and the major organs (heart, lung, liver, spleen and kidneys) 
were harvested and immediately weighed. The coefficients of these organs to body 
weight were calculated as the ratio of tissues (wet weight) to body weight. The 
variation in the weight of the organs were compared with that excised from age 
matched untreated control animals. 
C. Hematology and blood biochemistry: For complete blood count, fresh mouse blood 
(≈500 µl) was collected into a BD Microtainer Tube K2 EDTA at different time-
points ranging from 4 h to 28 d following intravenous injection of 50 mg/kg anti-
EGFR-PEG-TiO2-UCN. Analysis of hematological parameters, total RBCs, WBCs, 
differential leucocyte counts and hemoglobin were done by Quest Laboratories, 
Singapore. Similarly for blood biochemical analysis, 200 ul of plasma was prepared 
as mentioned above and plasma levels of urea, creatinine alkaline phosphatase (ALP) 
and alanine aminotransferase (ALT) were determined by Quest Laboratories, 
Singapore. 
D. Histopathology: Following intravenous administration of 50 mg/kg anti-EGFR-
PEG-TiO2-UCN, animals were sacrificed at different time-points (ranging from 4 h to 
28 d) and the organs (heart, lung, liver, spleen, kidneys and small intestine) were 
harvested, fixed in 10% formalin and processed in a tissue processor as mentioned 
above. The tissues were sectioned and H & E stained, and analysed for 
histopathological variations. 
6.2.8.  Biodistribution 
A. Imaging: Organs harvested following intravenous delivery of 50 mg/kg anti-
EGFR-PEG-TiO2-UCN, at different time-points (ranging from 5 min to 24 h), were 





snap frozen in liquid nitrogen, cryosectioned (7 µm) and fixed in 4% 
paraformaldehyde. The sections washed 3 X 5 min in PBS, stained with 5 µg/ml 
Wheat Germ Agglutinin, Alexa Fluor® 488 Conjugate for 2 h, followed by 500 nM 
PI for 30 min. The sections were again washed 3 X 5 min, coverslipped and imaged 
using a Nikon 80i Fluorescence Microscope (Nikon, Tokyo, Japan) equipped with a 
980 nm Laser Wide-field Fluorescence add-on (EINST Technology Pte Ltd, 
Singapore) using a 20X objective (200X magnification). The cell membrane and 
nuclei were visualized under excitation with Hg arc lamp and a standard FITC and 
TRITC filter set, respectively. 
B. ICP-AES: The tissue samples were incubated in 60% nitric acid, and digestion was 
allowed to take place at 60 °C overnight. The samples were then diluted with distilled 
water to a 5% acid solution, filtered through a 0.22-μm filter and then analyzed for 
titanium content by ICP-AES analysis 
6.2.9. Statistical analysis 
Data points represent mean ± SD. Statistical analyses were performed using the 
GraphPad Prism version 6.0 software (GraphPad Software, San Diego California 
USA). One-way ANOVA was used to analyze the variance or multiple comparison 
tests were done using two-way ANOVA followed by Bonferroni's post-hoc test. P 
values less than 0.05 (P<0.05) were considered significant. 
6.3. RESULTS AND DISCUSSION 
6.3.1. Blood contact properties of anti-EGFR-PEG-TiO2-UCNs 
As soon as the nanoparticles are administered in to the blood stream they interact with 
the components of the blood, which is largely composed of proteins and blood cells 
(40–45% packed cell volume in blood), as well as the endothelial cells.233 Depending 
on their physicochemical properties such as their shape, size, surface area, surface 







 the nanoparticles may induce undesirable effects in the 
balanced function of these cells and proteins resulting in severe toxicities. Thus, 
detailed evaluation of the blood-contact properties of the nanomaterials, such as 
hemolytic activity, platelet activation and aggregation as well as clot formation, 
complement activation (which can result in undesirable immune response), are 
essential to assess its safety for clinical applications. Hemolysis (damage to RBCs), is 
a fundamental in vitro test to determine the safety of a blood-contacting nanomaterial 
material. Hemolysis results in the release of iron-containing protein hemoglobin into 
plasma which may lead to adverse health effects such as haemolytic anemia, jaundice 
and renal failure. The degree of hemolysis caused by both PEGylated and anti-EGFR 
conjugated TiO2-UCNs exposed to diluted mouse blood is shown in Figure 6.1A. The 
percent hemolysis remained below 1% across all the concentration range tested, and 
according to ASTM E2524-08 standard, percent hemolysis < 5% indicates that the 
test material is non-hemolytic.
236
  
For in vivo studies of nanoparticle blood contact properties, a dose range of 10-100 
mg/kg was chosen based on literature. Cui et al. reported a 100% death in animals 
that were intravenously injected with 220 mg/kg FA-modified chitosan coated UCN, 
within 7 days and the median lethal dose (LD50) was determined to be approximately 
149 mg/kg.
129
 As the onset of nanoparticle induced reactions associated with blood 
components could occur almost immediately after its systemic exposure, the blood 
was drawn at different time-points within the first 60 min to check for the various 
markers that indicate variations of normal hemostasis. 
 
 















Figure 6.1 (A) Rate of hemolysis in RBCs upon 2 h incubation with nanoparticles at 
incremental concentrations, data are mean (n=2) ± SD.  (B) Platelet activation assay 
presented in terms of concentration of PF4 mouse blood plasma following intravenous 
administration of anti-EGFR-PEG-TiO2-UCNs, data are (n=3) ± SD. (C) Comparison 
of level of Prothrombin in blood plasma following intravenous injection of different 
doses of anti-EGFR-PEG-TiO2-UCNs; *P<0.0001, data are (n=3) ± SD. (D) Total 
complement activation assay presented in terms of C3 protein concentration in blood 
sera post intravenous delivery of anti-EGFR-PEG-TiO2-UCNs at different doses; 
*P<0.05, Data are presented as mean ± SD (n = 3 per group). 
 
Platelets (thrombocytes) are anucleate cytoplasmic discs, 2–3 μm in diameter, that 
secrete factors necessary to convert soluble fibrinogen to insoluble fibrin, and results 
in the formation of blood clot at the site of injury. Now, foreign or synthetic materials 
in contact with blood may trigger thrombogenicity and formation of blood clots 
without any injury may lead to undesirable effects and eventually leading to fatal 
consequences.
237
 Nanoparticle induced platelet aggregation can occur due to direct 
interaction of the nanoparticles with platelets releasing thrombin, which triggers the 
intrinsic pathway of blood clotting; whereas the extrinsic pathway (tissue factor 





dependent pathway) involves the release of blood clotting factors in to the blood 
stream following vascular injury.
237
 To check for the activation (and ultimately 
aggregation) of platelets following intravenous administration of anti-EGFR-PEG-
TiO2-UCNs, the concentration of PF4  (chemokine (C-X-C motif) ligand 4 or 
CXCL4)) was determined in mouse plasma based on the principle that PF4 that has an 
anti-heparin function is released during platelet aggregation, thus playing a role in 
blood clot formation.
238
 It was found that there was no significant variation in the 
concentration of PF4 in the plasma of mice injected with any dose tested up to a 1 h, 
compared to PF4 in the untreated control mice (Figure 6.1B). However, there was a 
significant increase in the level of prothrombin in blood plasma as early as 10 min 
post injection of anti-EGFR-PEG-TiO2-UCNs at a dose of 100 mg/kg (Figure 6.1C). 
This observation indicates that anti-EGFR-PEG-TiO2-UCNs displayed an acute dose-
dependent thrombogenic activity that triggered the intrinsic pathway of blood clotting. 
Complement activation is another rapid-acting, first-line host defense mechanism that 
could be triggered by the exposure of nanoparticles in the bloodstream. The activation 
of this protein/glycoprotein network triggers a cascade of downstream events, 
resulting in effector functions such as lysis, opsonization, inflammation, secretion of 
immunoregulatory substances and immune clearance.
237
  All the three complement 
pathways, namely classical, alternative and lectin, lead to the cleavage of C3 to form 
C3b (the major complement opsonin), and C3a (an anaphylatoxin that initiates 
inflammatory responses).
239
 Hence, to assess in vivo complement activation, ELISA-
based quantification of C3 in blood serum was done within 60 min of nanoparticle 
exposure (Figure 6.1D). The results showed increase in the level of C3 protein in 
serum of animals injected with 100 mg/kg anti-EGFR-PEG-TiO2-UCNs compared to 
the untreated controls, as early as 10 min post administration. Hence, the dose range 













Figure 6.2 Change in body weight of mice in different groups following intravenous 
injection of different doses anti-EGFR-PEG-TiO2-UCNs for up to 28 days. Data are 
presented as mean ± SD (n = 3-5 per group). 
 
6.3.2. In vivo multi-dose sub-acute and sub-chronic toxicity  
Although the doses above 50 mg/kg were found to activate clot formation and trigger 
complement activation, an in vivo multi-dose (10-200 mg/kg) sub-acute (28 d) 
toxicity profiling of anti-EGFR-PEG-TiO2-UCN was performed to determine the 
immediate and acute toxic responses, physiological or behavioral changes, survival 
rates as well as sub-chronic (120 d) toxic effects of the nanoparticles. Mice injected 
with higher doses of nanoparticles (100 and 200 mg/kg), showed some signs of 
discomfort like pain and exhibited a decreased motor activity while and up to a few 
minutes after administration of the nanoparticle suspension, after which they did not 
differ noticeably from the control animals. The behavior of the mice in the other low 
dose groups was normal throughout the study. While there were no significant weight 
changes in animals in any of the groups (Figure 6.2), nor a significant variation in 
their food or water intake (Figure 6.3A and B) , 40% of the animals injected with a 
dose of 200 mg/kg died in with in the first 3 d post intravenous delivery of the 





nanoparticles (Figure 6.3C). These mice showed obvious symptoms of labored 
breathing and difficulty in movement post injection. The mice in the other groups 












Figure 6.3 Comparison of food (A) and water (B) intake in animals injected with 
different dose of anti-EGFR-PEG-TiO2-UCNs up to a period of 28 d. Data are 
presented as mean ± SD (n = 3-5 per group). (C) Survival rates of mice in different 
treatment groups within 120 d. Data are presented as mean ± SD (n = 5 per group). 
 
Histopathological evaluation of the tissues harvested at 120 d, revealed clusters of 
macrophages with intracytoplasmic pigments which probably were the ingested 
nanoparticles and were seen mostly in spleen, some in the liver and a very few in the 
lung (Figure 6.4). The nanoparticles were found to be localized within the interstitial 





macrophages in the lung, Kupffer cells in the liver and in macrophages both in the red 
and white pulp of the spleen. The amount of nanoparticles in these tissues were also 
found to be dose-dependent, with the highest concentration seen in animal injected 
with 200 mg/kg and a very few rather dispersed clusters of nanoparticles containing 
macrophages in the 50 mg/kg group. Although there was a very minimal to mild 
neutrophil infiltration in these organs, they were not necessarily associated with the 
presence of nanoparticles in the lung, liver or spleen. All other organs (heart, kidney 



















Figure 6.4 Representative pictures from H&E stained sections of the heart, lung, 
liver, spleen, kidney and small intestine, harvested from mice at 120 d following 
intravenous administration of different doses of anti-EGFR-PEG-TiO2-UCNs. Black 
arrows denote clusters of macrophages with ingested nanoparticles. The 
magnification: 200X. Scale bar: 50 µm. 
 
Thus, from the above multi-dose hemocompatibility and long term toxicity studies, 
the dosage of 50 mg/kg body-weight was found to have minimal toxic effects on the 
animals and hence was chosen for the subsequent single dose toxicity, biodistribution 
and therapeutic studies. 
6.3.3. In-vivo single-dose sub-acute toxicity 
 
No obvious differences were found in the weight coefficients of the heart, lung, liver 
or kidneys between the control mice and mice injected with 50 mg/kg anti-EGFR-
PEG-TiO2-UCN up to 28 d (Figure 6.5A). However, there was an obvious increase in 
the coefficient of spleen compared to control group from 24 h and remained high up 








Figure 6.5 (A) Organ weight coefficients, data are presented as mean ± SD (n = 4-5 
per group), *P=0.0011, 
#
P=0.0031 (B) Biochemical parameters in blood plasma 
(Mean ± SD, n= 3-4) at different time-points, *P<0.0001. 
 
Analysis of biochemical parameters in the plasma at various time-points up to 28 d 
revealed no significant changes in kidney function markers urea and creatinine and 
one of the liver injury marker ALP, compared to the control group (Figure 6.5B). 





However there was a significant difference in the level of another marker for liver 
damage - ALT, which increased right from 24 h post administration of 50 mg/kg anti-
EGFR-PEG-TiO2-UCN. The ALT levels peaked (3 fold increase compared to 
controls) between 7 to 14 d, and then dropped back to normal levels at 28 d post 
injection. ALP and ALT are two liver enzymes that are associated to the 
hepatocellular damage. ALP is present in the cells lining the hepatic biliary ducts, 
while ALT exists in the cytoplasm of hepatocytes.
240
 Increase in the plasma ALT 
concentration indicates altered hepatocellular membrane permeability resulting in the 
leakage of the enzyme into the bloodstream,
241
 perhaps due to the presence of the 
nanoparticles. This could eventually progress to hepatocellular damage/necrosis, 
hepatocyte proliferation or hepatocellular degeneration. However, the fact that at 28 d 
the ALT levels are not significantly different from control, suggests that the altered 
membrane permeability could probably be reversed. Nevertheless, the increase in 
ALT level at 24 h post administration does indicate the probability of an acute liver 
damage, which could be further confirmed by histopathological analysis.  
Evaluation of hematological parameters did not reveal any significant variations 
except for significantly high platelet counts as early as 24 h. Similar observations 
were reported following intraperitoneal administration of TiO2 nanoparticles in rats.
242
 
In addition to the increased platelet counts there was a mild increase in the white 
blood cell and neutrophil counts. A high white blood cell and neutrophil count 
signifies chronic inflammatory reaction in response to the exposure of the 
nanoparticles,
243
 however in this case the increase was not really significant. While, 
platelets are known to assist in the modulation of inflammatory and immune 
responses, neutrophils play a role in the phagocytosis of small particles. On the whole, 





there was no major hematological variation, except for a mild inflammatory/ immune 
response. 
Table 6.1 Hematological parameters of mice treated with 50 mg/kg anti-EGFR-PEG-
TiO2-UCN at different time points (Data are mean ± SD, n= 3-4). 
 
  Controls 4 h 1 day 7 day 14 day 28 days 
Red cell count 
(1012/L) 
9.5 ± 0.6  9.6 ± 0.1 10.2 ± 1.0 9.5 ± 0.1 9.9 ± 0.3 9.8 ± 0.3 
White cell count 
(109/L) 
2  ± 0.5 2.4 ± 0.2 5.6 ± 2.0 3.1 ± 1.1 4.1 ± 1.1 2.6 ± 0.2 
Hemoglobin (g/dL) 14.4 ± 1.1 15.2 ± 0.6 15.7 ± 0.6 15.0 ±  0.2 15.2 ± 0.4 14.8 ± 0.2 
Platelets (109/L) 426 ± 190.6 345.5 ± 54.4 438.3 ± 7.8* 694 ±144.6* 603 ± 104.4 763.75 ± 129.1* 
Neutrophils (%) 24.2  ± 7.5 78.5 ± 16.3 76.5 ± 13.9 52.3 ± 1.7 44.1 ± 20.3 51 ± 9.8 
Lymphocytes (%) 42.05 ±9.7 17.5 ± 13.4 18.2 ± 8.9 39.3 ± 4.1 50  ± 19.8 42.575  ± 9.4 
Monocytes (%) 6.2 ± 1.1 4 ± 2.8 6.2 ± 3.8 8.4 ± 2.7 5.8 ± 1.3 6.45  ± 1.6 
Eosinophils (%) 0 0 0 0 0 0 
Basophils (%) 0 0 0 0 0.1 ± 0.1 0 
Haemocrit (%) 46.7 ± 3  48.5 ± 0.7 50 ± 2 48.3 ± 0.6 49.7  ± 1.5 48.8 ± 0.5 
MCV (fL) 48  ± 0.6 50.5 ± 0.7 49.3 ± 3.1 50.7 ± 1.2 50.3 ± 1.2 50.3  ± 1 
MCH (pg) 15.3 ± 0.6 16 16 ± 1 16 15.3 ± 0.6 15 
MCHC (g/dL) 31.5 ± 1.2 31.5 ± 0.7 31.7 ± 0.58 31.3 ± 0.6 30.7 ± 0.6 30 
RDW (%) 21.3 ± 0.4 19.2 ± 3.4 17.4 ± 1.2 17.2  ± 0.1 17.2 ± 0.2 17.5 ± 0.2 
*P<0.05, 
#
MCV Mean corpuscular volume, 
‡
MCH Mean corpuscular haemoglobin, 
┴
 MCHC Mean 
corpuscular hemoglobin concentration, 
†
RDW Red cell distribution width 
Furthermore, histopathological analysis of the major organs, revealed very minimal to 
mild neutrophil infiltration in lung, liver and spleen between 24 h up to 28 d. Liver 
had normal hepatic architecture and hepatocytes, although some inflammatory cells 
were found in or adjacent to the bile ducts of the liver. Despite the high plasma ALT 
level, no obvious histopathological signs of liver injury were observed. However, 
minor lesions were observed in the spleen due to increased proliferation of local 
macrophages. All other organs seemed to be histologically normal and devoid of any 
signs of toxicity.  
 

















Figure 6.6 Representative H & E stained images of the major organs (heart, lung, 
liver, spleen, kidney and small intestine) in mice harvested at different time-points (24 
h to 28 d) following intravenous administration of 50 mg/kg anti-EGFR-PEG-TiO2-
UCNs. Magnification: 200×. Scale bar: 50 µm. 
 
As, the hematological results showed signs of immune system modulation, the 
expression of cytokines in the plasma of the mice was analyzed using a 64 target 
antibody array. It turned out that majority of the cytokine expression determined were 
significantly upregulated compared to that of controls, indicating a pronounced 
variation in the immune response within 30 min post exposure of anti-EGFR-PEG-
TiO2-UCNs in the blood stream (Figure 6.7).  























Figure 6.7 Differential expression of various cytokines in the plasma of mice at 10, 
30 and 60 min post injection of 50mg/kg anti-EGFR-PEG-TiO2-UCNs.*P<0.05, Data 
presented are mean spot intensity in 2 membranes ± SD. 
 
A detailed evaluation of the upregulated cytokines revealed that they mostly belonged 
to the Th2 class of cytokines (IL-4, IL-5, IL-6, IL-10, IL-13) which induced the 
macrophage polarization to M2 phenotype that were less phagocytic, and played a 





role in anti-inflammatory and wound healing process.
244
 On the contrary, among the 
cytokines that did not vary significantly (IL-3, IL-2, IL-1β and IFN-γ) compared to 
that of the control group, are the Th1 type cytokines that generally favor the induction 
of highly phagocytic macrophages with M1 phenotype resulting in a pro-
inflammatory immune response. Besides, the overexpression of GCSF, GM-CSF and 
IL-6 at 30 min post systemic exposure of nanoparticles, could have consequently lead 
to the mild increase in cytokine regulated production of the neutrophils,
243
 as 
observed in the hematology data. Taken together, our results suggests that the 
systemic administration of anti-EGFR-PEG-TiO2-UCNs at a dose of 50 mg/kg does 
trigger an anti-inflammatory immune response, presumably due to the presence of the 
targeting agents that invariably reduce the stealth nature of the shielding molecules 
such as PEG and are recognized by the cells of the innate immune system such as 
monocytes, macrophages and dendritic cells. 
 
6.3.4. In vivo biodistribution of anti-EGFR-PEG-TiO2-UCNs 
Biodistribution following the systemic administration of anti-EGFR-PEG-TiO2-UCNs 
were first studied by imaging of the sections from different organs, to generally locate 
the organs with high accumulation of nanoparticles. As expected, the UCL was 
observed primarily in the heart and lung, with in first 5 min of systemic 
administration (Figure 6.8A). At 4 h, the nanoparticles were mostly cleared form the 
heart but were localized in the lung, liver and spleen  (Figure 6.8B); and continued to 
remain in these organs up to 24 h (Figure 6.8C). The kidney and small intestine did 
not show detectable levels of the nanoparticles with in the first 24 h.  
 
 
















Figure 6.8 Representative images of UCL imaging and the corresponding 
fluorescence images (Green represents the plasma membrane and red represents 
nucleus) of cryosections of various organs harvested at (A) 5 min, (B) 4 h and (C) 24 
h following systemic administration of 50 mg/kg anti-EGFR-PEG-TiO2-UCN. 
Magnification: 200X, Scale bar: 20 µm). 
  
However, UCL imaging method is not quite apt to study the long-term biodistribution 
of the UCNs, as the signals might fade away with time. Hence, to quantitatively 
determine the biodistribution of the nanoparticles in mice, ICP-AES analysis of the 
tissue digest was performed to measure titanium ion concentrations in the organs that 
showed positive UCL signal in the imaging experiment. The result suggests that the 
nanoparticles accumulated in the lung, liver and spleen, as early as 4 h post 
administration (Figure 6.9). The highest uptake, about 60% of the injected dose (ID), 
was observed in spleen 24 h post systemic administration (P<0.0001 compared to 





uptake at 4 h); meanwhile lung and liver seem to take up about 10% each of the total 
ID. Thereafter, the concentration of the nanoparticles in the various organs were 
found to drop, and by 120 d there was negligible amount of nanoparticles in the lung, 
and <5% of the ID in liver and spleen. This is in good agreement with our 
histopathological data (Figure 6.4), as well as previous study that reported slow 










Figure 6.9 Biodistribution of UCNs measured by ICP-AES analysis, showing uptake 
of nanoparticles at 4 h, 24 h, 7 d, 28d and 120 d post-injection of 50 mg/kg anti-
EGFR-PEG-TiO2-UCN expressed in terms of percentage of injected dose per gram of 
tissue. Data presented are mean (n= 2-3) ± SD. 
 
6.4. CONCLUSION 
In summary, anti-EGFR-PEG-TiO2-UCNs were found to be hemocompatible and did 
not lead to undesirable platelet aggregation, clot formation or complement activation 
up to a dose of 50 mg/kg, and exhibited 100% survival with no obvious toxic side 
effects in animals up to 120 d. A sub-acute toxicity study, on the other hand, suggests 
an induction of mild inflammatory response indicated by the significant increase in 
platelet counts and slight elevation of white blood cells and neutrophil counts in the 
plasma. In addition to this, elevated levels of Th2 cytokines such as IL-4, IL-5, IL-6,  





IL-10, IL-13 further confirms triggering of an anti-inflammatory immune response as 
early as 30 min post exposure of the nanoparticles in the bloodstream. Although 
affibodies are generally known to be less immunogenic, perhaps the high number of 
targeting ligands could have resulted in the quick recognition by the immune 
system,
245, 246
 triggering the production of neutrophils and macrophages, with 
simultaneous activation of cytokines. Meanwhile, the biodistribution data suggests 
that majority of the nanoparticles are taken up by the spleen, the largest unit in the 
MPS system, that primarily functions to filter out the blood and remove pathogen and 
foreign materials.
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 The macrophage cells in the spleen and liver (Kupffer cells), are 
known to sequester nanoparticles resulting in the accumulation of the nanoparticles in 
these organs. This could invariably reduce the circulation half-life and bioavailability 
of the nanoparticles, and result in off-site toxicities, as indicated in this case by 
elevated ALT levels. Thus, as reported by many others, high in vitro nanoparticles 
targeting efficiency due to the presence of a targeting ligand might not necessarily 
translate into in vivo efficiency, and hence in future it is important to perform and 
validate in vitro results in suitable in vivo models.
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 Further optimization of the PEG 
chains, in terms the chain length/molecular weight and surface coverage as well as 
fine-tuning of the number of targeting ligands linked to the PEG chains, without 
compromising the stability, the targeting ability and ROS generation of the 
nanoconstruct, is essential. This would probably generate an improved nanoconstruct 
that is less immunogenic with long circulation time and desirable biodistribution. 
 





CHAPTER 7  
Targeted delivery of TiO2-UCN to oral cancer: 
Therapeutic efficiency    
 
7.1. INTRODUCTION 
PDT holds significant interest as an alternative therapeutic modality to treat early 
head and neck cancers.
217, 249
 As oral cancer can be highly aggressive and recurrent in 
nature, PDT could be a treatment of choice as it can be repeated indefinitely with no 
cumulative toxicity. It could also be utilized as a safe and repeatable alternative 
treatment for the management of cancers in certain critical areas, such as the early 
stage cancers of the larynx (which involve the vocal cords), where excessive tissue 
loss could result in significant functional disabilities that affect speech, swallowing 
and voice. Additionally, there is only a very thin layer of mucosa lining the oral cavity 
which adds to the advantage of PDT as the visible light used to excite most of the 
conventional photosensitizers cannot penetrate deep in the biological tissues. Data 
from a retrospective review including 276 patients suggests that the cure rates for 
early carcinomas of the oral cavity and larynx treated with photofrin-PDT were 91% 
and 94%, respectively.
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  However, due to the limited penetration depth of the visible 
light (630 nm) used to excite Photofrin, tumors greater than 3 mm in depth were 
irradiated using cylindrical diffusers placed in the tumor bed using an 18 gauge 
catheter. This makes it an invasive procedure, due to which the whole point of 
employing PDT becomes meaningless. Thus, new and improved methods are urgently 
required to expand the applicability of this promising modality for the treatment of 
thick solid, advanced and recurrent oral cancers. 





In the previous Chapters, a UCN based PDT agent was developed to specifically 
target oral cancer cells expressing EGFR receptors. The anti-EGFR affibody 
conjugated PEGylated TiO2-UCNs, showed excellent targeting abilities and 
reasonable ROS generating abilities in vitro. In vivo biocompatibility and 
biodistribution studies following systemic administration of anti-EGFR-PEG-TiO2-
UCNs revealed that a dose of 50 mg/kg was well tolerated by the animals, with 100 % 
survival up to 120 d. Biodistribution studies suggested that the nanoparticles were 
slowly cleared from the system, without causing any major adverse toxic effects in the 
various organs that accumulated the nanoparticles as revealed by the long term 
histopathological results. As the next and the final step, the therapeutic efficiency of 
the developed targeted nanoparticles, for the treatment of solid oral cancers following 
intravenous delivery of the optimized dose (50 mg/kg) will be assessed in this study.  
7.2. MATERIALS AND METHODS 
7.2.1. Xenograft oral cancer tumor model 
OSCC purchased from ATCC were cultured in RPMI-1640 medium supplemented 
with 10% FBS and 1% penicillin-streptomycin. Cells were maintained at 37°C in a 
humidified atmosphere containing 5% CO2. Once confluent the cells were washed 
with 1X PBS and trypsinized with 0.05% Trypsin-EDTA (Gibco, USA). The cells 
were then re-suspended in HBSS (Gibco, USA). A cell suspension of 5 × 10
6
 was 
prepared in 100 μl of HBSS and was injected subcutaneously into the flanks of 6-8 
week female balb/c nude mice, weighing an average of 17 g, obtained from Animal 
Research Centre, Australia. All procedures were approved by the Institutional Animal 
Care and Use Committee, SingHealth, Singapore, and performed in accordance with 
international standards. The animals were anesthetized with by intraperitoneal 





injection of an anaesthetic cocktail (Ketamine: diazepam: saline 6: 9: 10) during any 
procedure involving light irradiation. 
7.2.2. In vivo PDT using NIR light post intratumoral administration of UCNs 
For intratumoral administration, animals were assigned to 5 different groups: (i) 
Control (mice with untreated tumors), (ii) NIR-light alone control (1000 J/cm
2
) (iii) 
anti-EGFR-PEG-TiO2-UCN alone (0.1 mg/tumor) (iv) anti-EGFR-PEG-TiO2-UCN 
(0.1 mg/tumor) + PDT (1000 J/cm
2
) – single dose, and (v) anti-EGFR-PEG-TiO2-
UCN (0.1 mg/tumor) + PDT (1000 J/cm
2
) – repeated dose , and each group comprised 
of 3-5 animals each. For group (ii), tumors were irradiated with 980 nm NIR light at a 
power of 500 mW for 33 min 20 sec. For group (iii) tumors were intratumorally 
injected with 40 μl of anti-EGFR-PEG-TiO2-UCN in sterile saline. For group (iv and 
v) 4 h post intratumoral administration of 40 μl of anti-EGFR-PEG-TiO2-UCN, the 
tumors were irradiated with NIR light on Day 1. Animals in group (v) were again 
injected with anti-EGFR-PEG-TiO2-UCN and irradiated with NIR light on Day 8 and 
Day 19. For all groups, tumor volume was measured on at least 3 alternate days a 
week, for up to 35 d. The tumor volume was calculated using the following formula: 
Volume = (π/6 × d1 × d2 × d3), where d1, d2 and d3 are tumor dimensions in 3 
orthogonal directions.  
7.2.3. Uptake of anti-EGFR-PEG-TiO2-UCN in tumor tissue 
Following intravenous administration of 50 mg/kg anti-EGFR-PEG-TiO2-UCN, the 
animals were sacrificed at different time-points (ranging from 4 h to 7 d), and the 
tumor tissues were harvested. The tissue samples were then digested with 60% nitric 
acid at 60 °C, overnight. The samples were then diluted with distilled water to form a 





5% acid solution, filtered through a 0.22-μm filter and then analyzed for titanium 
content by ICP-AES analysis. 
 
7.2.4. In vivo PDT using NIR light post systemic administration of UCNs 
 
Animals were randomly assigned into 6 different groups: (i) Control (mice with 
untreated tumors), (ii) NIR-light alone control (1000 J/cm
2
) (iii) anti-EGFR-PEG-
TiO2-UCN alone (0.1 mg/tumor)  (iv) anti-EGFR-PEG-TiO2-UCN (0.1 mg/tumor) + 
PDT (1000 J/cm
2
) , (v) anti-EGFR-PEG-TiO2-UCN  + PDT (1000 J/cm
2
) + 6 mm 
tissue phantom and (vi) anti-EGFR-PEG-TiO2-UCN + PDT (1000 J/cm
2
) + 10 mm 
tissue phantom, and each group comprised of 3-5 animal each. Again for group (ii), 
tumors were irradiated with 980 nm NIR light at a power of 500 mW for 33 min 20 
sec. For groups (iii) to (vi), animals were injected with 50 mg /kg anti-EGFR-PEG-
TiO2-UCN (volume of injection: 100 µl). For group (iv - vi) 4 h post systemic 
administration of anti-EGFR-PEG-TiO2-UCN, the tumors were irradiated with NIR 
light. To demonstrate the tissue penetration abilities, tumors of animals in group (v) 
and (vi) were blocked either by a 6 mm or 10 mm thick tissue phantom, respectively 
during NIR light irradiation. Briefly, the tissue phantoms were prepared using 0.5% 
(w/v) ultrapure agarose (Invitrogen, USA), 1% (v/v) of intralipid-10% (KabiVitrum 
Inc., USA) as the scatterer and 0.1% (v/v) Nigrosin, as the absorber.  
7.2.5. In vivo Ce6-PDT using red light  
 
For conventional PDT study, animals were randomly assigned to 6 groups: (i) Control 
(mice with untreated tumors), (ii) 665 nm light alone, (iii) Ce6 alone, (iv) Ce6 + PDT, 
(v) Ce6 + PDT + 6 mm tissue phantom and (vi) Ce6 + PDT + 10 mm tissue phantom. 
For group (ii) the tumors were irradiated with a laser light source emitting a 
wavelength of 665 nm (LVI Technology Inc, South Korea). A light dosage of 150 







 and fluence rate of 100 mW/cm
2
 was used. For group (iii) the animals were 
intravenously injected with 20 mg/kg Ce6 (ApoCare GmBH, Germany) and did not 
receive any light irradiation. For group (iii) to (vi),  3 h post systemic administration 
of 20 mg/kg Ce6, the tumors were irradiated with a 665 nm laser light source (LVI 
Technology Inc, South Korea). For group (v and vi) the tumors were blocked either 
by a (v) 6 mm or (vi) 10 mm thick tissue phantom, respectively and then irradiated 
with 665 nm laser light.  
7.2.6. Immunohistochemistry 
Tumor tissue samples were fixed in 10% formalin for 24 h, and then processed using 
a tissue processor (Leica TP 1020, Germany) and embedded in paraffin. The paraffin 
embedded samples were cut using a microtome (Leica RM 2135, Germany) at 5 µm 
thickness. The sections were mounted on superfrost/plus slides (Fischer Scientific, 
USA) and air-dried. On the day of staining the slides, the paraffin was cleared in Neo-
clear (Merck Millipore, USA) two times for 10 min before rehydrating in ethanol 
series. Following 10 min incubation with hydrogen peroxide to block the endogenous 
peroxidase activity, the sections were incubated overnight at 4°C with primary 
antibodies, Ki-67 (1:100; Abcam, USA).. To confirm the specificity of binding, 
normal mouse serum IgG1 (1:500) was used as a negative control. Following 
extensive washing, sections were incubated for 30 min in the secondary biotinylated 
antibody, rinsed and followed by DAB Chromogen (Vector Laboratories, UK) for 10 
min. Sections were then counter-stained with Harris’s hematoxylin and dehydrated in 
ascending grades of ethanol before clearing in xylene and mounting with a cover slip. 
Images were captured using a Nikon 80i Fluorescence Microscope (Nikon, Tokyo, 
Japan) using a 20X objective (200X magnification). Image J (1.49p, National institute 
of Health, USA) software was used to analyze and quantify the percentage of Ki-67 





staining. For H&E staining, serial 8 μm thick cryosections were fixed in acetone, 
stained with H&E stain as mentioned elsewhere, and imaged by a Nikon 80i digital 
microscope (Nikon, Tokyo, Japan) using a 20X objective (200X magnification). 
7.2.7. Evan’s blue staining 
For Evan’s blue staining, 400 μl of 1% Evan’s blue dye in saline was injected 
intraperitoneally into the animals 48 h post treatment and 6 h later the animals were 
sacrificed to excise the tumors. 2 – 3 mm thick cross-section slices of tumors were cut 
and imaged under a stereoscopic microscope (Stemi 2000C, Zeiss, Germany).  
7.2.8. Statistical Analysis 
Statistical analyses were performed using the GraphPad Prism version 6.0 software 
(GraphPad Software, San Diego California USA). One-way ANOVA was used to 
analyze the variance. Multiple comparison was done by two-way ANOVA followed 
by Bonferroni's post-hoc test. P values less than 0.05 (P<0.05) were considered 
significant. 
7.3. RESULTS AND DISCUSSION 
7.3.1. NIR-PDT post intratumoral administration of UCNs 
 
Although the developed anti-EGFR-PEG-TiO2-UCN was found to generate good 
amount of ROS and cell destruction in vitro, their behaviour in a complex biological 
milieu have to be tested. Thus before studying the therapeutic efficiency following a 
more challenging intravenous route, the ability of the developed targeted 
nanoparticles in destroying or controlling the tumor growth following intratumoral 
administration was first determined. Results revealed that even after surface 
modification of the nanoparticles with anti-EGFR affibodies, the ROS production and 
tumor growth controlling ability of the nanoparticles following intratumoral 





administration and NIR irradiation, remains as efficient as the PEGylated TiO2-UCNs 
(Chapter 4). As expected, again the tumor growth of mice in the control groups 
(untreated, anti-EGFR-PEG-TiO2-UCN alone and NIR light alone control) reached 
the maximum ethical size limit (Figure 7.1A) and had to be sacrificed between 19 and 
42 d (Figure 7.1B). Animals with tumors that were treated with a single 
administration of anti-EGFR-PEG-TiO2-UCN followed by PDT with NIR light, 
demonstrated excellent tumor control up to 3 weeks. Thereafter, the tumors seemed to 
regrow slowly reaching an average size of about 1000 mm
3








Figure 7.1 (A) In vivo OSCC tumor growth up to 60 d on different groups of mice 
after various treatments indicated. Red arrows indicate the days when the PDT was 
repeated; n=3-5 per group. Error bars represent SD of the mean. (B) Survival rates of 
mice in different treatment groups within 60 d. 
 
In an effort to achieve complete tumor control, both nanoparticle administration and 
light irradiation was repeated on 2 more occasions (Day 8 and 19) as and when the 
tumors were starting to show signs of regrowth. As seen in Figure 7.2A and B, there 
was complete tumor regression in mice of the repeat PDT group. This observation 
clearly suggests that the developed nanoparticles are efficient as NIR-excitable PDT 





















Figure 7.2 Images of 2 different animals (A) and (B), completely free from tumor 
burden at 60 days following 3 intratumoral administration of anti-EGFR-PEG-TiO2-
UCN and NIR irradiation sessions (repeat PDT).  
 
 
7.3.2. Tumor accumulation of nanoparticles following systemic administration 
To determine the optimal DLI, it is essential to find out the time at which maximum 
nanoparticles reach the tumor following their systemic administration. ICP-AES 
analysis of the whole tumor digest revealed that the maximum uptake of anti-EGFR-
PEG-TiO2-UCN occurs 4 h after systemic administration (Figure 7.3A). At 24 h there 
seems to be considerable decrease in the amount of nanoparticles in the tumor tissue, 
and following that even at 7 d the amount of anti-EGFR-PEG-TiO2-UCN seems to 
remain the same as at 24 h. This suggests that at 4 h the nanoparticles might still have 
been circulating in the blood and hence were present in the blood vessels of the 
tumor; some amount of which might have extravasated into the tumor tissue.  
 
 



















Figure 7.3 (A) Comparison of UCN uptake at different time-points in tumor tissues 
by ICP-AES analysis, following systemic administration of 50 mg/kg anti-EGFR-
PEG-TiO2-UCN. Data are mean (n=2-3) ± SD. Images of sections of tumor tissue 
excised  from Evan’s blue stained mouse treated with (B) NIR light alone and (C) 
NIR light irradiation 4 h post systemic administration of 50 mg/kg anti-EGFR-PEG-
TiO2-UCN. (D) Tumor volumes charted against days to assess the tumor response in 
various treatment groups. Data are mean (n= 4-5 per group) ± SD. (E) Survival rates 
of mice in different treatment groups within 60 d. 
 
To further assess the suitability of the selected DLI, and the efficiency as well as 
depth of penetration following NIR light irradiation 4 h post systemic administration 
of 50 mg/kg anti-EGFR-PEG-TiO2-UCN, Evan’ blue vital staining was done 48 h 





following the PDT treatment. Compared to the NIR light alone (Figure 7.3B), the 
treatment group (50 mg/kg anti-EGFR-PEG-TiO2-UCN + NIR light) exhibited clear 
unstained necrotic areas with a depth reaching about 1.5 cm (Figure 7.3C). This 
shows that the chosen dose of 50 mg/kg and 4 h DLI has the potential to display good 
therapeutic outcome. 
7.3.3. NIR-PDT post systemic administration of UCNs 
 
The effectiveness of PDT following systemic administration of 50 mg/kg anti-EGFR-
PEG-TiO2-UCN and subsequent irradiation with NIR light was studied by measuring 
the tumor volume and charting the survival curve of the mice in the treatment as well 
as the control groups. As expected the animals that received intravenous 
administration of 50 mg/kg anti-EGFR-PEG-TiO2-UCNs followed be irradiation with 
980 nm light showed significant delay in tumor growth with a mean tumor volume 
reaching about 728  ± 41.2 mm
3
 at 35 d (Figure 7.3D) and demonstrated 80% survival 
at 60 d (Figure 7.3E). Whereas, the tumors of the mice in control groups (untreated, 
NIR light alone, and anti-EGFR-PEG-TiO2-UCN alone) reached the ethical size limit 
and all animals had to be sacrificed between 24 and 33 d (Figure 7.4 A and B). In 
order to highlight the advantage of using NIR in PDT, tissue phantoms of various 
thickness (6 and 10 mm) was placed in the path of the light. It was found that the NIR 
light could penetrate up to 10 mm thick tissue phantom to excite the nanoparticles in 
the tumor tissue and achieve reasonable tumor growth control, with mean tumor size 
when irradiated in the presence of 6 and 10 mm tissue phantom being 1061.8 ± 45.5 
and 1343 ± 63.1 mm
3
, respectively (Figure 7.3D, 7.4 D and E). In addition to this, the 
survival rate of the animals also improved significantly compared to the control 
groups, with 50% of the animals surviving up to 45 and 55 d when tumors were 
irradiated in the presence of 10 and 6 mm tissue phantom, respectively (Figure 7.3E). 





This observation undoubtedly proves that the developed nanoparticles have the 













Figure 7.4 Representative images of mice in different groups: (A) Untreated control, 
(B) 980 nm NIR light alone (C) anti-EGFR-PEG-TiO2-UCN + 980 nm light, (D) anti-
EGFR-PEG-TiO2-UCN + 980 nm light + 6 mm tissue phantom, (E) anti-EGFR-PEG-
TiO2-UCN + 980 nm light + 10 mm tissue phantom. 
 
7.3.4. Assessment of tumor growth and proliferation  
  
H & E staining of the tumors excised at day 15 following NIR-PDT with anti-EGFR-
PEG-TiO2-UCNs without tissue phantom and with 10 mm tissue phantom revealed 
large areas of necrosis compared to the tumors from untreated control animals (Figure 





7.5A). To   further analyse the status of tumor growth and cell cycle the presence of 
Ki-67, a nuclear antigen that is strictly associated with cell proliferation, was 
determined by immunohistochemistry. Ki-67 staining was significantly lower in the 
tumors from mice treated with anti-EGFR-PEG-TiO2-UCN + NIR without tissue 
phantom (3.1%) and with tissue phantom (11.3%) compared to control untreated 































Figure 7.5 (A) Representative H & E stained images of tumor sections from different 
groups 15 days after respective treatment. (Scale bar: 50 µm, Magnification: 200X) 
(B) Representative photomicrograph showing Ki-67 proliferative index in tumor 
sections from different groups 15 days after respective treatment (Scale bar: 50 µm, 
Magnification: 200X) (C) Quantitative data for the proliferation index is shown as 
percent of Ki-67-postive cells, *P<0.05 compared to control, error bars indicate SD of 
the mean. 





7.3.5. Conventional Ce6-PDT using 665 nm light 
 
To further emphasize the effectiveness of the developed nanomaterial for NIR based 
PDT of solid and deep seated tumors; we compared it with conventional PDT using 
the PS Ce6. The results of tumor volume measurement following Ce6-PDT revealed 
complete tumor remission up to 35 d (Figure 7.6A) and 100% survival at 60 d (Figure 
7.6B), compared to the mice in the control groups that were sacrificed between 24 and 








Figure 7.6 (A) In vivo OSCC tumor growth up to 35 d on different groups of mice 
after various treatments indicated.; n=3-4 per group. Error bars represent SD of the 
mean. (B) Survival rates of mice in different treatment groups within 60 d. 
 
Now, when a 6 mm tissue phantom was placed over the tumor, there was slight delay 
in the tumor growth with the average tumor size reaching 1388.3 ± 146 mm
3 
at 35 d.  
But in the presence of a 10 mm tissue phantom, Ce6-PDT at 665 nm had no effect on 
the tumor growth, which followed a similar trend as the mice in the control group 
reaching a mean size of 2078.1 ± 36 mm
3 
at 33 d. The results undoubtedly suggest 
that conventional PDT is far more effective in the treatment and control of small 





tumors that are within a few mm thick. However, when the tumors are or greater than 
10 mm in thickness, Ce6-PDT using 665 nm light fails as a therapeutic option, 
apparently due to the limited penetrating capability of 665 nm red light.   
7.4. CONCLUSION 
Systemic delivery of nanoparticles are challenging as in most cases the amount of 
nanoparticles a that ultimately reaches the tumor tissue is only a few percent of the 
total injected dose.
251
 Although, the presence of the targeted agent is considered to 
play a critical role in the attachment of the nanoparticles to the cancer cell-surface 
receptors and further uptake into the cells by receptor mediated endocytosis, the EPR 
effect accounts for much of its accumulation in the tumor site. Here, when the 
developed nanoparticles were intratumorally delivered, they seemed to have a better 
therapeutic outcome compared to systemic delivery, with complete remission of the 
tumors following repetition of PDT. Nonetheless, NIR-PDT following systemic 
delivery also demonstrated considerable control of tumor growth, exhibiting 
reasonable therapeutic effect and improved survival rates even when the tumors were 
blocked with a 10 mm tissue phantom. On the other hand, though conventional Ce6-
PDT using 665 nm red light demonstrated complete tumor remission with a single 
PDT application, it terribly failed to penetrate the 10 mm tissue phantom and display 
any therapeutic effect. Undeniably, the nanoparticle fabricated in this study has the 
potential to be developed as a NIR-PDT agent for the treatment of solid and deep-
seated tumors. Further refinement of the surface characteristics could fine-tune the 
biodistribution of these nanomaterials, to enhance its accumulation in the tumor and 
also improve the therapeutic effect.  





CHAPTER 8  
Summary of findings 
In spite of being an effective and safe alternative cancer treatment modality, with 
numerous advantages, PDT has not yet gained clinical acceptance due to its inability 
to treat solid or bulky tumors. One major reason behind this reluctance is the 
penetration depth limit of the visible light that is often used to excite the conventional 
PSs, limiting the application of PDT to the treatment of superficial and flat lesions. 
Recently, the use of NIR excitable UCN based PDT systems has garnered a lot of 
attention and there is a growing number of literatures in this field. However, the major 
roadblock in this area is the limited availability of PS at the target site either due to 
inefficient PS loading or leakage of the PS from the UCN based nanocarrier, before it 
reached the tumor. This led to decreased bioavailabity at the tumor site, in addition to 
other issues like batch to batch variations in PS loading; thus affecting the overall 
PDT efficiency. Hence, the main aim of this thesis was to find a method to stably 
load, precise and sufficient amount of PS, to completely eliminate the possibility of 
PS leakage and reduce batch to batch variations in the amount of PS loading.  
A facile method of directly surface coating a photocatalyst TiO2 on a NIR to UV 
upconverting NaYF4:Yb:Tm UCN core is demonstrated in Chapter 3. The synthesized 
nanoparticles (TiO2-UCNs) were found to generate significant amount of ROS and 
reasonable amount of cell death in vitro, however the nanoparticles were found to 
form large aggregates in physiologically relevant solutions. As aggregation could lead 
to reduced bioavailability and affect the ROS production ability, it became important 
to surface modify these nanoparticles to tackle these issues, before developing it 





further for in vivo applications. In Chapter 4, the developed nanoparticles were further 
surface modified with a maleimide functionalized PEG to form Mal-PEG-TiO2-UCN. 
PEGylation of TiO2-UCNs was found to improve its dispersion stability, reduce 
undesirable protein adsorption to nanoparticle surface and reduced macrophage 
recognition and uptake. On the other hand, surface modification with maleimide 
functionalized PEG, enhanced the uptake of the nanoparticles by OSCC cells due to 
the binding of maleimide group to the cell surface thiols. This increase in the uptake 
of nanoparticles resulted in a significant amount of dose dependent cell death 
following NIR-PDT in vitro, and the mechanism of cell death was found to be mainly 
via a necrotic pathway. “Proof of concept” in vivo study to determine the therapeutic 
efficiency post intratumoral administration of Mal-PEG-TiO2-UCNs revealed 
significant delay in tumor growth and 100% survival up to 60 d.  
In order to develop targeted nanoparticles for systemic delivery against EGFR 
expressing oral cancers, anti-EGFR affibodies were tagged to the PEGylated TiO2-
UCNs. Next in Chapter 5, the in vitro targeting ability, toxicity, ROS production and 
cell killing ability of the anti-EGFR-PEG-TiO2-UCNs were studied. The results 
demonstrated good targeting ability towards EGFR positive cells, excellent 
biocompatibility and selective cell killing following NIR PDT. Further in vivo studies 
in Chapter 6, post systemic delivery of anti-EGFR-PEG-TiO2-UCNs revealed that a 
dose of 50 mg/kg was well tolerated by the animals, with 100 % survival up to 120 d. 
Although blood biochemical results showed a significant increase in hepatic injury 
marker ALP following systemic administration of 50 mg/kg anti-EGFR-PEG-TiO2-
UCNs, the histopathological results did not show any obvious signs of liver damage. 
Furthermore hematological and cytokine release profiling results revealed a mild 
inflammation and stimulation of a Th2 type, anti-inflammatory immune response. 
Chapter 8: Summary and future directions 





Biodistribution studies suggested that the nanoparticles were slowly cleared from the 
system, without causing any major adverse toxic effects in the various organs. Thus, 
further fine-tuning of the surface modification strategy to optimize the chain length, 
number and surface coverage of the stabilizing polymer PEG as well as the number of 
the targeting moiety would help in minimizing the immune response and undesirable 
uptake by the RES organs, which will be the major aim of the study in future. In the 
last and final chapter, the therapeutic efficiency of NIR-PDT post systemic 
administration of anti-EGFR-PEG-TiO2-UCN was compared with conventional 
Chlorin-e6 PDT at 665 nm red light. The results clearly showed that Ce6-PDT fails as 
a therapeutic option, when the tumors are or greater than 10 mm in thickness. At the 
same time, NIR-PDT following systemic delivery of anti-EGFR-PEG-TiO2-UCN 
demonstrated considerable control of tumor growth, exhibiting reasonable therapeutic 
effect and improved survival rates even when the tumors were blocked with a 10 mm 
tissue phantom. The results of this study undeniably suggest that the developed 
nanoparticles have the potential to be developed as a NIR-PDT agent for the treatment 















PDT using UCNs doped with PS is certainly becoming the new sensation in the field 
with clear advantages over conventional PDT. UCNs act both as carriers of PS as well 
as enables indirect excitation of the accompanying PS with upconverted light upon 
excitation with low energy NIR light. Recently, there has been a growth in the number 
of literature available in this area which clearly depicts the growing interest, clear 
advantages and possibility of further developments in the field. However, long multi-
step reaction methods associated with UCN synthesis as well as lack of precise 
control and instability in PS loading often leads to batch to batch differences, making 
it difficult to compare results and determine the efficiency of each nanoconstruct in 
PDT. Subtle changes in composition arising from minute deviations in the 
manufacturing or surface modification process could substantially affect the 
pharmacokinetics, biodistribution and toxicity in vivo.
20, 21
 Thus, stringent quality 
control measures in terms of uniformity in particle composition, size, surface 
chemistry, PS loading etc. is necessary for commercialization of this technology. 
Further simplification of the synthesis steps, standardization of nanoparticle 
preparation, testing and validation protocols, utilization of automated nanoparticle 
fabrication processes while implementing good manufacturing practices, would allow 
greater consistency in the quality of the UCNs synthesized, besides enabling easy 
scaling up for commercialization.  
For effective PDT, optimisation of the PDT parameters such as the drug light interval, 
laser dosimetry including the fluence, fluence rate and time of irradiation, is 
necessary. For PDT using UCNs, a laser power density ranging between 0.4 W/cm
2
 to 
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 and fluence > 1000J/cm
2
 have been typically used. However, in clinical 
application and PDT experiments using conventional PS, power density < 1 W/cm
2
 
and fluence <1000 J/cm
2
 will probably be enough for efficient tumor cell death.
252, 253
 
Apparently, UCN based PDT works via anti-stokes emission process that is reported 
to have a quantum yield of less than 1% in general.
254
 Hence, the efficiency of this 
process is less than direct excitation of PS by visible light source in conventional 
PDT, and there is an urgent need to find new strategies to improve the upconversion 
efficiency of these nanomaterials. Coating of an undoped shell (such as NaYF4 or 
CaF2) around the UCN core have shown to improve quantum yield  by the suppression 
of surface quenching effects.
163
 The low quantum yield also results in unsatisfactory 
brightness of the UCNs under low excitation power densities. The brightness of the 
UCNs is dependent on the 4f-4f optical transition probabilities of the lanthanide ions, 
which are remarkably affected by their local crystal field.
255
 Consequently, fine-
tuning the local crystal field of the lanthanide ions is an effective strategy to increase 
the UCL of lanthanide ion-doped nanocrystals.
256
 Doping the UCNs with other 
elements or dyes with strong absorption and further optimization of the doping ion 
ratios,
257-259
 varying the crystal phase of the nanocrystals,
260, 261
 fabricating core–shell 
structures
262, 263
 and utilizing metal-enhanced fluorescence
264, 265
 are among the 
methods being explored to improve the brightness and quantum yield.  
Currently, much of the research in this field uses an NIR excitation wavelength of 980 
nm that matches the absorption of the commonly utilized sensitizer Yb
3+
. However, 
water has strong absorption around 970 nm, which could lead to heating up of 
biological tissues when excited around this wavelength. In addition to the heating 
effects, a significant reduction in the penetration depth is anticipated as the 980 nm 
light gets attenuated, while travelling through tissues. A shift in excitation wavelength 





from 980 nm to a lower NIR wavelength that does not cause a thermal effect could be 
more clinically appropriate. Efforts to excite UCNs with using another absorption 
peak of Yb
3+
 at 915 nm were accompanied by a reduction in excitation efficiency.
266
 
As an alternative,  NIR dye sensitized UCNs were reported to harvest light in the 
shorter NIR wavelengths (740 to 850 nm), where the surface bound NIR dye served 
as an antenna that absorbed light in the specified spectrum enabling FRET to UCN 
core to produce an upconverted light.
267
 However, such NIR absorbing organic dyes 
may succumb to photobleaching, making them unsuitable for long-term 
imaging/activation applications. Recently, co-doping with a second sensitizer such as 
neodymium (Nd
3+
) (that has a absorption maxima around 800 nm) was shown to 
absorb NIR light at 800 nm following which it sensitizes Yb
3+
, which then initiates a 
typical upconversion process with the activator ions.
257, 268, 269
 Although, this 
technique seem quite promising in alleviating the short penetration depth and 
overheating effect associated 980 nm excitation, no in vitro or in vivo work using such 
UCNs in PDT has been reported till date.  
PDT using UCN is definitely a promising treatment modality, however currently it 
faces many limitations apart from the issues pertaining to the UCN itself. One main 
issue encountered in the current study and several earlier studies was the relatively 
low accumulation of nanoparticles in the tumor following systemic administration, 
despite of the surface modification of the UCNs with biocompatible materials that 
helps to evade macrophage recognition and the presence of tumor homing motifs. 
This often results in sub- optimal PDT and tumor recurrence in majority of the 
studies. This indicates at the importance of optimizing the molecular weight, surface 
structural conformation, and surface coverage ratio of the biocompatible polymer like 
PEG that is grafted to improve stealth properties of UCNs.
270
 Furthermore, it is well 





known that presence of targeting ligands at high densities could promote nonspecific 
interactions with endothelial and other non-cancerous cells, trigger immune response 
resulting in opsonization-mediated clearance of nanoparticles from the circulation.
271, 
272
 Development of truly tumor “homing” nanoparticles might require stringent 
optimisation of number of targeting ligands on the surface of nanoparticles, targeting 
multiple receptors that are overexpressed in the tumor as well as tumor vasculature, 
and inclusion of cleavable “antibiofouling agents” that masks the targeting ligands till 
it reaches the tumor.  
In this study, we have conducted a multi-dose sub-chronic toxicity study in mice to 
assess the long term (120 d) effects of UCNs in vivo. However, a lot of unanswered 
questions still remain such as the exact route of clearance of the nanoparticles, and 
whether the UCNs or the outer TiO2 shell might be degraded in the system, and if so 
what will be the effects of the degradation products. It must be noted that most of the 
in vivo toxicology profiling is limited to small rodents like mice, which may not be 
translatable to the clinics.  Extensive pharmacokinetic-pharmacodynamic (PK-PD) 
analysis, together with long-term toxicity and clearance studies, remains unexplored 
and deserves immediate attention. It is clear that UCNs have the potential of being 
developed into a multimodality theranostic probe, so that it can be simultaneously 
used both as multimodality imaging tool as well as therapeutic agent. Nevertheless, 
there is still much room for improvement in terms of reduction in size of the 
construct, enhancing the upconversion efficiency, stability in PS loading, optimization 
of PDT parameters and thereby increasing the PDT efficacy. Owing to the 
multidisciplinary nature of this field, it is imperative to have frequent facilitations 
between scientists, academicians, engineers, clinicians and industrial innovators to 
share and discuss the opportunities and challenges in the field, so as to bring PDT to 





the forefront of oncological diagnosis and intervention. The future of the PDT lies in 
the development of a single versatile and efficient nanoparticle that encompasses its 
applicability in both bioimaging as well as PDT. 
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